Haemodynamics and biochemistry of a hypertensive response to exercise by Nikolic, SB
  
 
 
 
 
 
 
Haemodynamics and Biochemistry of a Hypertensive 
Response to Exercise 
 
By 
Sonja B. Nikolic 
BMedRes (Hons), BPharm 
 
A thesis submitted in fulfilment of the degree of Doctor of Philosophy 
November 2014 
 
 
 
 
Menzies Institute for Medical Research  
University of Tasmania 
Hobart, Tasmania, Australia 
i 
 
Statements and Declarations 
 
Declaration of Originality 
This thesis contains no material which has been accepted for a degree or diploma by the 
University of Tasmania or any other institution, except by way of background information 
and of which is duly acknowledged in the thesis. To the best of my knowledge and belief, this 
thesis contains no material previously published or written by another person except where 
due acknowledgement is made in the text of the thesis, nor does the thesis contain any 
material that infringes copyright. I have also acknowledged, where appropriate, the specific 
contributions made by co-authors of published and submitted manuscripts. 
Authority of Access 
The publishers of the manuscripts comprising Chapter 2 (Review of Literature – Part II), 
Chapter 5 and Appendix 1 hold the copyright for that content, and access to the material 
should be sought from the respective journals. The remaining non-published content of the 
thesis may be made available for loan and limited copying and communication in accordance 
with the Copyright Act 1968.  
Statement of Ethical Conduct 
All research associated with this thesis abides by the International and Australian codes on 
human and animal experimentation, and full ethical approval from the relevant institutions 
was obtained for all studies outlined in this thesis. All individual participants provided written 
informed consent for involvement in the respective research studies. 
 
 
_____________________ 
Sonja B. Nikolic 
November 2014 
  
ii 
 
Publications by the Author and Statement of Co-Author 
Contributions to Papers Contained Within This Thesis 
The following papers are incorporated into Chapters of this thesis and were either published 
or submitted for publication in peer reviewed scientific journals during the course of 
candidature. 
Chapter 2 – Review of Literature – Part II 
Nikolic SB, Sharman JE, Adams MJ, Edwards LM. Metabolomics in hypertension. 
J Hypertens.  2014; 32:1159-1169 
Author contributions: 
Nikolic B. Sonja Conception and design, literature review, manuscript preparation 
Sharman E. James Conception and design, critical manuscript revision 
Adams J. Murray Critical manuscript revision 
Edwards M. Lindsay Conception and design, critical manuscript revision 
Chapter 4  
Nikolic SB, Adams MJ, Otahal P, Edwards LM, Sharman JE. Association of von Willebrand 
factor blood levels with exercise hypertension – Submitted to European Journal of Applied 
Physiology, July 2014  
Author contributions: 
Nikolic B. Sonja Conception and design, data collection, data analysis and 
interpretation, manuscript preparation 
Adams J. Murray Study conception and design, data interpretation, critical 
manuscript revision 
Otahal Peter Data analysis, critical manuscript revision 
Edwards M. Lindsay Critical manuscript revision 
Sharman E. James Study conception and design, data interpretation, critical 
manuscript revision 
Chapter 5  
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Spironolactone 
reduces aortic stiffness via blood pressure-dependent effects of canrenoate. Metabolomics. 
2014, 10:105-113 
Author contributions: 
iii 
 
Nikolic B. Sonja Conception and design, data collection, data analysis and 
interpretation, manuscript preparation 
Wilson Richard Data collection, critical manuscript revision 
Hare L. James Data collection, critical manuscript revision 
Adams J. Murray Critical manuscript revision 
Edwards M. Lindsay Study conception and design, data interpretation, critical 
manuscript revision 
Sharman E. James Study conception and design, data collection, data interpretation, 
critical manuscript revision 
Chapter 6  
Nikolic SB, Edwards LM, Karpievitch YV, Wilson R, Horne J, Adams MJ, Sharman JE. 
Serum metabolic profile predicts adverse central haemodynamics in patients with type 2 
diabetes mellitus – Submitted to Metabolomics, August 2014 
Author contributions: 
Nikolic B. Sonja Study conception and design, data collection, data analysis and 
interpretation, manuscript preparation 
Edwards M. Lindsay Study conception and design, data interpretation, critical 
manuscript revision 
Karpievitch V. Yuliya Data analysis, critical manuscript revision 
Wilson Richard Data collection, critical manuscript revision 
Horne James Data collection, critical manuscript revision 
Adams J. Murray Critical manuscript revision 
Sharman E. James Study conception and design, data interpretation, critical 
manuscript revision 
Appendix 1 
Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few extra 
minutes before measuring blood pressure has potentially important clinical and research 
ramifications. Journal of Human Hypertension. 2014 Jan; 28(1):56-61  
Author contributions: 
Nikolic B. Sonja Study conception and design, data collection, data analysis and 
interpretation, manuscript preparation 
Abhayaratna P. Walter Critical manuscript revision 
Leano Rodel Data collection, critical manuscript revision 
Michael Stowasser Critical manuscript revision 
Sharman E. James Study conception and design, data interpretation, critical 
manuscript revision 
iv 
 
Appendix 2 
Karpievitch YV, Nikolic SB, Wilson R, Sharman JE, Edwards LM: Metabolomics data 
normalisation with EigenMS. Submitted to PLoS ONE, July 2014 
Author contributions: 
Karpievitch V. Yuliya Study conception and design, data analysis and interpretation, 
manuscript preparation 
Nikolic B. Sonja Study conception and design, data collection, critical manuscript 
revision 
Wilson Richard Data collection, critical manuscript revision 
Sharman E. James Critical manuscript revision 
Edwards M. Lindsay Study conception and design, data interpretation, critical 
manuscript revision 
 
 
 
We, the undersigned agree with the above stated contributions for each of the above 
published (or submitted) peer-reviewed manuscripts contained within this thesis: 
 
 
 
________________________________ 
Associate Professor James E. Sharman 
Primary candidate supervisor 
Menzies Institute for Medical Research  
University of Tasmania  
 
 
 
 
_________________________________ 
Professor Thomas H. Marwick 
Director 
Menzies Institute for Medical Research  
University of Tasmania  
v 
 
Abstracts and Presentations at Scientific Conferences that Relate 
to This Thesis 
The following abstracts relate specifically to this thesis and were presented at national and/or 
international scientific conferences during the period of candidature. 
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Spironolactone 
reduces aortic stiffness in people with a hypertensive response to exercise via the blood 
pressure-dependent effects of canrenoate. ARTERY 12 (Association for Research into 
Arterial Structure and Physiology). Young Investigator Oral presentation - student 
finalist. Vienna, Austria. October 2012  
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Effects of 
downstream drug metabolites of spironolactone on aortic stiffness and ambulatory blood 
pressure. The 2nd ISH New Investigators Symposium. Oral presentation. Sydney, Australia. 
September 2012 
Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few extra 
minutes before measuring central blood pressure has potentially important clinical and 
research ramifications. High Blood Pressure Research Council of Australia (HBPRCA) 
annual scientific meeting. Oral presentation - student finalist. Perth, Australia. December 
2011 
Nikolic SB, Otahal P, Adams MJ, Edwards LM, Sharman JE. Exercise systemic vascular 
resistance and raised triglycerides independently predict a hypertensive response to exercise. 
HBPRCA (High Blood Pressure Research Council of Australia) annual scientific meeting. 
Early Career Moderated Poster presentation. Melbourne, Australia. December 2013 
Nikolic SB, Edwards LM, Karpievitch YV, Wilson R, Horne J, Adams MJ, Sharman JE. 
Serum metabolic profile predicts adverse central haemodynamics in patients with type 2 
diabetes mellitus. Joint meeting ESH-ISH, Hypertension. Poster presentation. Athens, 
Greece, June 2014 
vi 
 
Nikolic SB, Otahal P, Adams MJ, Edwards LM, Sharman JE. Increased systemic vascular 
resistance during moderate exercise independently predicts a hypertensive response to 
exercise. ARTERY 13 (Association for Research into Arterial Structure and Physiology). 
Poster presentation. London, UK. October 2013 
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Effects of 
downstream drug metabolites of spironolactone on aortic stiffness and ambulatory blood 
pressure. Omics Australasia Symposium. Poster presentation. Perth, Australia. December 
2012 
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Effects of 
downstream drug metabolites of spironolactone on aortic stiffness and ambulatory blood 
pressure. ISH 2012 - 24th Scientific Meeting of the International Society of Hypertension. 
Poster presentation. Sydney, Australia. October 2012 
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Effects of 
downstream drug metabolites of spironolactone on aortic stiffness and ambulatory blood 
pressure. Central Haemodynamics Satellite Meeting: The 4th Pulse of Asia. Poster 
presentation. Sydney, Australia. October 2012 
Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few extra 
minutes before measuring central blood pressure potentially has important clinical and 
research ramifications. ARTERY 11 (Association for Research into Arterial Structure and 
Physiology). Poster presentation. Paris, France. October 2011 
Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few extra 
minutes before measuring central blood pressure potentially has important clinical and 
research ramifications. Sharing Excellence in Research Conference (UTAS Graduate 
Research). Poster presentation. Hobart, Australia. August 2011 
  
vii 
 
Abstract 
A hypertensive response to exercise (HRE) at moderate intensity is associated with an 
increased cardiovascular (CV) risk, irrespective of a normal resting BP. This is an important 
observation, as moderate intensity exercise blood pressure (BP) is akin to the condition 
experienced during normal daily life activities and may better represent a chronic BP load 
that people experience on a daily basis when compared to resting office BP. However, the 
pathophysiological mechanisms of an HRE are unclear. Therefore, the overall aim of this 
thesis was to explore the haemodynamic and biochemical (haemostatic and metabolic) 
correlates of an HRE. 
In study 1 (Chapter 4), haemodynamic and haemostatic factors were examined in 64 
participants (aged 57 ± 10 years, 71% male) with a clinical indication for exercise stress 
testing. This study showed for the first time that people with an HRE have higher blood 
levels of the von Willebrand factor (vWf; a haemostatic marker of endothelial dysfunction), 
as well as a significantly different response of vWf to exercise compared to people with 
normal exercise BP. Moreover, vWf was associated with moderate intensity exercise systolic 
BP, independent of resting office BP and other CV risk factors, whereas haemodynamic 
factors (including increased aortic stiffness) were not independently related to exercise 
systolic BP. This study suggests that haemostatic abnormalities reflecting endothelial 
dysfunction, rather than haemodynamic irregularities, may contribute to an HRE at moderate 
intensity.  
In study 2 (Chapter 5), retrospective metabolomics analysis of data collected in a clinical trial 
of people with an HRE was conducted in 115 participants (aged 55 ± 1 years, 58% male) in 
order to develop a metabolomics technique, as well as to investigate the underlying 
mechanisms of spironolactone’s action on exercise BP and other haemodynamics. This study 
showed that spironolactone reduced exercise BP, as well as aortic stiffness, via BP-dependent 
effects of canrenoate, a downstream drug metabolite of spironolactone. Importantly, this 
study also showed that a reduction in exercise BP was not associated with the decrease in 
aortic stiffness, giving further support that aortic stiffness may not be as relevant to an HRE 
as is widely believed.  
viii 
 
In study 3 (Chapter 6), untargeted metabolomics analysis was used to explore possible 
metabolic factors related to an HRE in 39 participants with type 2 diabetes mellitus (T2DM; 
62 ± 9 years; 51% male; a population with the high prevalence of an HRE) compared with 39 
non-diabetic controls (52 ± 10 years; 46% male). Metabolomics analysis demonstrated that a 
metabolic pattern of disordered carbohydrate metabolism in T2DM may be a possible 
metabolic mechanism explaining central (but not peripheral) exercise hypertension. These 
findings have clinical relevance as central haemodynamics have shown a greater 
pathophysiological importance when compared with peripheral haemodynamics. Also, 
inosine levels (a metabolite with anti-inflammatory actions) were found to be decreased in 
people with T2DM and were also inversely associated with the peripheral moderate intensity 
exercise systolic BP. This indicates that inflammation may be a contributing factor to an HRE 
in people with T2DM. 
 
This research program also involved publication of a review article on the application of 
metabolomics analysis in hypertension research (Journal of Hypertension, 2014; Chapter 2- 
Review of Literature – Part II), which will allow especially the non-experts in this field to 
better understand and interpret studies utilising metabolomics techniques. Importantly, the 
research program contained in this thesis demonstrates how metabolomics analysis could be 
used for exploring new insights into the underlying pathophysiological processes associated 
with high BP (which could be easily applied to different disease conditions). Also, the 
research projects included the development of methodology regarding metabolomics analysis 
(manuscript in submission - Appendix 2), as well as the development of a protocol for resting 
BP measurements (Journal of Human Hypertension, 2014; Appendix 1). 
 
Overall, the work contained in this thesis has found that people with an HRE have abnormal 
haemodynamics, but these do not explain exercise hypertension. However, people with an 
HRE have abnormal blood biochemistry (haemostasis and metabolic markers related to 
carbohydrate metabolism and inflammation in T2DM) and these explain exercise 
hypertension independent of resting BP and other CV risk factors. Taken altogether, this 
thesis provides novel information, and represents a significant advancement to the 
understanding of the pathophysiology of an HRE at moderate intensity. 
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Chapter 1. Introduction 
  
2 
 
Hypertension or high blood pressure (BP) is associated with adverse cardiovascular (CV) 
outcomes
1, 2
 and is a leading risk factor for global disease burden.
3
 The current 
recommendations for identifying individuals with hypertension and estimating the overall CV 
risk is based on resting office peripheral BP measurements.
4
 However, some individuals, 
despite having normal resting office peripheral BP, experience an exaggerated BP during 
exercise, a condition defined as a ‘hypertensive response to exercise’ (HRE). A recent meta-
analysis in people with a clinical indication for exercise stress testing showed that those with 
an HRE at moderate intensity (akin to the condition experienced during normal daily life 
activities) were at greater risk for CV events and mortality, independent from resting office 
peripheral BP and other CV risk factors.
5
 This may support the notion that physiological 
stress during exercise may be a useful tool to reveal CV abnormalities that fail detection by 
conventional BP screening.
6
 The mechanisms of an HRE are unclear, but may be due to 
haemodynamic, haemostatic and/or metabolic factors. The overall aim of this thesis was to 
explore the haemodynamic and biochemical (haemostatic and metabolic) correlates of an 
HRE. 
Chapter 2 – Review of Literature - Part I of this thesis provides an overview of the literature 
regarding the clinical relevance of an HRE and potential mechanisms underlying an HRE. 
Previous studies examining metabolic factors associated with high peripheral BP (rest and 
exercise) involved the detection and analysis of already known ‘targeted’ metabolites. This 
approach reduces the possibility for new discoveries. The recent development of 
metabolomics analysis has allowed the detection of a large number of unknown ‘untargeted’ 
metabolites and the potential discovery of new pathophysiological mechanisms associated 
with diseases. Metabolomics analysis has never been used before to reveal the underlying 
metabolic mechanisms of an HRE, and Chapter 5 and Chapter 6 of this thesis represent the 
first studies of this kind. Due to limited information available regarding the application of 
metabolomics analysis in hypertension research, Review of Literature – Part II represents the 
synthesis of the literature available in this field. Analytical techniques, pre-analytical steps 
and study designs used in metabolomics studies, as well as the emerging role for 
metabolomics in gaining mechanistic insights into the development of hypertension have 
been summarised. Also, suggestions as to the future directions for metabolomics research in 
the field of hypertension are proposed. This literature summary has been published as a 
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review article in the Journal of Hypertension,2014
7
 and it represents a separate presentation 
of the review of literature in this thesis.  
In Chapter 4, haemodynamic and haemostatic factors of an HRE have been examined in 64 
participants (aged 57 ± 10 years, 71% male) with a clinical indication for exercise stress 
testing. Study participants underwent CV assessment at rest and during moderate intensity 
exercise, aligning with the intensity of exercise BP shown to best predict CV events.
5
 Twenty 
participants with an HRE had higher von Willebrand factor levels (vWf; a haemostatic 
marker of endothelial dysfunction),
8
  as well as a significantly different response of vWf to 
exercise compared to people with normal exercise BP. Moreover, vWf was associated with 
exercise peripheral systolic BP, independent of resting office peripheral BP and other CV risk 
factors. Although haemodynamic factors such as aortic stiffness or exercise systemic vascular 
resistance were higher in people with an HRE and related to exercise peripheral systolic BP, 
these associations were not independent of other CV risk factors. These findings suggested 
that haemostatic abnormalities reflecting endothelial dysfunction, rather than haemodynamic 
irregularities, may contribute to an HRE.  
To investigate possible metabolic mechanisms of an HRE in an exploratory and ‘untargeted’ 
way using a metabolomics technique (applied in Chapter 5 and Chapter 6), it was first 
necessary to develop methodology regarding the metabolomics analysis. Chapter 5 represents 
a retrospective analysis of data (including haemodynamic measures and serum samples for 
metabolomics analysis) collected in a clinical trial of 115 participants with an HRE (aged 
55 ± 1 years, 58% male).9 Serum samples collected in this clinical trial were primarily used to 
develop metabolomics protocols and methodology. This clinical trial also represented a 
convenient sample to explore the metabolic actions of the aldosterone antagonist 
spironolactone on exercise BP, and other haemodynamics, in people with an HRE. 
Downstream spironolactone metabolites were identified using metabolomics techniques, and 
exercise peripheral BP (as well as aortic stiffness) was reduced by active spironolactone 
metabolite canrenoate via BP-dependent effects. Also, there was no significant relationship 
between the reduction in exercise peripheral BP and aortic stiffness by spironolactone 
treatment, giving further support that aortic stiffness is less relevant to an HRE than is widely 
believed. The results of this study were published in Metabolomics, 2014.
10
  
In Chapter 6, metabolomics analysis was used to explore the metabolic factors that may 
contribute to an HRE in a population with the high prevalence of exercise hypertension, such 
4 
 
as those with type 2 diabetes mellitus (T2DM).11 Serum samples from 39 participants with 
T2DM (62 ± 9 years; 54% female) and 39 non-diabetic controls (52 ± 10 years; 49% female) 
were analysed using untargeted metabolomics to investigate the relationships between 
metabolic profiles and haemodynamic variables measured at rest and during moderate 
intensity exercise. The metabolomics analysis demonstrated that a signature metabolic pattern 
of disordered carbohydrate metabolism in T2DM was independently associated with exercise 
central, but not peripheral, BP haemodynamic indices in patients with T2DM. These findings 
have clinical relevance as central haemodynamic indices have been shown to have greater 
pathophysiological importance compared with conventional peripheral BP indices.
12
 
Metabolic perturbations with the decreased inosine levels in people with T2DM (naturally 
occurring purine with anti-inflammatory properties) were inversely and independently 
associated with the peripheral exercise systolic BP. This may suggest that inflammation may 
be a contributing factor of an HRE in people with T2DM. 
In Appendix 1, a retrospective analysis of data collected in 250 people with treated 
hypertension (64 ± 8 years; 52% male) was conducted to define the appropriate timing 
(protocol) for resting peripheral and central BP measurements. Current guidelines for 
peripheral BP measurements recommend that office resting peripheral BP should be 
measured after five minutes of seated rest,
4
 but peripheral BP may decrease for up to 10 
minutes. This drop in peripheral BP over time may have significant implications when 
assessing BP-related risk and managing patients with hypertension. Therefore, this 
retrospective analysis of data aimed to determine the change and its clinical relevance in 
peripheral, as well as in central, BP from five to 10 minutes of seated rest. Office peripheral 
and central BP were significantly lower at 10 minutes compared with five minutes peripheral 
and central BP. But importantly, peripheral and central BP measured at 10 minutes better 
correlated with end-organ damage (left ventricular [LV] mass index), and was a better 
representative of true BP control compared to five minutes BP. Therefore, a 10 minute 
waiting period was used before the resting office peripheral and central BP was measured in 
all studies within this thesis. These findings have relevance for the appropriate diagnosis of 
hypertension, as well as the design of research studies in which resting office peripheral and 
central BP is measured. The results were published in the Journal of Human Hypertension, 
2014.
13
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Appendix 2 represents a separate study conducted in the same study population as in Chapter 
6 (people with T2DM and non-diabetic controls) to investigate a method for the 
normalisation of metabolomics data. Normalisation of serum spectral data is an important 
step in metabolomics analysis due to variations in instrument sensitivity (mass spectrometer) 
and signal intensity loss, but it is complicated by the high complexity of biases. A novel 
singular value decomposition-based normalisation method was developed through 
collaboration with Karpievitch et al.
14
 The main finding was that normalisation removed 
systematic bias from the metabolomics data and normalised values better correlated with the 
corresponding haemodynamic data. Thus, this method proved to be useful and was used for 
the metabolomics data normalisation in Chapter 6, with the details explained in Appendix 2. 
The primary analysis was conducted by Dr Karpievitch, with significant input regarding 
haemodynamic measures, study conception/design and data collection provided by the author 
of this thesis.    
Overall, this research further supports that exercise hypertension is associated with CV 
abnormalities and it represents a clinically important entity, irrespective of normal resting 
peripheral BP. People with an HRE have increased aortic stiffness and exercise systemic 
vascular resistance, but these do not explain exercise hypertension independent of resting 
peripheral BP and other CV risk markers. However, people with an HRE have abnormal 
blood biochemistry (haemostasis, lipids, metabolic markers related to carbohydrate 
metabolism and inflammation in T2DM) and these explain exercise hypertension independent 
of resting peripheral BP and other CV risk factors. The research program contained in this 
thesis also highlights the emerging role of metabolomics analysis for exploring new insights 
into the underlying pathophysiological processes associated with high BP. 
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Chapter 2. Review of Literature   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter includes two sections: Part I reviews the clinical importance and proposed 
mechanisms of a hypertensive response to exercise; Part II contains a review article that has 
been published in the Journal of Hypertension, 2014, and includes a synthesis of the literature 
on the application of metabolomics analysis in hypertension research. Metabolomics analysis 
is used in two studies within this thesis to reveal the underlying metabolic contributors of a 
hypertensive response to exercise.   
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2.1 Part I. Hypertensive response to exercise: reviewing the clinical 
importance and physiology 
2.1.1 Hypertension and cardiovascular risk 
Hypertension or high blood pressure (BP) is associated with adverse cardiovascular (CV) 
outcomes, including myocardial infarction, stroke, kidney disease and death
1, 2
 (Figure 2.1), 
and is a leading risk factor for global disease burden.
3
 There are approximately one billion 
individuals with hypertension worldwide, with an annual death rate associated with the 
disease of around seven million people.
15
 In 2003, up to 29% of the adult population in 
Australia were diagnosed with hypertension.
16
 Due to the increasing prevalence of 
contributing factors of hypertension including obesity, unhealthy diet and physical inactivity, 
the number of people with hypertension is predicted to rise, and is estimated that the total 
number of hypertensive individuals in 2025 will reach approximately 1.56 billion 
worldwide.
17
 The pathogenesis of hypertension is greatly influenced by genetic, lifestyle and 
environmental factors, but the exact underlying pathophysiological mechanisms of the 
development of hypertension are still unclear, except in only a small number of cases such as 
in those with renovascular disease, aldosteronism or over-activity of the sympathetic nervous 
system.
18
  
 
Figure 2.1 The association of systolic BP (left) and diastolic BP (right) with mortality due to 
stroke in each age category increasing by decade.
2
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The general recommendation for identifying individuals with hypertension is based on resting 
office peripheral BP measurements, usually taken in a clinical environment.
4
 However, this 
conventional type of BP measurement has some limitations that may interfere with the 
correct diagnosis of hypertension and estimation of the overall CV risk. Relying solely on 
resting office peripheral BP may lead to the incorrect diagnosis of hypertension in individuals 
who have white coat hypertension or ‘isolated clinic hypertension’.19 More importantly, 
office peripheral BP measurement may miss a significant number of people who have normal 
resting office peripheral BP, but who are hypertensive ‘out-of-office’ or during normal daily 
life activities.
20
 It appears that these individuals have uncontrolled BP that is not easily 
identified at rest. These individuals have masked hypertension and have almost equal CV risk 
to those having sustained hypertension.
21
 If we consider the high prevalence of masked 
hypertension in the general community (up to 19%),
22
 the consideration of other means of BP 
measures including out-of-office BP, or even exercise BP as recently suggested,
6
 may be 
important in identifying these individuals at higher risk and appropriately evaluating their 
‘true BP’.23  
2.1.2 A hypertensive response to exercise – definition and prevalence  
Irrespective of apparently normal resting office peripheral BP, some people may have 
exaggerated peripheral BP during exercise, a condition defined as a ‘hypertensive response to 
exercise’ (HRE). Although there is no specific threshold to define an HRE, most studies have 
widely used values of peripheral systolic BP exceeding the 90
th
 to 95
th
 percentile of the 
studied population
24
 or in most cases a systolic BP of ≥ 210 mmHg for men and ≥ 190 mmHg 
for women.
25, 26
 Due to the inconsistent definition of an HRE and different study populations 
examined, the prevalence of an HRE varies between studies. A prevalence of 3% to 4% 
across most of cohort-based studies was identified in a recent systematic review, from which 
one third had normal resting peripheral BP.
27
 However, the prevalence of an HRE in a cohort 
of consecutive 2216 men and 1229 women with known or suspected coronary artery disease 
referred for exercise stress testing was 39% (a total of 1319 individuals).
28
 An HRE is also 
highly prevalent in people with type 2 diabetes mellitus (T2DM), reported to be more than 
50% of the studied population.
11
 Given the high prevalence of an HRE in people with masked 
hypertension (up to 58%),
29
 exercise BP may be a useful tool to identify individuals with 
masked hypertension or to ‘unmask’ those with uncontrolled BP.6 
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2.1.3 The prognostic significance of a hypertensive response to exercise 
There is a growing evidence that BP recorded during exercise may be more useful than 
conventional office resting BP measurements with respect to determining an individual’s risk 
related to BP.
5, 30
 To determine the prognostic significance of an HRE, Allison et al
24
 
conducted a follow-up study in 150 healthy, normotensive individuals with exercise systolic 
BP over 90
th
 percentile (equating to ≥ 214 mmHg) and 150 age- and gender-matched subjects 
with normal BP response to exercise. Investigators found that exaggerated exercise systolic 
BP was a significant independent predictor of total CV events and future onset of essential 
hypertension, suggesting that an HRE carries an additional CV risk irrespective of normal 
resting office BP.
24
 Similarly, in a study of Kohl et al
31
 maximal exercise systolic BP of 
20387 men and 6234 women followed-up for an average of 8.1 years was associated with the 
increased risk of all-cause, CV and coronary heart disease mortality. Relative risk of CV 
mortality increased with the increase in exercise systolic BP and the change in systolic BP 
from rest to exercise was associated with total, CV and non-CV mortality in the study of 
Filipovsky et al.
32
 A population-based follow-up study in 1731 middle-aged men without 
prior history of coronary heart disease showed that exercise systolic BP ≥ 230 mmHg was 
associated with a 2.47 fold risk of acute myocardial infarction, even after adjustment for 
resting systolic BP and other CV risk factors.
33
  
2.1.4 A hypertensive response to exercise at moderate intensity 
Exercise BP in previous studies was measured during both moderate and maximal exercise 
intensity. However, the prognostic value of maximal exercise BP for predicting adverse CV 
outcomes is less consistent and less powerful when compared to moderate intensity exercise 
BP. Indeed, an increase of 10 mmHg in moderate intensity exercise systolic BP recorded 
during stage 2 Bruce protocol had a stronger association with the risk of CV mortality than 
systolic BP measured at maximal exercise intensity.
34
 A follow-up study in 1999 apparently 
healthy individuals that performed a bicycle ergometer exercise test at baseline and were 
followed for 21 years demonstrated that exercise systolic BP taken at an early moderate 
workload provided independent prognostic information on CV mortality, whereas maximal 
exercise systolic BP failed to show this independent association.
35
  
Schultz et al
5
 have recently conducted a systematic review and meta-analysis to investigate 
the prognostic value of exercise systolic BP at maximal and moderate intensity exercise in 
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people with a clinical indication for exercise stress testing. The authors found that an HRE at 
moderate intensity, but not maximal, was associated with a 36% increased risk of CV events 
and mortality when compared to those having a normotensive BP response to exercise, 
independently of resting office BP (Figure 2.2).
5
 An increase of 10 mmHg in moderate 
intensity exercise systolic BP was associated with a 4% increased risk for CV events and 
mortality.
5
 The stronger association of moderate intensity exercise may partially be attributed 
to difficulties associated with measuring BP especially during maximal intensity exercise BP 
due to movement artefacts and measurement errors.  
 
Figure 2.2 Forest plots for categorical exercise BP (maximal and moderate intensity) 
Pooled hazard ratio (95% confidence intervals) of an HRE at moderate and maximal intensity 
for predicting CV outcomes after adjusting for resting BP and other CV risk factors. 
Moderate intensity: p = 0.039, I
2 
= 51.8%; maximal intensity: p = 0.118, I
2
 = 65.0%.
5
 
Besides having the higher prognostic values compared to maximal intensity exercise systolic 
BP, moderate intensity exercise systolic BP may also have an important clinical significance. 
Exercise BP at moderate intensity is akin to the ambulatory condition experienced during 
normal daily life activities. As people spend most of a day in ambulatory condition, moderate 
intensity exercise BP may represent a chronic BP load that people experience on a daily basis 
and may provide better representation of an individual’s true BP when compared to resting or 
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maximal exercise BP.
6
 Nevertheless, the underlying pathophysiological mechanisms that link 
an exaggerated moderate intensity exercise BP and adverse CV outcomes are still unclear.  
2.1.5 Central haemodynamics and exercise  
Although current recommendations for identifying individuals with hypertension and 
increased CV risk is based on peripheral BP measurements, recent research findings have 
placed an emphasis on central BP, the pressure to which the vital organs (heart, brain and 
kidneys) are directly exposed. It has been shown that central haemodynamic indices 
(including augmentation index [AIx]; a marker of left ventricular afterload) predict CV 
events independently of brachial BP.
12
 Therefore, measuring central BP (at rest and during 
exercise) may add clinically relevant information to the overall assessment of CV risk 
associated with hypertension. However, central BP may not be truly represented by BP 
measured at the periphery,
36
 as peripheral systolic BP is not the same as central systolic BP, 
due to pulse pressure (PP) amplification from large central elastic arteries towards the 
smaller, more muscular peripheral arteries (Figure 2.3).
37
 Indeed, central systolic BP is 
normally lower than brachial systolic BP (up to 30 mmHg), and this difference is highly 
variable between individuals even with similar brachial systolic BP.
38-40
  With advancing age 
or CV diseases, the central large arteries undergo changes and become stiffer, due to a greater 
recruitment of collagen fibres, resulting in an increase in BP in the predominantly central 
arteries when compared to peripheral, and a decrease in PP amplification.
41
 
 
Figure 2.3 Pulse pressure amplification 
The amplitude of the pressure wave and systolic BP (the highest point of the pressure wave) 
increases as the pressure wave propagates away from the large central arteries towards the 
smaller, peripheral muscular arteries.  
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The role of exercise central BP has been rarely investigated. Invasive measurements of 
central BP during exercise demonstrated that central systolic BP increases to a lesser extent 
than peripheral systolic BP, leading to the increased PP amplification.
42, 43
 Indeed, a study of 
Sharman et al
44
 showed that PP amplification increased from rest to moderate intensity 
exercise in healthy individuals.
44
 However, in older individuals with hypercholesterolemia 
and increased CV risk, the PP amplification is blunted due to a higher central systolic BP 
relative to peripheral systolic BP when compared to healthy controls.
45
 These finding also 
support the fact that risk related to BP may be more evident from moderate intensity exercise 
central BP, rather than resting peripheral BP. Central BP can be readily estimated via a non-
invasive measurement of the radial pulse, in a technique that is both valid and reproducible at 
rest and during exercise.
46-49
 Future research should be directed towards gaining further 
insight into the pathophysiological role of central BP during exercise, as this may likely add 
significant information to the clinical understanding of an HRE. 
2.1.6 Mechanisms of a hypertensive response to exercise  
Normal physiological response to exercise 
With exercise onset, the metabolic needs of skeletal muscles increase which requires the body 
to simultaneously coordinate multiple physiological responses in order to meet this demand 
and maintain blood flow to vital organs, such as heart and brain.
27
 Heart rate and cardiac 
output rise as a result of elevated sympathetic activity, and blood flow is diverted from low-
priority vascular areas to the activated muscles.
27
 An increase in peripheral vascular dilatation 
allows blood to be supplied to the periphery which consequently decreases the systemic 
vascular resistance.
27
 As workload of exercise increases, the rise in cardiac output 
predominates over the decrease in systemic vascular resistance leading to an elevation of 
mean arterial pressure by approximately 40%.
27
 Systolic BP raises gradually with exercise 
intensity, whereas diastolic BP goes down slightly.
27
 However, in some cases, exercise 
systolic BP increases excessively, although the underlying pathophysiological mechanisms of 
this rise are unclear.
27
 This excessive rise in exercise BP (irrespective of normal BP at rest) is 
associated with adverse CV outcomes (as previously described), and as such, the BP response 
to exercise may help reveal CV abnormalities that are not otherwise detected at rest.
6
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Haemodynamic contributors to a hypertensive response to exercise 
Although the mechanisms of an HRE remain unclear, abnormalities in haemodynamics 
(which represent BP and flow within the arterial system) are thought to play a key role. 
Appropriate vascular function is essential in maintaining BP, especially during exercise. 
Previous studies have suggested that possible causative factors of an HRE might be increased 
large arterial stiffness, as this may fail to buffer the rise in BP that will occur with increased 
cardiac output and blood flow during exercise.
50
 Indeed, increased aortic stiffness (as 
measured by carotid-to-femoral pulse wave velocity; PWV) has been shown to be 
significantly associated with moderate intensity exercise systolic BP in Framingham 
Offspring cohort study in 2115 participants even after adjusting for known CV risk factors.
50
 
Tsioufis et al
51
 also found a significant positive association between aortic stiffness 
(measured by the same method) and maximal exercise systolic BP, although study 
participants included those with established essential hypertension, which may have 
influenced the results. Increased aortic stiffness may also lead to raised central BP and left 
ventricular (LV) afterload, and ultimately affect cardiac structural and functional 
characteristics.
11, 25
 A cross-sectional study showed that people with an HRE have a higher 
prevalence of LV hypertrophy and diastolic dysfunction than those with normal systolic BP 
during exercise.
52
 
Aortic PWV is an independent predictor of CV risk, observed in different populations, 
including people with hypertension, T2DM, and in older adults.
53
 The prognostic importance 
of aortic PWV is most likely reflected by being a measure of the effect of different CV risk 
factors (including aging and high BP) on the arterial wall. Indeed, with advancing age, 
arteries undergo major structural and functional changes, predominantly in large central and 
elastic arteries and least in muscular arteries, such as those of the upper limb.
54
 Large arteries 
become stiff and dilated due to a degeneration of elastin fibres and greater recruitment of 
inelastic collagen, progressively affecting the aortic cushioning function.
55
 Previous studies 
also reported a close association between aortic PWV and BP.
56
 It is possible that high BP 
(and its pulsatile load over time) further contributes to structural alterations within the wall, 
and increase age-related changes and arterial stiffness, leading to ‘premature arterial 
stiffening.’ Furthermore, a number of metabolic CV risk factors including dyslipidaemia, 
insulin resistance and altered carbohydrate metabolism are also associated with increased 
large artery stiffness, and this is described in more details below. Thus, arterial stiffness 
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appears to be an important marker of CV risk; and therefore, represents a potential 
therapeutic target for the prevention of increased CV morbidity and mortality. 
Aldosterone has also been implicated as an important mediator of increased arterial stiffening 
by acting through the mineralocorticoid receptors in vascular walls.
57
 Recent studies have 
indicated that BP-lowering drugs that interfere with the renin-angiotensin-aldosterone system, 
such as spironolactone, exert potentially beneficial effects on vascular structure (may prevent, 
or lessen, arterial stiffening) beyond the reduction in BP, probably due to blocking the 
adverse effects of aldosterone.
58-60
 Indeed, Edwards et al
60
 showed that 25mg of 
spironolactone daily for 40 weeks, reduced aortic stiffness (measured by aortic PWV) in 56 
patients with early-stage chronic kidney disease when compared to controls, even after 
correcting for mean BP. Aortic stiffness was also reduced by 50mg of spironolactone in 24 
previously untreated patients with essential hypertension, which remained significant after 
correcting for the reduction in mean BP.
61
 As increased aortic stiffness has been suggested as 
a possible causative factor of an HRE, a recent clinical trial has been conducted in order to 
investigate the role of aldosterone antagonism with spironolactone on the reduction in aortic 
stiffness and exercise BP in 115 subjects with an HRE. Spironolactone has been found to 
decrease aortic stiffness, as well as exercise BP in these people;
62
 however, the exact 
mechanism of its action on these haemodynamic measures remained unclear. To explore this 
in more detail, Chapter 5 of this thesis represents a retrospective analysis of data 
(haemodynamic and metabolic) collected in this clinical trial.  
Several previous studies have suggested that the condition of the peripheral vasculature (or 
endothelium function) may also significantly contribute to an HRE.
63, 64
  Failure of the 
endothelium to regulate endothelial-dependent vasoactivity, also referred as endothelial 
dysfunction, will disable peripheral vasculature to appropriately dilate and compensate for an 
increase in blood flow. An impaired capacity for exercise-induced vasodilatation will lead to 
an excessive rise in systemic vascular resistance and consequently exercise BP.
65
 Indeed, a 
study of healthy untreated subjects with high normal BP or mild hypertension showed that 
exaggerated exercise systolic BP was associated with reduced endothelial-dependent 
vasodilatation (assessed by brachial artery reactive hyperaemia).
63
 Also, flow-mediated 
vasodilation was negatively associated with exercise systolic BP at moderate intensity in a 
large community-based population cohort from the Framingham Heart Study.
50
 However, 
most of the previous studies examined the haemodynamic variables at rest to uncover the 
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underlying mechanisms of exercise hypertension. Therefore, studies contained in this thesis 
include examination of haemodynamics measured during resting and exercise conditions.  
Arterial stiffness has been traditionally viewed as a measure of vessel wall structural 
elements and mean BP. However, the increasing body of evidence suggest that arterial 
stiffness is also regulated by the vascular endothelium,
66-69
 and these two should not be 
studied independently. Indeed, besides the distribution of elastic and collagen fibres that 
change with arterial ‘aging’,55 arterial walls also have a layer of smooth muscle cells that can 
be modified by a number of vasoactive modulators including nitric oxide. The changes in 
nitric oxide levels may alter vascular smooth muscle tone and potentially regulate arterial 
stiffness.
70
 Endothelial dysfunction is generally characterized by the reduction in nitric oxide 
bioavailability, and numerous studies utilizing therapeutic interventions to improve 
endothelial function (or nitric oxide bioavailability) also demonstrated the reduction in 
arterial stiffness. A glyceryl trinitrate (drug metabolized to nitric oxide within the vascular 
wall) reduced brachial artery stiffness
66
 and decreased the AIx,
68
 a composite measure of 
arterial stiffness, without any effects on mean BP in humans. Furthermore, intra-arterial 
infusion of glycerol trinitrate also decreased PWV in the common iliac artery in sheep, 
without any observed changes in mean BP,
67
 whereas intra-arterial infusion of the nitric oxide 
synthase inhibitor (N
G
-monomethyl-L-arginine) increased brachial artery compliance.
69
 
Together, this data suggests that nitric oxide may act to reduce large artery stiffness, 
independent from BP changes. Therefore, therapeutic intervention aimed at increasing the 
nitric oxide bioavailability may potentially be useful in conditions associated with endothelial 
dysfunction, as well as increased arterial stiffening, such as an HRE. 
The potential relation of haemostatic factors with an HRE 
Haemostasis represents the body’s physiological system that involves an integrated effort 
between platelets, vascular endothelial cells and haemostatic clotting factors to ensure normal 
blood fluidity and blood vessel integrity. Under normal physiological conditions, the vascular 
endothelium plays a crucial role in regulating normal haemostasis by expressing various 
membrane molecules and synthesising/releasing a spectrum of regulatory (procoagulant and 
anticoagulant) substances of coagulation. The endothelium is constantly exposed to different 
CV risk factors (e.g. high shear pressure, hyperglycaemia, dyslipidaemia, inflammation), and 
under pathological conditions, a delicate balance of endothelium-derived factors may be 
disturbed in favour of procoagulant substances. Furthermore, sub-endothelial cells in vascular 
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vessel walls (e.g. smooth muscle cells) express haemostatic markers, including tissue factor 
(TF)
71
 leading to the rapid initiation of the coagulation cascade and an increase in markers of 
thrombin generation when the vessel walls are damaged. Indeed, it has been suggested that 
high BP confers a prothrombotic state, which may have considerable importance in the 
pathogenesis of target-organ damage and CV disease.
72
 Abnormalities of haemostasis, 
characterised by endothelial dysfunction and an activation of procoagulant haemostatic 
markers, including TF,
73-75
 are present in hypertension and are related to target organ damage 
and adverse CV prognosis.
76-78
  
Von Willebrand factor (vWf) is a pro-coagulant haemostatic marker synthesized/stored in 
endothelial cells with an important role in mediating platelet aggregation and adhesion to the 
vascular endothelium.
79
 Since vWf is released into the circulation by secretion from 
endothelial cells when cells are damaged, the concentrations of vWf has been proposed as an 
indicator of endothelial damage or dysfunction.
79
 Increased plasma vWf levels may lead to 
thrombin generation and eventually adverse CV events. It has been demonstrated that people 
with hypertension (a state of endothelial dysfunction)
80
 have increased vWf levels that are 
positively associated with both systolic and diastolic BP.
8
 Also, elevated plasma vWf levels 
are associated with CV events in the general population,
8, 81
 as well as in those with 
established CV disease.
82
 Given that an HRE is also a state of endothelial dysfunction,
63
 this 
may suggest that vWf levels may also be raised in people with an HRE. In support of this 
statement, Lee et al
83
 have found that vWf was increased in people with high ambulatory BP 
indices measured during normal daily-life activities (akin to moderate intensity exercise) in 
73 patients with stable coronary artery disease, even after adjustment for mean BP. Therefore, 
endothelial dysfunction may represent a platform on which impaired haemostasis might be 
contributing to an HRE and associated CV complications.  
Other haemostatic markers, such as fibrinogen (an acute phase haemostatic marker that is 
converted to insoluble fibrin during the clotting process) has also been found to be elevated in 
people with high BP (rest and ambulatory)
83, 84
 and significantly associated with the presence 
of hypertension-related target organ damage.
85
 Importantly, fibrinogen is highly predictive of 
CV risk progression,
77
 where fibrinogen levels over 3.5 g/L were reported to be associated 
with a 12-fold higher CV risk than those with normal levels.
86
 Whilst there are few studies 
exploring haemostatic markers in people with an HRE, better understanding of potential 
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haemostatic abnormalities in this population would provide a significant advance in 
knowledge regarding HRE development and its associated CV risk. 
Metabolic influences to a hypertensive response to exercise 
An HRE is associated with various metabolic CV risk factors including increased total 
cholesterol and triglyceride levels. The Framingham Offspring cohort study of 2115 
participants has demonstrated that the total cholesterol-to-high-density cholesterol ratio was 
independently associated with moderate intensity exercise systolic BP in multiple regression 
analysis, independent of other CV risk factors.
50
 Men with high levels of total cholesterol had 
significantly higher levels of mean BP during exercise than age-matched men with normal 
total cholesterol levels in the study of Sharman et al.
45
 Also, increased triglyceride levels 
were significantly associated with central exercise systolic BP.
78
 Some of the mechanisms 
proposed for these associations include the effects of lipids on the arterial wall leading to 
arterial stiffening.
87
 However, a recent systematic review failed to show these strong 
associations between aortic stiffness and lipids.
56
 On the other hand, dyslipidaemia is also 
associated with endothelial dysfunction and reduced nitric oxide bioavailability.
88
 This has 
been evidenced by impaired endothelium-dependent vasodilatation of forearm resistance 
vessels in response to acetylcholine in patients with hypercholesterolemia
88
 as well as 
hypertriglyceridemia
89
 compared with controls.  
Insulin resistance and altered carbohydrate metabolism may be involved in haemodynamic 
abnormalities that lead to an HRE, given the high prevalence of an HRE in people with 
T2DM.
11
 Indeed, insulin resistance assessed by HOMRIR (homeostasis model of insulin 
resistance) index was found to be significantly higher in subjects with an HRE and 
independently related to the magnitude of elevation in systolic BP from rest to exercise, even 
after adjusting for age, sex, body mass index and resting systolic BP.
90
 Insulin is a vasodilator 
of peripheral resistance arteries due to stimulation of endothelial nitric oxide synthesis.
91
 In 
the presence of insulin resistance, endothelial vasodilatation is impaired leading to increased 
peripheral vascular resistance and increased BP.  
The large Hoorn Study
92
 reported reduced compliance of large arteries in individuals with 
impaired glucose metabolism compared to non-diabetic controls, suggesting that changes in 
vascular structure may occur even before the onset of T2DM.
92
 Cameron et al
93
 reported 
higher values of PWV in all segments of large arteries in individuals with T2DM compared 
with non-diabetic age-matched controls,
93
 most likely due to formation of advanced glycation 
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end-products by non-enzymatic crosslinks between sugars and amino acids.
94
 These 
alterations in vascular structure may possibly lead to increased large artery stiffness, although 
the strength of the association between arterial stiffness and the presence of T2DM has 
recently been found to be rather weak.
56
 Hyperglycaemia may also cause increased 
production of oxidative reactive species and lead to a generalized state of increased oxidative 
stress,
95
 which can further damage vascular wall properties. Nevertheless, the underlying 
mechanisms linking the high prevalence of an HRE in people with T2DM are still unclear. 
2.1.7 Metabolomics profiling - potential for new discoveries   
Previous studies examining the metabolic abnormalities associated with high BP involved the 
detection and analysis of already known ‘targeted’ metabolites (e.g. triglycerides, total 
cholesterol). In recent years, development of analytical techniques and bioinformatics has 
allowed the ‘untargeted’ systematic detection of 100s to 1000s of low-molecular weight 
metabolites in a single sample and this new approach, called metabolomics profiling, is an 
ideal platform for new discoveries, as it may provide a metabolic ‘fingerprints’ for different 
disease states.
96
 Since metabolic irregularities appear to play a significant part in abnormal 
BP control and also occur even before appreciable increases in office resting BP are 
recognised, metabolomics has increasingly been used in hypertension research to gain 
mechanistic insights into hypertension development.  
Importantly, no study has conducted metabolomics profiling in people with an HRE, and it 
appears that metabolomics analysis may have potential for uncovering the mechanisms of this 
condition. Indeed, metabolomics profiling or mapping of all endogenous metabolites in 
individuals with an HRE and their healthy-matched controls, and identifying metabolites (and 
associated metabolic pathways) that discriminate these two groups may provide unique 
information on underlying mechanisms of an HRE. This type of analysis is able to identify 
completely novel metabolites associated with the disease, and is ideal for discovery-based 
investigations. Since an HRE may represent a ‘warning signal’ of uncontrolled BP,6 
identified new metabolic perturbations of an HRE may elucidate early stage development of 
essential hypertension and these discoveries would represent a major clinical advance. 
Metabolomics-based studies in an HRE population, however, should also include a 
comprehensive haemodynamic assessment of BP (rest and exercise), alongside measures of 
arterial stiffness, endothelial dysfunction, as well as haemostatic markers, in order to provide 
a broad picture of possible mechanisms of an HRE. 
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Metabolomics analysis in hypertension research is still in its early stages. Previous 
metabolomics studies in hypertension research have had many limitations, including a poor 
characterisation of the hypertensive phenotype (e.g. relying solely on office resting BP 
measurements) which may have led to spurious results and inappropriate conclusions. Being 
a powerful technique for new discoveries and due to the limited information available 
regarding the application of metabolomics analysis in the hypertension research, Review of 
Literature – Part II represents the synthesis of the literature available in this field. This 
literature summary has been published as a review article in the Journal of Hypertension, 
2014 and it is included as a separate part of the review of literature.   
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2.2 Part II. Metabolomics in hypertension 
2.2.1 Abstract 
Hypertension is the most prevalent chronic medical condition and a major risk factor for 
cardiovascular (CV) morbidity and mortality. In the majority of hypertensive cases, the 
underlying cause of hypertension cannot be easily identified due to the heterogeneous, 
polygenic and multifactorial nature of hypertension. Metabolomics is a relatively new field of 
research that has been used to evaluate metabolic perturbations associated with disease, 
identify disease biomarkers and to both assess and predict drug safety and efficacy. 
Metabolomics has been increasingly used to characterise risk factors for CV disease, 
including hypertension, and appears to have significant potential for uncovering mechanisms 
of this complex disease. This review details the analytical techniques, pre-analytical steps and 
study designs used in metabolomics studies, as well as the emerging role for metabolomics in 
gaining mechanistic insights into the development of hypertension. Suggestions as to the 
future direction for metabolomics research in the field of hypertension are also proposed.  
 
 
 
 
 
 
 
 
 
 
 
Review of Literature - Part II has been previously published: 
Nikolic SB, Sharman JE, Adams MJ, Edwards LM. Metabolomics in hypertension. 
J Hypertens. 2014; 32:1159-1169  
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2.2.2 Introduction 
Hypertension is a complex, multifactorial disease that has a significant positive association 
with adverse cardiovascular (CV) outcomes, including myocardial infarction, stroke, kidney 
disease and death.
1, 2
 There are approximately one billion individuals with hypertension 
worldwide, with an annual death rate associated with the disease of around seven million 
people.
15
 Hypertension can occur as a consequence of renovascular disease, renal failure, 
aldosteronism or over-activity of the sympathetic nervous system, but these forms of 
hypertension account for only a small number of cases.
18
 In the majority of cases 
hypertension occurs without evidence of other disease. Although the pathogenesis of 
hypertension is greatly influenced by genetic, lifestyle and environmental factors, the 
underlying physiological and metabolic drivers remain to be fully elucidated. 
The traditional method for identifying hypertension is via blood pressure (BP) measurements 
at the upper arm, usually taken in a clinic environment.
97
 However, pathophysiological 
changes may occur during the development of hypertension before appreciable increases in 
clinic upper arm BP are recognised.
98
 The identification of these early perturbations - whether 
physiological or biochemical - is expected to lead to a better understanding of the 
pathogenesis of hypertension and, consequently, new opportunities for the development of 
novel therapies and improved diagnostic methods.   
In recent years, technical developments have allowed the unbiased detection, identification 
and semi-quantification of an increasing range of low-molecular weight compounds 
(metabolites) that are present within cells, tissues, and body fluids.
96
 This component of 
systems biology called metabolomics (i.e. the study of the metabolic phenotype or 
metabolome) is often thought to have emerged quite recently (following genomics, 
transcriptomics and proteomics);
99
 however, its true roots emerged some decades ago.
100
 
Since metabolites represent the final products of cellular processes including genes, mRNA, 
protein activity and bidirectional, complex interactions between these system biology 
components,
101
 metabolomics offers an unique view of the metabolic phenotype and 
phenotypic perturbations associated with diseases as well as the influence of environmental 
factors (e.g. diet, activity, behaviour, disease and medical/surgical treatment).
102-104
 To date, 
however, relatively few studies have employed metabolomics in the study of hypertension in 
animals or humans.
10, 105-114
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In this review, the analytical tools, pre-analytical steps and study designs used in 
metabolomics studies are described, and the challenges associated with metabolomics 
analysis are appraised. It is also discussed how metabolomics has been used to study 
hypertension in animals and humans, provided insights into the potential benefits that this 
approach offers, and proposed future directions in hypertension metabolomics research.  
2.2.3 Metabolomics: analytical tools, preanalytical steps and study design 
Analytical tools 
Current estimates suggest that the human metabolome comprises many thousands of small 
molecules, both confirmed
115
 and predicted.
116
 However, unlike DNA or peptide chains, 
where information is encoded via repeating patterns of relatively uniform chemical subunits, 
the information contained within the metabolome is intrinsic to the metabolites themselves. 
Metabolites vary profoundly in polarity, size and concentration (e.g. µmol/L, nmol/L, 
pmol/L), ranging from hydrophilic, polar metabolites with a low molecular weight (e.g. 
amino acids) to hydrophobic, non-polar high molecular weight metabolites (e.g. lipids). This 
diversity means that the unbiased detection, identification and quantification of the entire 
metabolome is extremely technically challenging.
117
 Indeed, there is currently no single 
analytical approach that can detect or quantify all metabolites present in human samples. 
However, multiple analytical techniques have been employed to provide complementary 
coverage of a range of metabolites with considerable success.
118
 The combination of nuclear 
magnetic resonance (NMR) spectroscopy with mass spectrometry (MS) has proven 
particularly effective and has, therefore, gained increasing popularity.
119
  
The principle of NMR spectroscopy is that atomic nuclei with nonzero spin (a quantum 
property corresponding to angular momentum), when placed in a powerful magnetic field and 
irradiated with radiofrequency waves, emit a characteristic radiofrequency signal as they 
relax from the induced state and return to equilibrium.
120
 This signal is a rich source of 
information regarding the composition of the irradiated sample, including data regarding 
chemical structure and abundance.
120
 NMR spectroscopy is quantitative in nature and offers 
precise structural information that enables relatively easy metabolite identification.
96
 
Furthermore, this technique is not destructive (i.e. samples can be re-used many times) and 
does not require extensive sample preparation.
120
 However, it is somewhat disadvantaged by 
relatively low analytical sensitivity that allows only the detection of high abundance 
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metabolites (concentration of 100 nmol/L to 1 µmol/L or higher; with usually less than 100 
metabolites in a human sample).
96, 120
 Furthermore, typical one-dimensional NMR results in 
complex metabolite profiles with many signals lying close to, or directly on top of each other, 
such that low abundance metabolites can be masked by high abundance metabolites with a 
similar or identical chemical shift (a technical term for the ‘frequency’ of an NMR signal). 
Sophisticated and expensive solutions to this latter problem exist, including two-dimensional 
NMR spectroscopy and hyphenated methods such as liquid chromatography–NMR (LC-
NMR). However, complex biological matrices can also be simplified using cost-effective, 
traditional analytical preparations prior to analysis (e.g. solid-phase extraction or the use of 
organic solvents to separate hydrophobic and hydrophilic metabolites). 
Mass spectrometry, coupled with separation techniques such as LC or gas chromatography 
(GC), has a higher sensitivity than NMR spectroscopy, and has the potential to detect a 
significant number of very low abundance metabolites (as low as 1 pmol/L).
121
 The initial 
chromatography step, coupled with the extremely high resolution of modern instruments, 
such as ThermoFisher’s Orbitrap, means that thousands of species can be resolved in a single 
experiment. In MS, molecules are charged or ionized in the ionization process, and these 
charged molecules and their fragments are separated according to their mass-to-charge 
ratio.
121
 In metabolomics experiments, where ions only rarely carry a charge greater than one, 
the mass-to-charge ratio is equivalent to their mass. Multiple ionization techniques have been 
used in efforts to increase the number of detected metabolites, with some doubling the 
number of detected metabolic features (e.g. electrospray ionization in both positive (+) and 
negative (-) ionization modes).
122
 However, even though it is possible to resolve many 
thousands of signals in a single experiment using such sophisticated MS techniques, their 
unambiguous assignment and identification still represents a significant bioinformatics (and 
experimental) challenge and one that is difficult, slow and can only be partially resolved.
123
 
For a metabolite to be positively identified, a number of orthogonal parameters such as 
accurate mass, isotope abundance pattern, retention time and/or MS/MS spectrum should 
match with those of a purified standard under identical conditions.
123, 124
 Clearly this is not 
plausible for more than a few dozen metabolites. Thus, it is currently broadly accepted that 
metabolites must be ‘putatively annotated’ unless their unambiguous annotation is absolutely 
necessary. This specific use of language (e.g. ‘putative annotation’) has been recommended 
by the Metabolomics Standards Initiative.
124
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An alternative approach to metabolomics using MS is to develop a ‘targeted’ protocol, in 
which metabolites are unambiguously identified in pilot experiments and methods for their 
quantitation are developed in parallel. In subsequent experiments, only these targeted 
metabolites are measured. This approach can yield quantitative information on hundreds of 
polar and thousands of lipid species in a single run and is immediately attractive (more lipids 
can be measured simultaneously because they have repeating structural motifs similar to 
proteins). There are two disadvantages to this approach. First, metabolites that are not 
targeted are not detected, reducing discovery opportunities. Second, a major development 
effort is required in each laboratory before the technique can be used. The second remains a 
major hurdle to many; the first is being addressed through the use of ‘hybrid’ protocols.125 
Another general limitation of MS is its low reproducibility compared with NMR. Retention 
times and signal intensity are sample- and instrument-dependent, thus requiring the use of 
carefully standardized sample handling and the judicious use of internal standards and/or 
quality control (QC) samples in each analytical run to provide robust quality assurance.
124
 
Yet despite these limitations, MS-based metabolomics represents the method of choice for 
those seeking data on low abundance metabolites or resolution of large numbers of 
metabolites simultaneously – situations where NMR is poorly suited.124, 126 Given their 
respective strengths and weaknesses, (summarised in Figure 2.4) the complementary and 
simultaneous use of NMR and MS supplies excellent depth and breadth of metabolome 
coverage.  
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Figure 2.4 Strengths and weaknesses of nuclear magnetic resonance spectroscopy and mass spectrometry. 
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Pre-analytical steps 
Selection of sample types. A huge range of biological samples have been used for 
metabolomics studies each providing different information and each with particular strengths 
and weaknesses (Table 2.1). These include extracellular fluids (e.g. blood, urine, 
cerebrospinal fluid, saliva), tissue extracts from biopsies, or cell extracts (e.g. from primary 
cultures). The selection of sample source is largely dependent on the study question and 
sample availability.
121
 The most frequently used samples in human metabolomics studies are 
blood and urine. This is due to the relative easy and minimally invasive nature of collection 
alongside the widely-held belief that these samples can provide a metabolic overview or 
‘footprint’ of a biological system as a whole.127 These sample types are commonly described 
as ‘integrative body fluids’ and represent the net metabolic outflow and uptake of every tissue 
and organ in the body (and renal function and glomerular filtration, in the case of urine).
127
 
Nevertheless, these samples may not accurately reflect pathophysiological changes in specific 
tissues or cells that could still have important implications in many disease states, including 
hypertension. For instance, local tissue renin-angiotensin systems (RAS) that are believed to 
play a role in systemic BP control 
128
 may not mediate changes in tissue metabolite exchange 
at a level that could be detected in serum by current methods. In this case, tissue samples may 
provide valuable additional information; however, biopsies present ethical and technical 
challenges that can be difficult to meet.
129
 For example, metabolites that are substrates for 
enzymes with rapid turnover rates may be significantly degraded in the time taken to extract a 
biopsy and freeze it.
130
 In addition, many tissues are compositionally heterogeneous (e.g. 
skeletal muscle is a mix of myocytes, fibroblasts, adipocytes and satellite cells); this 
complicates interpretation of the metabolic profile.
129
 One strategy to address this is to 
establish primary cultures of specific cell types from biopsies and profile these.  
Sample acquisition and sample handling. Different sample acquisition and subsequent 
handling can introduce systematic bias into data that may consequently interfere with the 
metabolomics analysis and possibly produce false discoveries. The process of sampling (e.g. 
invasive vs. non-invasive techniques) may produce different metabolic patterns as it has been 
shown that invasive techniques such as venepuncture may increase blood levels of 
catecholamine due to subject’s anxiety or fear of needles.131 Many studies have also reported 
the influence of diurnal variations (daytime vs. night-time) on metabolite profiles, and hence, 
the sampling time should be consistent; particularly in longitudinal investigations.
106
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Consumption of a standard diet before the sample collection may also reduce the inter-
subjects variations, as differences in diet may cause metabolic changes (especially in urine 
metabolites) that may be difficult to differentiate from normal physiological variations.
132
 
Table 2.1 Strengths and weaknesses of example sample types used in metabolomics analysis 
  Strengths Weaknesses 
Blood  Provides a metabolic overview or 
‘footprint’ of a biological system 
as a whole.  
Easy, minimally invasive sample 
collection.  
Reflects changes in tissue 
metabolism almost immediately. 
 
Requires deproteination for mass 
spectrometry. 
May not reflect tissue-level changes. 
Changes in intra/inter-tissue metabolite 
flux may not appear.  
Urine Provides a metabolic overview or 
‘footprint’ of a biological system 
as a whole.  
Easy, non-invasive sample 
collection. 
Less complex biological fluid 
composition compared to blood (at 
least in healthy subjects). 
Represents a period of several hours of 
systemic metabolism, so not able to 
provide metabolic information at smaller 
timescales. 
Contains high urea concentrations 
harmful to GC-MS instrumentation.  
Can contain protein in diseased 
individuals which can interfere with 
analysis. 
Variable pH a challenge for NMR 
analysis. 
 
Tissue Provides highly selective 
metabolite information. 
Technically demanding, time consuming 
and expensive sample collection. 
Complex and experimentally difficult 
metabolite extraction. 
Usually more than 20 mg of tissue is 
required. 
Delays in quenching metabolism can 
significantly affect results. 
 
Primary 
cell 
culture 
Homogeneous. 
Can be subjected to further 
experimentation. 
Phenotype can depart from host. 
Sufficient quantity of cell material for 
NMR can be challenging. 
Blood requires an additional step of preparation to allow separation of serum or plasma which 
is recognised as one of the major sources of pre-analytical variation in blood-based 
metabolomics studies. The selection of tubes containing appropriate anticoagulants (lithium 
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heparin, potassium ethylenediamine-tetra-acetic acid-EDTA and citrate) for plasma collection 
is vital as these substances differently affect detection of endogenous metabolites.
133
 Citrate 
and EDTA produce various large peaks in the NMR spectrum that selectively mask smaller 
endogenous metabolite peaks and inhibit information recovery in downstream metabolomics 
analysis.
133
 However, lithium heparin (recommended for plasma collection) produces only a 
weak and broad peak (from polysaccharide metabolites) and does not significantly mask 
metabolites of importance.
133
 Also, MS-based metabolomics studies have found that 
commercially available tubes for serum collection with gel separators shed polymeric 
substances into blood samples that may cause artificially high levels of analytes and produce 
false results.
134
  
The time interval between blood sample collection and cell separation (centrifugation) can 
also impact on metabolite composition. The optimal time is considered to be no more than 35 
minutes and preferably over ice, as longer waiting time may increase lactate levels due to 
continued glucose metabolism in blood cells.
135
 Many studies have also examined the impact 
of the short- and medium-term storage of samples (up to 13 months) and shown minimal 
impact on metabolic profiles.
136
 However, limited data is available on long-term storage, 
although a recent pilot study of heparinised bovine plasma samples stored for up to 15 years 
reported minimal effects.
137
 Nevertheless, experience in our laboratory suggests that some 
metabolites may degrade rapidly at -20°C. Stability of samples stored for extended periods of 
time still has to be fully investigated. Differences caused by freeze-thaw cycles were found to 
be minimal; however, repeated freeze-thaw steps should be avoided.
138
  
Metabolite extraction. Serum and plasma are complex biological biofluids consisting of low 
molecular weight metabolites (organic and inorganic) that are present in a manifold range of 
concentrations combined with high molecular weight lipids and proteins. Thus, an additional 
step of metabolite extraction is often required.
124
 The type of metabolite extraction is largely 
dependent on the metabolites of interest (and budget!), and numerous studies have 
investigated different methods and organic solvents for extraction and separation of polar and 
nonpolar metabolites (ethanol, methanol, acetonitrile or acetone). However, we have found 
that the addition of cold methanol in a ratio of 3:1 (vol/vol) is highly efficient in metabolite 
extraction and protein depletion, while remaining straightforward to perform (as reported by 
others).
124
 Urine samples have less complex biological composition compared to blood 
samples and usually do not require additional metabolite extraction steps due to low protein 
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content (except for diseased patients that may have high levels of proteins and consequently 
interfere with the analysis).
121
 However, a disadvantage of urine samples is high urea levels 
which may damage GC-MS instruments, as well as the presence of magnesium and calcium 
that bind with various metabolites and broaden NMR resonances.
121
 Buffers are also typically 
required to minimize peak-shifting in NMR spectra due to large variations in urinary pH. 
Traditionally, tissue analysis also requires laborious metabolite extraction including 
homogenization and lysation of cell walls to release the metabolites.
129
 However, high 
resolution magic-angle spinning 
1
H NMR spectroscopy can be used for analysis of intact 
tissues and is possible even without any pre-treatment of samples.
139
 
Data acquisition and data normalisation. A number of technical issues can introduce 
systematic bias in metabolomics studies. These mostly relate to mass spectrometry; a great 
strength of NMR is the relative analytical robustness and reproducibility. In small-scale 
studies when the number of samples is low (< 100), samples can be analysed in a single batch 
in a relatively short time period. However, large-scale studies require more care when 
designing the analytical protocol, especially in MS-based studies, due to low instrument day-
to-day reproducibility; several groups (including ours) experience signal attenuation over 
time as samples directly interact with the instrument. In these cases, samples should be 
analysed in multiple batches (up to 60 study samples per batch), with three to five study 
samples bracketed with quality controls (QC) and regular instrument cleaning.
124
 There are 
three types of QC samples used in metabolomics studies: 
1. Pooled QC samples consisting of small aliquots taken from each study sample (good 
representation of the composition of study samples),  
2. Predetermined mixtures of ‘representative’ metabolites,  
3. Commercially available samples.  
Profiles of QC samples can be analysed later to ensure analytical consistency, and correct for 
systematic drift where it exists.
124
 Computational methods are also being developed to 
address these issues, in our lab and elsewhere. Even in small-scale studies, it is critical to 
distribute experimental and control samples evenly throughout an MS run to reduce the risk 
of systematic bias. 
Study design in metabolomics research 
Given that full coverage of the metabolome is not currently possible (and may never be), 
there are two approaches to metabolomics research, termed untargeted and targeted analysis, 
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respectively.
121
 Targeted analysis was discussed briefly above. Untargeted analysis, or 
metabolic profiling, comprises an agnostic profile of as wide a range as possible of 
metabolites (tens to thousands) within the biological system.
121
 The advantage of this 
approach is that it allows the detection of previously unpredicted metabolic perturbations and 
discriminatory metabolites (potential disease biomarkers) associated with a certain disease (or 
condition). To conduct an untargeted metabolomics experiment, one designs analytical 
approaches that allow the unbiased detection of as wide a range of metabolites as possible. 
Metabolic ‘features’ that discriminate between conditions (e.g. individuals diagnosed with 
disease, such as hypertension, and their healthy-matched controls)
112
 are identified, and these 
features are then annotated (i.e. the corresponding metabolites are unambiguously identified).  
Untargeted analysis does not require prior knowledge of biologically relevant metabolites and 
is usually referred to as hypothesis-generating or discovery-phase experimentation.
140
 In 
contrast to this approach, targeted methods aim to measure a more focused number of 
previously defined metabolites (e.g. metabolites from a single metabolic pathway or a 
specific class of small molecule, such as glycero-phospholipids) in order to test a previously 
defined scientific hypothesis (however broad) or perhaps validate a biomarker or biomarkers 
(usually identified in an earlier untargeted experiment).
121
 The advantages of targeted over 
untargeted methods are: i) that detection and quantification can be robustly validated in 
advance (particularly if MS is the technical platform) and; ii) they do not require post-hoc 
metabolite annotation (as this is a component of the initial technical development phase). The 
advantage of untargeted methods is that they are able to identify completely novel 
compounds and pathways without recourse to an a priori hypothesis. 
The sample size required to detect differences between two phenotypes in metabolomics 
studies varies and is predicated, as ever, on two factors: first, the effect size; and second, the 
metabolic homogeneity of the biological system under study (e.g. laboratory animals vs. 
humans).
141
 Metabolomics analyses in laboratory animals are usually conducted in a small 
number of samples (up to 20 in total),
105, 106
 as these animals are often homogeneous, are kept 
under well-controlled conditions (e.g. controlled humidity, temperature, light exposure, diet), 
and so the influence of genetics, environment and diet on their metabolic profile is 
(hopefully) minimized. The resulting reduction in inter-individual variability means that 
orthogonal differences (i.e. those due to treatment or experimental intervention) should be 
more readily detectable. However, one should always be alert to the law of unintended 
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consequences: the possibility that other factors related to different animal models (e.g. 
normotensive versus hypertensive rats) cannot be excluded.
142
 On the other hand, 
considerable variation in genetic, environmental, and dietary factors in humans provides 
significant diversity in individual phenotypes (large inter- and intra- individual variability) 
and, consequently, in metabolomic profiles.
113, 143
 That being the case, slight but clinically 
important effects in disease states may not be detected if studies are underpowered.
141
 Thus, a 
significantly larger number of samples are required in human studies if effect sizes are 
unknown in advance, sometimes to the extent of epidemiological proportions (i.e. 100s to 
1000s).
141
 
Besides potentially being underpowered, confounding factors and comorbidities in complex 
diseases such as hypertension, can also hinder interpretation of results.
144
 For example, statin 
treatment, hormonal status, exercise/cardiorespiratory fitness and gender are all known to 
change the lipid profile in human serum and, thus, a diagnosis of disease based on lipids may 
also be affected.
144-147
 Furthermore, hypertension is associated with the development of other 
CV, cerebrovascular and renal complications that create unique signatures in the metabolic 
profile.
148, 149
 The influence of these potential confounders should be taken into consideration 
when identifying the study subjects and interpreting the results. Careful characterisation of 
the phenotype under examination using standardized methods and matching disease-case 
subjects with healthy controls by known confounders (e.g. age, gender, ethnicity or body 
mass index) would be the preferred approach in human metabolomics studies to address these 
limitations.
141
  
2.2.4 Metabolomics in hypertension research 
Studies in animals  
In hypertension research, metabolomics has mostly been used in animal models such as 
spontaneously hypertensive rats (SHR), as their pathophysiological processes have been 
recognised as similar to those of essential hypertension.
150
 The BP in SHR (typically 
measured by the tail-cuff method) gradually rises with aging and becomes significantly 
increased after approximately 10 weeks of age when compared with healthy-matched 
normotensive pairs (e.g. Wistar Kyoto; WKY).
150
 Akira et al
105
 analyzed urine samples of six 
SHR in the developing stage of hypertension (eight-weeks old) on the assumption that 
metabolic perturbations during this early-life phase would provide insights to the 
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pathogenesis of hypertension. Using NMR-based metabolomics and Principal Component 
Analysis (PCA), urine levels of citrate and α-ketoglutarate were decreased in SHR compared 
with WKY, presumably resulting from early metabolic perturbations of the citric acid cycle 
(Krebs cycle) in SHR - a common metabolic pathway for the oxidation of carbohydrates, 
lipids and proteins in which these two metabolites are intermediates.
105
 Metabolic 
impairments of the citric acid cycle with the increased levels of succinate were also noticed in 
slightly older male SHR (10 weeks of age) when compared with healthy normotensive 
control animals.
106
 Recent work has confirmed the presence of the succinate receptors GPR91 
in macula densa cells of the juxtaglomerular apparatus in kidneys, through which succinate 
can regulate renin release - an initial step in the activation of RAS.
151, 152
 Thus, increased 
levels of plasma (and hence urinary) succinate could have an influential role in modulating 
body fluid homeostasis and BP via the activation of these receptors.  
Metabolomics has also been applied to stroke-prone SHR (SHRSP) models that typically 
develop severe hypertension.
107
 Increased levels of taurine and creatine have been found in 
SHRSP rats at 12 and 26 weeks of age using NMR-based metabolomics.
107
 These findings 
are difficult to place in context with previous studies (although mostly conducted in humans) 
in which decreased (rather than increased) urinary levels of taurine have been linked with 
essential hypertension.
153
 Furthermore, an oral administration of taurine attenuated BP of 
patients with hypertension,
154
 as well as SHR and SHRSP rats,
155
 possibly via actions on the 
local RAS in the brain.
156
 Differences in the metabolism of taurine between humans and 
animals, as well as the possibility of altered renal handling of taurine (and creatine) in the 
SHRSP model may potentially explain these contradictory findings. However, targeted 
metabolomics analysis using an LC-NMR method in the same study samples identified a 
novel urinary metabolite, succinyl-taurine, that was only detected in WKY urine.
157
 The 
absence of succinyl-taurine in SHRSP rats, as well as the structural similarity with the 
hypotensive-acting taurine, may elucidate the involvement of succinyl-taurine in the 
regulation of BP in these rat models; however, the pathophysiological significance of 
succinyl-taurine still remains to be examined.  
A profound set of metabolic differences between hypertensive and normotensive rat models 
were also reflected in blood samples. A GC/time-of-flight (TOF)-MS-based metabolomics 
study investigated age/hypertension-related metabolic changes in blood plasma samples from 
10 to 18 weeks of age in SHR compared with WKY controls.
109
 Similar age-related changes 
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in many metabolic compounds (e.g. decrease in amino acids: serine, methionine, ornithine, 
phenylalanine and an increase in lysine) were detected in both animal models. However, an 
increase in free fatty acids (FFA) including oleic, linoleic, hexadecanoid and stearic acids 
were noted in SHR only, along with the rise in BP levels from 10 to 18 weeks of age, 
indicating a possible role of perturbed FFA metabolism in BP regulation. Indeed, normalised 
peak areas of increased levels of FFA (oleic, linoleic and palmitic acids) in SHR significantly 
correlated with systolic BP values on multiple regression analysis in the GC/TOF-MS-based 
metabolomics study of Aa et al.
108
 These investigators have also demonstrated that standard 
antihypertensive therapy (angiotensin-converting enzyme inhibition [captopril], calcium 
channel blockade [amlodipine], α1-adrenoreceptor blockade [terazosin] and diuretic 
[hydrochlorothiazide]) significantly reduced BP in SHRs, as expected, but treatment had 
minimal effects on the increased FFA levels.
108
 However, total ginsenosides (extracts of the 
medicinal plant, ginseng, purported to have beneficial antihypertensive properties through 
unknown mechanisms) caused not only a sustained reduction in BP that persisted even after 
the withdrawal of therapy, but also down-regulated the increased FFA levels toward normal 
levels.
108
 Therefore, FFA regulation may have some role in maintaining BP control, but his 
remains to be fully tested. 
Studies in humans  
As with animal work, the number of metabolomics studies related to hypertension in humans 
is limited. Among the first was an NMR- and PCA-based metabolomics analysis designed to 
investigate whether it was possible to distinguish between different BP categories based on 
metabolic profile.
110
 Only 64 individuals were studied and these participants were classified 
into three BP categories (low/normal [≤ 130 mmHg], borderline [131-149 mmHg] and high 
systolic BP [≥ 150 mmHg]) based on a single BP measurement taken in a hospital 
environment.
110
 Investigators used Orthogonal Signal Correction (a filtering method) on the 
NMR data to minimize/remove the differences between the samples unrelated to BP, and the 
model was validated against over-fitting using the SIMCA method.
110
 Interestingly, the PCA 
scores showed many similarities in serum metabolic profiles between subjects in borderline 
and high systolic BP categories, whereas regions of NMR spectra attributed to different lipids 
(in particular lipoproteins associated with very low-density [VLDL] and low-density [LDL] 
cholesterol) clearly distinguished the borderline/high BP categories from the low/normal BP 
category (lipids being higher in the higher BP categories).
110
 This tends to imply that 
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metabolic changes related to BP (e.g. lipids abnormalities) might be evident in blood samples 
before overt BP elevation. However, a limitation of this work was reliance on one in-hospital 
BP reading to classify BP status, which is a low standard of assessment and likely to 
misclassify true BP. In any case, the findings are generally supportive of many studies that 
have reported relationships between plasma lipoprotein abnormalities (e.g. increased levels of 
total cholesterol, high density lipoprotein subfraction HDL3, apolipoprotein B, and 
lipoprotein a) and raised BP, or other vascular abnormalities related to hypertension, such as 
increased arterial stiffness.
87, 98
  
Similar to the animal hypertensive models, GC/TOF MS-based metabolomics analysis has 
showed significantly increased serum FFA levels (heptanoic, oleic, nonanoic, eicosanoic and 
hexanoic acids) in 34 elderly patients diagnosed with hypertension compared to 29 age-
matched normotensive controls; however, limited information was provided as to  how BP 
measures were acquired.
111
 Although still unknown, some explanations for the causal 
relationship between FFA and the development of hypertension have been proposed. FFA 
may promote adverse effects on neurovascular tone by increasing the sensitivity of α1-
adrenoreceptors and sympathetic drive or have inhibiting effects on endothelium-dependent 
vasodilatation and endothelial nitric-oxide synthase.
158
 Furthermore, increased levels of FFA 
may potentially change membrane fluidity by altering the Na
+ 
K
+ 
ATPase pump, Na
+
, K
+
 and 
Ca
2+
 currents, as well as the structure of membrane phospholipids and increase intracellular 
levels of Na
+
 and Ca
2+
 (mechanisms that lead to increased vascular muscle tone and 
consequently BP).
159
 These findings also lend support to epidemiological studies in which 
FFA have been demonstrated to be independent risk factors for the development of 
hypertension, even after correcting for known confounders, such as body mass index, weight 
change, and baseline BP.
160
 Besides increased levels of FFA, altered carbohydrate 
metabolism (including high levels of glucose and galactose, and decreased levels of fructose) 
was also found in patients with hypertension compared to normotensive controls,
111
 
confirming the already known information on the high prevalence of impaired glucose 
tolerance in patients with essential hypertension.
161
 
People with an already established T2DM have high BP (affecting up to 40% of newly 
diagnosed T2DM patients)
162
 and also develop premature vascular aging and arterial 
structural remodelling, most likely due to underlying metabolic irregularities.
92
 An 
increasing number of metabolomics studies have been conducted in people with T2DM to 
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detect the underlying metabolic disturbances in this population, and to investigate their 
associations with CV complications.
163
 Besides identifying alterations of carbohydrate and 
lipid metabolism, metabolomics studies have also revealed abnormalities in tricarboxylic 
acid, amino acid and bile acid metabolism.
164
 These metabolic disturbances may adversely 
impact on arterial function and possibly contribute to CV complications (including high 
BP).
87
 Indeed, a metabolomics study in the Framingham Offspring cohort showed that 
increased levels of three amino acids (isoleucine, tyrosine and phenylalanine) were 
significantly associated with the future development of CV disease, independent of standard 
CV disease and diabetes risk factors.
165
 Also, a cross-sectional analysis in individuals free of 
CV disease reported that each increase in the score of the same three amino acids was 
associated with a higher risk of having subclinical carotid atherosclerosis.
166
 A more recent 
study by Ha et al
167
 also demonstrated increased levels of three amino acids in people with 
T2DM, as well as of lysophosphatidylcholines (lysoPC; intermediates of lipid metabolism), 
with levels significantly and positively correlated with the brachial pulse wave velocity 
(PWV; a measure of arterial stiffness). These findings may suggest that the association 
between metabolic abnormalities and the progression of CV complications may be mediated 
by irregularities in vascular function, although more studies are needed to investigate the 
causal mechanisms. Chapter 6 of this thesis represents one of the first studies using 
untargeted metabolomics analysis to investigate the relationships between abnormal 
metabolic profile in people with T2DM and arterial/hemodynamic measures under resting 
and exercise conditions. This was done toprovide mechanistic insights of CV complications 
and high BP in people with T2DM. 
Other BP metabolomics studies have also provided some evidence for the role of 
inflammation as a contributing factor in the development of hypertension. The acute phase 
inflammatory protein α-1 acid glycoprotein was at an increased level in a group of 40 patients 
with hypertension (defined as resting BP ≥ 140/90 mmHg) compared with 40 healthy 
controls (defined as resting BP < 130/80 mmHg).
112
 Inflammation may cause vascular 
endothelial dysfunction and modifications in the synthesis and degradation of endothelial 
vasodilators and vasoconstrictors and, consequently, influence the regulation of BP.
168
 This 
was a robust metabolomics study in terms of appropriate methods to define hypertension 
(triplicate measures of BP on each arm recorded at seated rest) and minimize the effects of 
potential confounders related to disease (two groups were well-matched by all known risk 
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factors). There are also some indications that metabolites associated with diet and gut 
microbial activity might also be linked to BP regulation.
113
 A large-scale hypertension-
metabolomics study conducted in 4630 subjects across four populations (United Kingdom, 
United States of America, China and Japan) has reported an inverse association between 
urinary excretion of formate (a by-product of fermentation of dietary fibre by the gut 
microbiome) and both systolic and diastolic BP, whereas alanine (being higher in people who 
consume predominantly a diet high in meat products) had a positive association with BP. 
Furthermore, hippurate (a normal constituent of urine typically increased with dietary 
consumption of phenolic compounds) had an inverse association with BP.
113
 This finding is 
in agreement with the previous work in the SHR model in which decreased urine levels of 
hippurate were observed when compared with control WKY rats, even though both rat strains 
were fed under the same conditions.
105
  The most recent human BP metabolomics study was 
in a population of 896 normotensive black men and women who were followed over 10 
years.
114
 In this study, a 1SD difference in serum metabolite 4-hydroxyhippurate (also an 
end-product of polyphenol metabolism by the intestine microflora) was associated with 17% 
higher risk of developing hypertension, even after correcting for conventional risk factors that 
included baseline BP.
114
 
Several metabolomics studies have been conducted in preeclampsia.
169-172
 This condition is 
characterised by maternal hypertension and proteinuria. It affects 3-5% of pregnancies 
annually and is one of the main causes of foetal and maternal morbidity and mortality 
worldwide.
173
 Essential hypertension and preeclampsia share numerous features including 
organ damage (renal and endothelial dysfunction), multifactorial origin and risk factors for 
future development of CV disease.
173
 A UPLC-MS-based metabolomics study showed 
metabolic perturbations in 60 women at 15 ± 1 weeks of gestation that subsequently 
developed preeclampsia.
169
 Forty five metabolites from 11 metabolic classes were 
significantly different in the plasma from women with preeclampsia (including amino acids, 
carnitines, fatty acids, lipids, phospholipids and carbohydrates). A more recent LC-MS-based 
metabolomics study in 41 women that developed preeclampsia also found carnitine 
(hydroxyhexanoylcarnitine) and amino acids (alanine, phenylalanine and glutamate) to be 
elevated compared to healthy controls.
170
 Badaho-Singh et al
171
 used NMR-based 
metabolomics to identify 20 discriminatory metabolites from which a set of four metabolites 
(citrate, glycerol, hydroxyisovalerate and methionine) was predictive of preeclampsia.
171
 The 
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same group also identified glycerol and carnitine to discriminate  late-onset preeclampsia.
172
 
These findings implicate abnormal lipid metabolism in the pathogenesis of preeclampsia, 
although much work remains to be done. Taken altogether, the utilisation of metabolomics in 
hypertension research highlights the potential for revealing the underlying (suspected and 
possibly unknown) pathophysiological processes of hypertension, but there is still much to be 
done.  
2.2.5 Future directions 
Better definition of the hypertensive phenotype 
Along with the analytical, technical and study design improvements, future directions in 
human metabolomics studies should include much stronger characterisation of the 
hypertensive phenotype than attempted to date. Dissimilar (and in some cases inadequate) 
methods to assess BP in previous metabolomics studies could have led to inappropriate 
interpretation of results. If we consider the high prevalence of white coat hypertension and 
masked hypertension in the general community (15% and 19%, respectively),
22, 174
 accurate 
office BP as well as the consideration of out-of-office BP measurements are essential to 
appropriately evaluate BP status.
23
 Individuals with masked hypertension have almost equal 
CV risk
21
 and may have similar metabolic profiles to those having sustained hypertension. On 
the other hand, individuals with white coat hypertension that experience an exaggerated 
sympathetic nervous system response to an experimental intervention may be prone to an 
acute elevation of FFA at the time of BP measurement (due to the activation of a hormone-
sensitive lipase by adrenaline),
175
 and this could potentially lead to spurious metabolomics 
conclusions. Importantly, the development of hypertension is usually accompanied by arterial 
structural remodelling, increased large artery stiffness and central systolic BP.
176
 Thus, 
rigorous BP examination that also includes measures of arterial stiffness and central BP could 
uncover important mechanistic insights when combined with metabolomics analyses.
10, 177
 
Furthermore, metabolomics may also prove to be a powerful tool for the detection of early 
signs of target organ damage, such as renal, heart or cerebrovascular complications that 
produce distinctive signatures in the metabolic profiles, even before disease symptoms are 
observed and medical attention is required.   
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Metabolomics in clinical trials 
Clinical trials conducted even decades ago have produced blood samples for subsequent 
disease phenotyping or disease risk studies. These remain in storage and may contain clinical 
information that can be recovered using metabolomics methods. Although the capital cost of 
instruments such as NMR magnets or high-resolution mass spectrometers is very high (more 
than $100000 per instrument), these analytical platforms are often already available to 
researchers (e.g. in chemistry departments) and can provide NMR or MS analysis at 
reasonably low cost (approximately $15-20 per sample). This potentially allows the 
application of metabolomics profiling to large-scale sets of study samples. A word of caution, 
however; although metabolomics data is relatively easy to acquire, robust analysis is a far 
greater technical challenge that requires significant experience in the field. Further, the highly 
dynamic nature of the metabolome and the significant influences that may arise from 
different sample acquisition, handling and storage methods may set some limitations for the 
use of samples acquired for other purposes (as previously described). Only samples collected, 
handled and stored in standard and identical ways may be directly compared using 
metabolomics methods, as any variations in sample handling would introduce systematic bias 
into the data and potentially produce spurious findings.
124
 It is also important that in case-
control studies, case and control samples were not collected at different centres, as this may 
also produce differences in metabolite patterns that should not be assigned to disease 
exposure.
124
 Finally, citrate and EDTA have been widely used as anticoagulants for plasma 
collection in most clinical trials but are generally not recommended for metabolomics 
analysis; yet in this last case, samples can still often be used and significant and valuable 
biological information recovered effectively.
133
  
Reproducible standard operating procedures that define the protocols for sample collection, 
handling and storage are important for clinical trials planning on analysis of the samples 
collected over extended time periods (several months or years for some clinical trials) and at 
different study centres.
124
 The Human Serum Metabolome (HUSERMET) project is an 
example in which samples are collected at different study cites in a reproducible and standard 
way and analysed in multiple analytical experiments and integrated into a single data set.
124
 
Quality control samples are implemented and used throughout the course of the study to 
provide the robust quality assurance. 
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Biomarker discovery 
Biomarkers are widely used diagnostic tools for the evaluation of normal physiological 
conditions, as well as the presence of pathophysiological processes.
178
 Given that metabolic 
perturbations associated with hypertension are most likely to develop before hypertension is 
detected by standard methods (rise in upper arm BP), a reliable biomarker and/or several 
biomarkers/metabolic patterns (due to the complexity of the underlying pathophysiological 
mechanisms associated with hypertension) that may elucidate early stage development of 
hypertension would represent a major clinical advance. To date, none of the potential 
metabolomic biomarkers have transitioned to being clinically useable. Moreover, abnormal 
metabolic patterns such as that associated with lipid metabolism do not provide significant 
improvements over well-established risk factors such as standard lipid profiles. This is a 
problem of all biomarker research, 
179
 but does not detract from the possibility that useful 
hypertension biomarkers of could yet be discovered to allow detection of early pathological 
changes beyond conventional risk factors.  
Pharmacometabolomics  
Pharmacometabolomics is a promising new field in metabolomics that uses the profiling of 
metabolites in body fluids (blood or urine) before drug treatment to predict patient responses 
to therapy, including drug metabolism, efficacy and adverse effects.
180-182
 Since 
pharmacometabolomics offers the possibility to optimize treatment more effectively 
according to the metabolic profile of each individual and avoid adverse drug effects, this 
approach has major potential for developing personalized drug treatment.
182
 As hypertension 
represents the most prevalent chronic condition worldwide with high costs of prescribed 
medications and health care services, individual tailored treatment could provide substantial 
benefits, not only in terms of efficacy and safety of drug treatment, but also in terms of cost 
savings and treatment efficiency. Further investigations in pharmacometabolomics will also 
be required to determine the metabolic effects of multiple drug usage, as polypharmacy is 
common in hypertension management. 
2.2.6 Conclusions 
Metabolomics in hypertension research has the potential to provide new insights into the 
underlying pathophysiological processes associated with hypertension, detect early metabolic 
perturbations (biomarkers) and monitor the efficacy and effects of drug (and other) therapies. 
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Future metabolomics studies should, however, include a more comprehensive physiological 
(phenotypic) assessment of BP, alongside more robust determination of BP control category. 
Although this review focused only on one part of the systems biology paradigm in the study 
of hypertension, metabolomics should also be interpreted in combination with other system 
biology methods such as computation, genomics, transcriptomics and proteomics. The 
genome provide predictive information regarding an individuals’ risk for the development of 
hypertension at any stages of life, as the genetic code itself remains stable and unchanged 
throughout life. On the other hand, other components of system biology such as 
transcriptome, proteome and metabolome change noticeably in parallel with the disease 
developments, as well as therapeutic measures, and therefore would be more appropriate to 
characterise the disease process while they integrate with environmental factors and genetic 
predisposition. Up until recently, big emphasis was placed on transcriptomics and 
proteomics; however, with the further development of analytical techniques and 
bioinformatics, the role of metabolomics among other system biology fields is expected to 
continue to grow.  
2.3 Review of literature summary and overall thesis aim 
An HRE during moderate intensity exercise is associated with an increased CV risk, 
irrespective of normal resting BP. The incidence of an HRE varies between different 
populations, but it is highly prevalent in people with masked hypertension and T2DM, 
reported to be more than 50%. The underlying mechanisms of an HRE and associated 
increased CV risk are unknown, although previous studies suggested that this may be due to 
abnormalities in haemodynamic, haemostatic and/or metabolic factors. Increased aortic 
stiffness and impaired endothelial dysfunction are widely believed haemodynamic 
contributing factors to an HRE. However, most of the previous studies included people with 
already developed essential hypertension, which may have led to spurious results. 
Furthermore, impaired haemostasis is present in people with hypertension, associated with 
increased CV events and correlated with high BP (rest and ambulatory BP), but still little is 
known about haemostasis in people with an HRE. Exaggerated exercise BP has been found to 
be associated with metabolic CV risk factors including elevated lipids and glucose 
intolerance, and importantly, the recent developments of metabolomics analysis have offered 
opportunities for exploring new insights into the underlying pathophysiological processes 
associated with high BP. The underlying contributors of an HRE are still unclear, but it is 
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important to understand this condition in order to improve detection of individuals with an 
increased CV risk, reduce the CV risk in these people and potentially develop new treatment 
strategies; therefore, the overall aim of this thesis was: 
 To explore the haemodynamic and biochemical (haemostatic and metabolic) correlates of 
an HRE. 
Each Chapter contains specific aims (outlined below) which contribute to the overall thesis 
aim. This is specifically outlined at the end of each thesis Chapter. 
Aim 1. To investigate the haemostatic and haemodynamic abnormalities in individuals with 
an HRE and determine their relationships with exercise BP 
Hypothesis 1. Individuals with an HRE will have haemostatic abnormalities (in 
particular raised haemostatic markers that reflect endothelial dysfunction) compared 
to individuals with normotensive response to exercise and these markers will be 
significantly associated with exercise BP 
Hypothesis 2. Individuals with an HRE will have arterial haemodynamic 
abnormalities (e.g. increased arterial stiffness and systemic vascular resistance) 
compared to individuals with normotensive response to exercise and these 
haemodynamic measures will be significantly associated with exercise BP  
Aim 2. To develop the methodology regarding metabolomics analysis and to explore the 
metabolic actions of the aldosterone antagonist spironolactone on exercise BP and aortic 
stiffness in individuals with an HRE 
Hypothesis 1. Aldosterone antagonist spironolactone will reduce exercise BP and 
aortic stiffness via BP-independent effects of spironolactone  
Hypothesis 2. The reduction in aortic stiffness by spironolactone treatment will be 
significantly associated with the reduction in exercise BP  
Aim 3. To investigate the metabolic abnormalities in a population with the high prevalence of 
an HRE (people with T2DM) using untargeted metabolomics analysis and determine their 
relationships with exercise BP (peripheral and central) 
Hypothesis 1. Individuals with T2DM will have metabolic abnormalities (including 
increased levels of glucose, fructose and lactate) compared to non-diabetic individuals 
and these metabolic markers will be significantly associated with exercise BP 
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Chapter 3. Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter describes methodology involved in examining the haemodynamic, haemostatic, 
and metabolic contributors of a hypertensive response of exercise in all studies that comprise 
this thesis.   
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3.1 Introduction 
Validated and highly reproducible haemodynamic measures were included in most of the 
chapters in this thesis, as individually described below. Haemostatic markers were measured 
in the study within Chapter 4 and included standard haemostatic protocols and measures. 
Importantly, a significant part of this research program also involved development of the 
protocol regarding resting blood pressure (BP) measurements (the details described in 3.2.1 
section), as well as metabolomics analysis. Metabolomics analysis is still in its infancy, and 
despite a lot of effort employed worldwide from various research groups, standard protocols 
and operating procedures involving the sample preparation, sample analysis and data analysis 
in metabolomics analysis are still not clearly defined. Inappropriate sample preparation and 
subsequent data analysis can introduce systematic bias into data that may consequently 
interfere with the metabolomics analysis and possibly produce false discoveries. Therefore, in 
order to apply metabolomics analysis to explore metabolic contributors of a hypertensive 
response to exercise (HRE), we first had to define the protocols that would be used for the 
subsequent analysis of study data (used in Chapter 5 and Chapter 6). In section 3.4, the final 
protocols for the sample preparation, sample analysis and data analysis are described, and in 
Appendix 2, a novel method for the normalisation of metabolomics data is presented as a 
separate study.   
3.2 Haemodynamic variables 
3.2.1 Office brachial blood pressure 
Resting office brachial BP was measured using a validated semi-automated oscillometric 
device
183
 (Omron HEM-907; OMRON Europe B.V. (OMCE), Hoofddorp, The Netherlands) 
or a validated mercury-free manual sphygmomanometer (UM-101B, A&D Medical, 
Thebarton, South Australia).
184
 Office brachial BP was measured by a trained non-clinician in 
duplicate and the mean of these two readings was used for subsequent analysis. Brachial 
pulse pressure (PP) was calculated as the difference between brachial systolic and diastolic 
BP. As number of factors may influence the BP measurement such as room temperature, 
background noise, alcohol or nicotine consumption,
4
 participants were examined in a quiet 
and temperature-controlled room. Participants were also asked to refrain from consuming 
heavy meals and caffeine or smoking for at least three hours prior to examination and avoid 
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exercise on a day of examination. Blood pressure was measured in accordance with 
guidelines, using an appropriately sized cuff with the arm supported at heart level.
4
  
Current guidelines for the management of hypertension recommend that office brachial blood 
pressure (BP) should be optimally measured after five minutes of rest,
4
 but brachial BP may 
decrease for up to 10 minutes of rest before reaching a plateau level.
185, 186
 In setting up the 
protocol for BP measurements for our studies, we conducted a retrospective analysis of data 
collected in the BP GUIDE study (http://www.anzctr.org.au; ACTRN12608000041358) in 
which brachial BP was measured after five and 10 minutes of rest to determine the most 
appropriate time for BP measurements.
13
 We found that BP recorded after 10 minutes was 
more representative of true blood pressure control which was assessed by comparison with 
patients’ out-of-office BP (regarded as a ‘gold-standard’ measure of BP).13 Also, BP recorded 
at 10 minutes but not after the conventional five minute wait was highly associated to BP-
related end-organ damage such as left ventricular (LV) mass.
13
 These findings suggest that 
BP measured after the recommended five minute rest period may not be an appropriate time 
for BP measurement and using this as the sole method to assess BP control may result in 
misclassification or inappropriate management of some individuals. Therefore, 10 minutes 
waiting period before the BP measurement was used in our studies. The results of this study 
were published in the Journal of Human Hypertension and are included in the Appendix 1.  
3.2.2 Exercise brachial blood pressure  
Stress test brachial BP. Exercise stress tests were performed at local cardiology departments 
where study participants were recruited for the Chapter 4 study. Brachial BP during the 
exercise stress testing (standard Bruce protocol) was measured using either a validated 
mercury-free sphygmomanometer (UM-101B, A&D Medical, Thebarton, South Australia)
184
 
or automated device (Tango, SunTech Medical Instruments, NC, USA)
187
 in the final two 
minutes of each three-minute exercise stage. The initial speed of the treadmill was set to 2.7 
km/h and the inclination was set to 10% (stage 1). At three minute intervals, the inclination of 
the treadmill was increased by 2% and the speed increased to 4.0 km/h at stage 2; 5.5 km/h at 
stage 3; 6.8 km/h at stage 4 and; 8.0 km/h at stage 5. 
Research clinic exercise brachial BP. Exercise brachial BP at the research clinic (moderate 
intensity) was measured using a validated mercury-free sphygmomanometer (UM-101B, 
A&D Medical, Thebarton, South Australia).
184
 Exercise was performed on an upright cycle 
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ergometer (WattBike, Wattbike Ltd, Nottingham, United Kingdom; Chapter 4) or on a 
bicycle ergometer positioned on the bed in a semi-recumbent position (Chapter 6), as 
described in Keith et al
188
 (Rehab Trainer 881, MONARK Exercise110 AB, Vansbro, 
Sweden). The workload of exercise was set for each individual to achieve a heart rate of 60% 
of age-predicted maximal heart rate calculated as per formula (220 - age × 0.60). Exercise 
brachial BP was measured in duplicate and the mean value was used for analysis. During the 
BP measurements, the participant’s arm was supported at the level of the heart using an 
adjusted platform, and the participant was asked to keep the arm as still as possible.  
3.2.3 Out-of-office blood pressure 
24 hour ambulatory BP. A validated device (TM-2430, A&D Mercury, A&D Medical, 
Thebarton, South Australia)
189
 was used for 24 hour ambulatory BP monitoring. Participants 
were advised to maintain routine daily activities during BP monitoring and to have their arm 
still and relaxed during each measurement. The device was set to record BP in previously 
determined intervals (every 20 minutes during the day and every 30 minutes during the night 
or every 30 minutes during the day and every hour during the night).
23
 The mean values of 
BP measured during daytime (daytime BP), night time (night time BP) and overall 24 hour 
(24 hour ambulatory BP) were used for the analysis.  
Home BP. Seven-day home BP was self-measured using a validated oscillometric device 
(UA-767, A&D Mercury, A&D Medical, Thebarton, South Australia).
190
 Participants were 
instructed to take BP measurements in a warm and quite room after at least five minutes of 
seated rest in a chair enabling back support, with feet flat on the ground and the arm 
supported at heart level.
191
 Home BP was measured in duplicate in the morning (between 
6am and 10am), midday and evening (between 6pm and 10pm). The first of two BP 
measurements was discarded and the second BP was recorded and used for analysis.  
3.2.4 Office central blood pressure 
Office central BP was measured at rest, as well as during exercise, using radial applanation 
tonometry and validated generalized transfer function (SphygmoCor 8.1, AtCor Medical, 
Sydney, NSW).
13, 14
 Central BP was measured in duplicate and the mean value was used for 
the analysis. Acquired pressure waveforms were calibrated by brachial BP values taken 
immediately prior to applanation tonometry. Central PP was calculated as the difference 
between systolic and diastolic BP (Figure 3.1). Augmentation index (AIx) was defined as the 
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difference between the second and first systolic peak of the central pressure waveform (or 
augmentation pressure [AP]) and expressed as a percentage of the PP. As AIx is influenced 
by heart rate, AIx was also normalised to a heart rate of 75 bpm. The ratio of brachial and 
central PP defined the PP amplification. 
 
Figure 3.1 Aortic pressure waveform  
Central (aortic) pressure waveform derived from the radial pressure waveform by applying 
generalized transfer function. Central systolic and diastolic blood pressure (BP) represents the 
highest and the lowest points of the pressure waveform, respectively. Central pulse pressure 
(PP) is calculated as the difference between systolic and diastolic BP, whereas augmentation 
pressure (AP) is calculated as the difference between the first and the second systolic peaks. 
Augmentation index (AIx) is defined as the percentage of AP to PP. 
3.2.5 Arterial stiffness  
Arterial stiffness was estimated by measuring aortic and brachial pulse wave velocity (PWV) 
using sequential applanation tonometry in combination with a three-lead electrocardiogram 
(SphygmoCor 8.1, AtCor Medical, Sydney, NSW).
177
 PWV represents the speed (expressed 
in m/s) at which the pressure waveform travels along the large arteries (aortic or brachial 
artery), during each cardiac cycle (Figure 3.2). Pressure waveforms were recorded at the 
common carotid artery and femoral (for aortic PWV) or radial (for brachial PWV) artery, and 
the ratio of the distance and the time delay between the pressure waves recorded at two sites 
defines PWV. The time delay of the pressure waveform is calculated by software by the using 
‘foot-to-foot’ method - time delay between the foot of each pressure waveform recorded at 
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two sites. The surface distance between the two recording sites is taken as the distance 
covered by the waves.  
 
Figure 3.2 Estimation of aortic stiffness using pulse wave velocity  
The ‘Foot-to-foot’ method for calculating the carotid-femoral pulse wave velocity (PWV) 
which is expressed in m/s. Pressure waveforms are recorded at the common carotid and 
femoral arteries and the speed of wave is calculated as the ratio of the distance (L) and the 
time delay (∆t) between the pressure waveforms recorded at two sites. 
Aortic PWV during moderate intensity exercise (Chapter 6) was measured in the semi-
recumbent position by the modified protocol as designed by Keith et al.
188
 Participants 
exercised on a bicycle ergometer (Rehab Trainer 881, MONARK Exercise AB, Vansbro, 
Sweden) that was placed on the bed and participants were instructed to pedal until they 
achieved a heart rate of 10 beats per minute (bpm) above the set heart rate target. When the 
required heart rate was reached, participants were asked to stop pedalling in order for the 
femoral (or carotid) pressure waveform to be acquired by the operator. The process lasted for 
approximately 15 seconds, during which time the participants heart rate declined towards the 
target heart rate. Duplicate measures were acquired and the mean value was used for the 
analysis.  
3.2.6 Bioimpedance cardiography 
Stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR) were 
measured at rest and during exercise using a validated and reproducible Physio Flow device 
(Physio Flow; Manatec Biomedical; Macheren, France).
192, 193
 This was achieved by placing 
six pre-gelled sensor electrodes on the participant’s chest and detecting changes in blood 
volume and velocity during each cardiac cycle which results in changes in electrical 
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conductivity and impedance. SV was estimated as the largest change in impedance during 
systole, whereas CO was defined by multiplying the heart rate (HR) with SV. SVR was 
defined as the ratio of the sum of mean arterial pressure and CO. 
3.3 Haemostatic and clinical biochemistry markers 
Vacutainer
®
 tubes with 3.8% sodium citrate were used for blood sample collection and 
analysis of haemostatic markers including von Willebrand factor (vWf), fibrinogen, tissue 
factor (TF) and thrombin-antithrombin complexes (TAT). Study participants were seated for 
at least 10 minutes after which blood was drawn by venepuncture from cubital veins via an 
inserted indwelling cannula to enable direct access for blood sampling during different 
physiological conditions (at rest, during exercise and post-exercise). Immediately following 
sample collection, the cannula was filled with heparin solution (to prevent blood clotting 
within the cannula) and collected blood samples were centrifuged for 20 minutes at 2000 g to 
obtain citrated plasma, with 0.5 mL aliquots stored at -80°C until analysis. Prior to analysis 
of haemostatic markers, plasma samples were thawed at 37°C. TF, vWf, and TAT were 
determined using commercially available immunoassays according to manufacturer’s 
instructions (ELISA; Assaypro, St. Charles, MO, USA). Fibrinogen was measured using a 
standardised clotting-based Clauss assay. Clotting times were measured using the STart®-4 
haemostasis analyser (Diagnostica Stago, Asniéres-sur-Seine, France) and compared to 
specialty assayed reference plasma (SARP, Helena Laboratories, Beaumont, TX, USA). 
A fasted or non-fasted blood samples were drawn to determine standard metabolic markers 
(total, low-density and high-density lipoprotein cholesterol, glucose, glycosylated 
haemoglobin [HbA1c], insulin and triglycerides) and samples were analysed in local hospital 
pathology laboratory, as per standard pathology procedures.  
3.4 Metabolomics 
3.4.1 Liquid chromatography-mass spectrometry (LC-MS) 
Sample preparation. Fasting serum samples were collected and 0.5 mL aliquots were stored 
at -80°C until analysis. Samples were thawed and a 100 µL aliquot of each sample was mixed 
with 300 µL of ice-cold methanol, incubated at 4°C for 20 minutes and centrifuged at 13200 
g for 10 minutes. The supernatant was lyophilized in a vacuum centrifuge (Labconco, Kansas 
City, USA) and re-stored at -80°C. The dried samples were reconstituted in 100 µL of HPLC-
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grade water prior to LC-MS analysis. Samples were vortexed and centrifuged for 15 minutes, 
and supernatant was transferred to vials. Quality control samples were prepared by pooling 
10 µL of random samples and analysed throughout the LC-MS runs (four study samples were 
bracketed by two quality controls) to assess the equipment drift and ‘batch-to-batch’ 
variability, as recommended in the paper of Dunn et al.
124
  
Sample analysis. Samples were analysed using an LTQ-Orbitrap XL mass spectrometer 
(ThermoFisher Scientific, Bremen, Germany) controlled by XCalibur v2 software 
(ThermoFisher Scientific). To prevent systematic bias, samples were randomly distributed 
throughout the runs. Chromatographic separation was performed on a Waters Nova-Pak 
4.0 µm C18 column (3.91x150 mm) with an injection volume of 10 µL. The mobile phases 
used for the sample elution were A) 0.1% formic acid in water and B) 0.1% formic acid in 
methanol, with a flow rate of 0.8 mL/minute. Gradient conditions were as follows: 0-4 
minutes hold at 10% B, 4-6.5 minutes linear gradient 10-50% B, 6.5-14.5 minutes linear 
gradient 50-80% B, 14.5-15.5 minutes linear gradient 80-100% B, 15.5-17.5 minutes hold at 
100% B, 0.5 minutes re-equilibration in 10% B. Centroid mass spectra was acquired in full 
scan mode at the resolution of 30,000 across a mass range of 50-1000 mass/charge (m/z). 
Data were acquired in both positive (+) and negative (-) ionization modes. Ionization 
conditions were as follows: capillary temperature of 300°C, flow rate of sheath gas of 30 au, 
auxiliary gas flow rate of 5 au, capillary voltage of 7 V for (+) ion acquisition and capillary 
voltage of -44 V for (-) ion acquisition. Spectra for tandem mass spectrometry (MS/MS) were 
acquired using FTMS Mode at an isolation width of two mass units and collision energy of 
20 V. Retention times for MS/MS targets were specified according to retention time values 
acquired by LC-MS. Raw LC-MS data were converted to mzXML format. Data were then 
processed for peak finding, grouping and retention time alignment using XCMS running in 
the R environment (R 2.14; http://cran.r-project.org/). Karpievitch et al
14
 have developed and 
applied a novel singular value decomposition-based method (EigenMS) for data 
normalisation to detect and correct for any systematic bias, caused by different batch effects, 
day-to-day variations in instrument performance, signal intensity loss due to time-dependent 
effects of the LC-MS column performance, accumulation of the contaminants in the MS ion 
source and MS sensitivity among others. The EigenMS normalisation technique is described 
in more details in Appendix 2. 
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LC-MS data analysis. The LC-MS data was analysed by either a repeated-measures ANOVA 
to compare each feature and then corrected the resulting p values using the Benjamini and 
Hochberg False Discovery Rate correction
194
 or principal component analysis (PCA). The 
LC-MS data were mean-centred and Pareto-scaled before using PCA to dimensionally reduce 
the data using PLS Toolbox 6.5 (Eigenvector Research Inc., Wenatchee, US). Visual 
inspection of a ‘scree’ plot of captured variance versus number of components was used to 
identify the number of PC comprising each model (prior to any further analysis). Plots of 
scores on each PC were visually inspected. Those that appeared to separate the groups were 
compared using an independent t-test. Loading coefficients were used to identify metabolites 
that significantly contributed to discriminatory PCs. In addition to PCA, individual 
metabolites were compared across groups by independent t-test with the false discovery rate 
held at 5% using the method of Benjamini and Hochberg.
195
 Features were accepted as being 
significantly different if the corrected p < 0.05. Metabolomics data, when included in an 
analysis with conventional data, was checked for normality and non-normally distributed data 
was square-root-transformed. The LC-MS data were checked for artefacts (for example, 
Fourier-transform ‘shoulders’), de-isotoped and putatively annotated using online databases 
(Human Metabolome Database [HMDB] and Metlin) and the Taverna workflows of Brown et 
al.
196
 Compounds of interest were further examined by tandem mass spectrometry (MS/MS) 
to provide additional structural information and to confirm annotation, where possible, by 
comparison with MS/MS spectra held in public databases.  
3.4.2 Proton nuclear magnetic resonance (1H NMR) spectroscopy  
Sample preparation for Bruker spectrometer operating at 800.13 MHz. Fasting serum 
samples were collected and 0.5 mL aliquots were stored at -80°C until analysis. Samples 
were thawed and 300 µL was added to 300 µL of D2O in a 1.5 mL Eppendorf tube. The 
mixture was briefly vortexed and then centrifuged at 16606 g for five minutes after which 
550 µL of the supernatant was transferred to a 5 mm NMR tube for analysis.  
Sample analysis. NMR data were acquired on a Bruker Avance III spectrometer operating at 
800.13 MHz (Bruker Biospin, Karlsruhe, Germany). Data were acquired with a Carr-Purcell-
Meiboom-Gill pulse sequence with presaturation during the recycle delay (2 s) and a total 
echo time of 51.2 ms. The time domain was 128 k and the sweep width was 20 ppm. Data 
were Fourier transformed with exponential line broadening of 0.5 Hz in the frequency 
domain. Spectra were phased and baselined in Topspin 3.0 (Bruker Biospin, Karlsruhe, 
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Germany) before being imported into Matlab (Mathworks, Natick, MA) at full resolution. 
Resulting spectra were normalised and bucketed using probabilistic-quotient normalisation
197
 
and adaptive intelligent binning
112
 respectively, both in Matlab. 
Sample preparation for Agilent/Varian Inova spectrometer operating at 400 MHz. Fasting 
serum samples were collected and 0.5 mL aliquots were stored at -80 °C until analysis. A 
500 µL aliquot of serum was mixed with 1 mL of methanol (2:1 v/v with original sample), 
incubated in a -20°C freezer for 20 minutes and centrifuged for 10 minutes at 13,200 g. 
Supernatants were dried in a vacuum centrifuge overnight (Labconco, Kansas City, USA), re-
suspended in 700 µL NMR buffer (2 mM 3-(trimethylsilyl)-1-proponesulfonic acid sodium 
salt in D2O). 
Sample analysis. 
1
H NMR spectra were acquired using an Agilent/Varian Inova 400 MHz 
wide bore spectrometer (Varian Medical Systems, Palo Alto, CA, USA), in a 5mm ID-PFG 
probe. Spectra were acquired with 90° pulse excitation, sweep width of 4,299 ppm and 
relaxation delay of 2 seconds at 25°C. A total of 128 transients were collected into 32000 
complex data points. The water resonance was set to the centre of the sweep width on the 
transmitter offset and attenuated using a presaturation pulse of 2 seconds during the 
relaxation delay and the mixing time (100 ms) of the NOESY pulse sequence. Resulting 
spectra were normalised and bucketed using probabilistic-quotient normalisation
197
 and 
adaptive intelligent binning
112
 respectively, both in Matlab. 
NMR data analysis. NMR data were mean-centred and Pareto-scaled, before being analyzed 
using PCA and partial least squares-discriminant analysis (PLSDA), both in PLS Toolbox 
(PLS Toolbox 6.5, Eigenvector Research Inc., Wenatchee, US). Visual inspection of a ‘scree’ 
plot of captured variance versus number of components was used to identify the number of 
PC comprising each model (prior to any further analysis). Plots of scores on each PC were 
visually inspected. Those that appeared to separate the groups were compared using an 
independent t-test. Loading coefficients were used to identify metabolites that significantly 
contributed to discriminatory PCs. Permutation testing was used to assess whether PLSDA 
models were the result of over-fitting; models were considered significant if the estimated 
p < 0.05. Data processing of metabolomics data were conducted in Matlab. Features of 
interest were putatively annotated using online databases HMDB and Metlin. 
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Chapter 4. Association of Von Willebrand Factor Blood 
Levels with Exercise Hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the time of thesis submission, this chapter is under resubmission in European Journal of 
Applied Physiology: 
Sonja B. Nikolic, Murray J. Adams, Petr Otahal, Lindsay M. Edwards, James E. Sharman 
 
This chapter reports on haemodynamic and haemostatic correlates of a hypertensive response 
to exercise at moderate intensity, akin to intensity of exercise blood pressure shown to best 
predict cardiovascular events, in participants with a clinical indication for exercise stress 
testing. 
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4.1 Abstract 
Background. A hypertensive response to moderate intensity exercise (HRE) is associated 
with increased cardiovascular (CV) risk. The mechanisms of an HRE are unclear, although 
previous studies suggest this may be due to haemostatic and/or haemodynamic factors. We 
investigated the relationships between an HRE with haemostatic and hemodynamic indices. 
Methods. Sixty four participants (aged 57 ± 10 years, 71% male) with indication for exercise 
stress testing underwent CV assessment at rest and during moderate intensity exercise, from 
which 20 participants developed an HRE (defined as moderate exercise systolic BP≥170 
mmHg/men and ≥160 mmHg/women). Rest, during exercise and post-exercise blood samples 
were analysed for haemostatic markers (von Willebrand factor (vWf), fibrinogen, thrombin-
antithrombin complexes and tissue factor), as well as haemodynamic measures of brachial 
and central blood pressure (BP), aortic stiffness and systemic vascular resistance index 
(SVRi).  
Results. HRE participants had higher rest vWf compared with normal BP response to 
exercise (NRE) participants (1927 mU/mL, 95% CI: 1240-2615, vs. 1129 mU/mL, 95% CI: 
871-1386; p=0.016). VWf levels significantly decreased from rest to post-exercise in HRE 
participants (p=0.005), whereas vWf levels significantly increased from rest to exercise in 
NRE participants (p=0.030). HRE participants also had increased triglycerides, aortic 
stiffness, resting BP and exercise SVRi (p < 0.05 for all). vWf at rest (but no other 
haemostatic marker) predicted exercise brachial systolic BP (β = 0.220, p = 0.043; Adjusted 
R
2 
= 0.451, p < 0.001) independent of age, sex, body mass index, triglycerides, resting 
brachial systolic BP and aortic stiffness.  
Conclusions: Increased resting blood levels of vWf are independently associated with 
moderate intensity exercise systolic BP. These findings implicate abnormalities in 
haemostasis as a possible factor contributing to an HRE at moderate intensity.  
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4.2 Introduction 
A recent meta-analysis in people with a clinical indication for exercise stress testing showed 
that those with a hypertensive response to exercise (HRE) at moderate intensity were at 
greater risk for cardiovascular (CV) events and mortality independent of resting blood 
pressure (BP)
5
. The mechanisms of an HRE are unclear, although abnormal haemostatic 
and/or haemodynamic factors may play key roles. With respect to haemodynamics, an HRE 
is associated with endothelial dysfunction
50
 and increased large artery stiffness,
51
 which 
together may lead to raised left ventricular (LV) afterload, and ultimately affect cardiac 
structural and functional characteristics.
11, 25
 However, little is still known on systemic 
haemodynamic function (including central BP, stroke volume, cardiac output and peripheral 
vascular resistance) during moderate intensity exercise in people with an HRE.  
Under pathological conditions (e.g. increased shear pressure), the vascular endothelium plays 
a crucial role in regulating normal haemostasis by expressing/releasing regulatory substances 
of coagulation including tissue factor (TF).
71
 This may lead to an initiation of the coagulation 
cascade, an increase in thrombin generation, and potentially CV complications. Indeed, 
fibrinogen (a haemostatic marker that is elevated during coagulation) has been shown to be 
associated with an increased CV risk.
77
 The von Willebrand factor (vWf) is also one of the 
haemostatic markers that is released with endothelial damage, and is therefore proposed to be 
an indicator of endothelial damage/dysfunction.
79
 Importantly, raised vWf is positively 
associated with both systolic and diastolic BP, and is higher in patients with hypertension 
compared with controls.
8
 VWf is also an independent correlate of increased 24-hour 
ambulatory pulse pressure in select patient populations.
83
 Altogether, the above data raises 
the possibility that irregularities of haemostasis, as well as arterial haemodynamics, may 
contribute to an exaggerated exercise BP. In this study, we investigated the relationships 
between haemostatic and haemodynamic markers with moderate exercise BP. We 
hypothesized that haemostatic markers (vWf, TF, fibrinogen and markers of thrombin 
generation) and systemic haemodynamics (including central BP, stroke volume, cardiac 
output and peripheral vascular resistance) would be significantly different in people with an 
HRE and significantly associated with moderate intensity exercise BP. 
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4.3 Materials and Methods 
4.3.1 Study participants  
The study population consisted of people with an indication for exercise stress testing who 
were free from coronary artery disease. The recruitment was conducted through local hospital 
cardiology departments, but all haemodynamic and haemostatic measurements (under rest 
and moderate intensity exercise conditions) were collected at the research clinic on another 
occasion. Participants were excluded if they were under 18 years of age, had a hypotensive 
response to exercise (failure of systolic BP to increase with increasing exercise intensity) or 
BP reading during exercise was not of good quality, had resting BP ≥ 140/90 mmHg when 
tested at the research clinic or were unable to attend the research clinic for comprehensive 
cardiovascular (CV) examination under resting and moderate intensity exercise conditions. 
From 109 potential participants, several were excluded due to coronary artery disease 
(n = 18), exercise hypotension (n = 1), poor quality exercise BP (cardiac nurses were not 
confident with the BP reading during exercise due to movement and noise; n=15) or were 
hypertensive at rest (n = 11). This left 64 participants who completed the study. The study 
was approved by the Human Research Ethics Committee of the University of Tasmania. 
Written informed consent was obtained from all participants and procedures were in 
agreement with the Declaration of Helsinki.  
4.3.2 Study protocol 
All participants underwent a standard maximal intensity treadmill exercise stress test (Bruce 
protocol) at local hospital cardiology departments. The initial speed of the treadmill was set 
to 2.7 km/h and the inclination was set to 10% (stage 1). At three minute intervals, the 
inclination of the treadmill was increased by 2% and the speed increased to 4.0 km/h at stage 
2; 5.5 km/h at stage 3; 6.8 km/h at stage 4 and; 8.0 km/h at stage 5. Those meeting inclusion 
criteria were invited to attend the research clinic on another occasion in the morning after an 
overnight fast (scheduled as soon as possible after exercise stress testing) for cardiovascular 
examination at rest and during moderate intensity exercise. An indwelling cannula was 
placed in the participant’s arm to enable direct access for blood sampling of haemostatic 
markers at three different conditions: 1) at rest, 2) during exercise, and 3) post-exercise. 
Samples used to measure standard clinical biochemistry markers were collected at rest only. 
Participants were examined in a quiet, temperature-controlled room that included 
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haemodynamic measurements of office brachial and central BP, arterial stiffness, cardiac 
output, stroke volume and systemic vascular resistance index (SVRi). After resting 
measurements, participants performed exercise at moderate intensity on an upright cycle 
ergometer (WattBike, Wattbike Ltd, Nottingham, United Kingdom). The workload of 
exercise was set for each individual to achieve a heart rate of 60% of age-predicted maximal 
heart rate, simulating the moderate intensity levels achieved during exercise stress testing 
(approximately stage 2, Bruce protocol), in keeping with the intensity of exercise BP shown 
to best predict CV events.
5
 Heart rate was calculated as per the formula (220 - age × 0.60). 
When steady-state heart rate was achieved, haemodynamic measurements were repeated. 
Exercise brachial systolic BP levels measured at this stage were used to identify those with an 
HRE. Blood samples ‘during moderate intensity exercise’ were collected immediately on 
stopping exercise, and this was completed within 30 seconds. Post-exercise samples were 
collected after 15 minutes of seated rest.  
4.3.3 Haemostatic markers  
Vacutainer
®
 tubes with 3.8% sodium citrate were used for blood sample collection and 
analysis of haemostatic markers that best reflect the coagulation activation and thrombin 
generation (TF and thrombin-antithrombin complexes; TAT), abnormal vascular function 
(vWf), as well as a marker previously reported to be significantly associated with adverse 
cardiovascular outcomes (fibrinogen).Tubes were centrifuged immediately following sample 
collection for 20 minutes at 2000 g to obtain citrated platelet-poor plasma, with 0.5 mL 
aliquots stored at -80°C until analysis until batched analysis at the end of the study. Prior to 
analysis of haemostatic markers, plasma samples from all participants were thawed at 37°C. 
TF, vWf, and TAT were determined using commercially available immunoassays according 
to manufacturer’s instructions (ELISA; Assaypro, St. Charles, MO, USA).  Fibrinogen was 
measured using a standardised clotting-based Clauss assay. Clotting times were measured 
using the STart®-4 haemostasis analyser (Diagnostica Stago, Asniéres-sur-Seine, France) 
and compared to specialty assayed reference plasma (SARP, Helena Laboratories, Beaumont, 
TX, USA).  All standards and controls were measured in duplicate, with participants’ samples 
measured singularly. All controls for each assay were within acceptable limits. Intra- and 
inter-assay coefficient of variations (CV) for immunoassays were 4.8% and 7.2% for TAT; 
4.9% and 7.0% for TF; 5.0% and 7.1% for vWF, and 1.4% and <5.0% for fibrinogen.    
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4.3.4 Haemodynamic variables 
A validated manual mercury-free sphygmomanometer (UM-101B, A&D Medical, Thebarton, 
South Australia) 
184
 or automated device (Tango, SunTech Medical Instruments, NC, USA)
187
 
were used for brachial BP measurements during exercise stress testing (in the final two 
minutes of each three-minute exercise stage) at hospital cardiology departments. Seated 
resting brachial BP at the research clinic was measured in duplicate after 10 minutes using a 
validated semi-automated oscillometric device (Omron HEM-907; OMRON Europe B.V. 
(OMCE), Hoofddorp, The Netherlands). 
183
 BP was measured by a trained non-clinician in 
accordance with guidelines.
4, 198
 Exercise BP at the research clinic was measured in duplicate 
using a validated mercury-free sphygmomanometer (UM-101B, A&D Medical, Thebarton, 
South Australia).
184
 A previous study in a large sample of apparently healthy subjects, 
including both men and women undertaking exercise stress testing, has defined an HRE as 
the upper limits of exercise BP responses.
199
 The same convention was followed in this 
current study conducted in a similar study population where an HRE was defined as moderate 
intensity exercise systolic BP in the highest tertile of the study population (this equated to 
systolic BP ≥ 170 mmHg for men and ≥ 160 mmHg for women). However, the criteria used 
in this study to define an HRE may not be applicable to different study populations, such as 
younger healthy individuals. Accordingly, a normotensive response to exercise (NRE) was 
defined as moderate intensity exercise systolic BP in the first and second tertiles of the study 
population. Central BP at rest and during moderate intensity exercise was recorded using 
radial applanation tonometry and calibrated by brachial BP values taken immediately prior to 
applanation tonometry (SphygmoCor 8.1, AtCor Medical, Sydney, NSW).
47, 48
 Pulse pressure 
(PP) was defined as the difference between systolic and diastolic BP. Augmentation index 
was defined as the difference between the second and first systolic peak of the central 
pressure waveform (or augmentation pressure) and expressed as a percentage of the PP. The 
ratio of brachial and central PP defined the PP amplification. Aortic and brachial pulse wave 
velocities (measures of arterial stiffness) were measured using applanation tonometry 
(SphygmoCor 8.1, AtCor Medical, Sydney, NSW).
177
 Cardiac output, stroke volume and 
SVRi were measured using a validated and reproducible Physio Flow device (Physio Flow; 
Manatec Biomedical; Macheren, France).
193
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4.3.5 Biochemical analysis 
Standard pathology laboratory procedures were performed using serum samples to determine 
levels of glucose, triglycerides, total, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL). 
4.3.6 Statistical analysis 
Data are presented as mean and standard deviation unless otherwise stated. The unequal-
variance independent t-test was used to compare clinical characteristics between HRE and 
NRE groups. Comparisons between categorical variables were conducted by chi-squared 
tests. Pearson correlation was used to determine the associations between continuous 
variables (after appropriate transformations, see below).  
Repeated measures regression analysis for haemostatic outcome variables was used to 
compare groups (HRE vs. NRE) over time (including an interaction of group with time). 
Residuals were found to be non-normally distributed and this was rectified by 
transformations; natural logarithm for vWf, square root transformation for TAT and TF, and 
square transformation for fibrinogen. Models were adjusted for age, sex, body mass index, 
triglycerides and resting systolic BP. Model contrasts were used to compare between groups 
at each time point and to compare time within each group. Multiple linear regression analysis 
was used to examine predictors (resting) of moderate intensity exercise brachial systolic BP.  
Regression diagnostics were examined in all models to ensure assumptions were not violated. 
A value of p < 0.05 was taken as statistically significant. Statistical analysis was conducted 
using SPSS 20.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp) and Stata 
12.1 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp 
LP). 
4.4 Results 
4.4.1 Clinical characteristics  
Table 4.1 summarises the clinical characteristics of study participants. Out of 64 participants, 
20 were identified with an HRE. The majority of study participants were male and there were 
no significant differences in age, sex or use of antihypertensive medications between HRE 
and NRE participants. Serum triglycerides were significantly higher in HRE participants 
compared with NRE participants.  
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Table 4.1 Clinical characteristics of study participants 
Characteristics NRE 
(n = 44) 
HRE    
(n = 20) 
p value 
Age (years) 56 ± 10 60 ± 10 0.140 
Sex, male (%) 31 (71) 14 (70) 1.000 
Body mass index (kg/m
2
) 26.6 ± 3.4 28.9 ± 5.1 0.075 
Antihypertensive medications (%) 10 (23) 8 (40) 0.261 
Angiotensin converting enzyme inhibitors (%) 2 (10) 6 (14) 1.000 
Calcium channel blocks (%) 3 (7) 4 (20) 0.257 
Angiotensin receptor inhibitors (%) 3 (7) 4 (20) 0.257 
Statins (%) 8 (18) 6 (30) 0.463 
Glucose (mmol/L) 5.9 ± 2.7 5.2 ± 0.5 0.138 
Triglycerides (mmol/L) 1.28 ± 0.56 1.62 ± 0.47 0.017 
Total cholesterol (mmol/L) 5.19 ± 0.89 5.38 ± 1.29 0.547 
High density lipoprotein (mmol/L) 1.40 ± 0.37  1.32 ± 0.26 0.348 
Low density lipoprotein (mmol/L) 3.18 ± 0.76 3.39 ± 1.19 0.478 
Data are mean ± standard deviation or n (%); NRE, normotensive response to exercise; 
HRE, hypertensive response to exercise: ACEi, angiotensin converting enzyme inhibitors 
4.4.2 Haemostatic markers 
Repeated measures regression analysis of vWf showed significant between groups effect 
(p = 0.016), no significant effect of time (p = 0.080) and a significant interaction effect for 
group*time (p = 0.003). Also, there was a significant effect of time (p < 0.001) for TF, but no 
significant interaction effect for group*time (p = 0.434) or between groups effect (p = 0.699). 
Fibrinogen and TAT had no significant main effects or interactions for time and/or group.   
Table 4.2 shows back-transformed predicted marginal means and 95% confidence intervals 
(CI) from the repeated measures regression and shows the tests for between group effects at 
each time point for the haemostatic markers in HRE and NRE participants across three 
conditions (rest, during exercise and post-exercise) after adjusting for age, sex, body mass 
index, triglycerides and resting systolic BP. vWf at rest was significantly higher in HRE 
participants compared to NRE participants, but there were no significant differences between 
groups in vWf during or post-exercise (also shown in Figure 4.1).  
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Examining within each group, vWf significantly increased from rest to exercise for the NRE 
group (355 mU/mL, 95% CI: 35 – 676, p = 0.030), whereas vWf significantly decreased from 
rest to post-exercise for the HRE group (-882 mU/mL, 95% CI: -1494 – -269, p = 0.005). 
Further, the NRE group showed significant changes for TF from rest to post-exercise (-
16.3 pg/mL, 95% CI: -28.0 – -4.6, p = 0.006) and from exercise to post-exercise (-
22.6 pg/mL, 95% CI: -35.2 – -10.1, p < 0.001). No further significant changes were observed 
within groups. 
4.4.3 Haemodynamic variables 
There were no significant differences between the groups in the duration of hospital exercise 
stress testing (NRE: 10.5 ± 2.6 minutes vs. HRE: 9.7 ± 2.6 minutes, p = 0.252), or in maximal 
exercise metabolic equivalents units (METS; NRE: 12.4 ± 2.5 METS vs. HRE 11.6 ± 2.7 
METS, p = 0.277). Table 4.3 summarises the haemodynamic variables measured during the 
hospital exercise stress testing (maximal and moderate intensity - stage 2 levels, Bruce 
protocol), and during rest and moderate intensity exercise at the research clinic. There was no 
significant differences between hospital stage 2 exercise systolic BP and clinic moderate 
intensity exercise systolic BP in NRE or HRE groups (mean difference 4.4 ± 23.7, p = 0.233; 
and -0.2 ± 23.2, p = 0.970; respectively). Although all participants were normotensive at rest, 
brachial systolic and central systolic BP variables were significantly higher in HRE 
participants compared to NRE participants. Also, aortic pulse wave velocity was significantly 
higher in HRE participants even after correcting for mean BP (p = 0.003). The change in 
brachial systolic BP from rest to moderate intensity exercise was significantly different 
between groups (NRE: 29 ± 10 vs. HRE: 47 ± 11; p < 0.001), as well as the change in central 
systolic BP (NRE: 12 ± 8 vs. HRE: 20 ± 11; p = 0.010). Augmentation pressure, 
augmentation index and PP amplification, and changes from rest to during moderate intensity 
exercise in these variables, were not significantly different between the groups. There were 
also no significant differences in heart rate, cardiac output or stroke volume at rest or during 
moderate intensity exercise between the two groups, although HRE participants had 
significantly increased SVRi at moderate intensity exercise compared to NRE participants. 
The duration of exercise was similar in both groups (NRE: 18 ± 7 minutes vs. HRE: 
19 ± 8 minutes, p = 0.630), and there were no significant differences in workloads between 
groups (NRE: 69 ± 23 watts vs. HRE: 76 ± 29 watts, p = 0.373).  
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4.4.4 Correlates of moderate intensity exercise systolic BP  
Moderate intensity exercise systolic BP was significantly, positively correlated with rest vWf 
but inversely correlated with the change in vWf from rest to exercise. However, the 
correlation with the change in vWf from rest to post-exercise was not significant (Figure 4.2). 
Furthermore, triglycerides (r = 0.411, p = 0.001), body mass index (r = 0.256, p = 0.046) and 
aortic pulse wave velocity (r = 0.325, p = 0.011) were also associated with the moderate 
intensity exercise systolic BP. During moderate intensity exercise, SVRi was significantly 
and positively correlated with exercise systolic BP (r = 0.385, p = 0.002).  
4.4.5 Multiple regression analysis  
A multiple regression model was constructed with moderate intensity exercise systolic BP as 
the dependent variable and age, sex, body mass index, vWf, triglycerides, resting brachial 
systolic BP and aortic pulse wave velocity as independent variables. Rest vWf (β = 0.220, 
p = 0.043) was a predictor of moderate intensity exercise systolic BP, independent of age 
(β = 0.024, p = 0.847), sex (β = 0.089, p = 0.432), body mass index (β = 0.109, p = 0.334), 
triglycerides (β = 0.228, p = 0.035), resting brachial systolic BP (β = 0.458, p < 0.001) and 
aortic pulse wave velocity (β = 0.064, p = 0.643). Adjusted R2 for the model = 0.451; 
p < 0.001. When we constructed the same model with exercise SVRi entered in the model 
instead of aortic pulse wave velocity, rest vWF (β = 0.225, p = 0.041) was still a predictor of 
moderate intensity exercise systolic BP, independent of age (β = 0.052, p = 0.632), sex 
(β = 0.073, p = 0.506), body mass index (β = 0.118, p = 0.290), triglycerides (β = 0.220, 
p = 0.048), resting brachial systolic BP (β = 0.462, p < 0.001) and exercise SVRi (β = 0.038, 
p = 0.643). Adjusted R
2 
for the model = 0.447; p < 0.001. When aortic pulse wave velocity 
and exercise SVRi were included in the same model, the association with vWf changed to the 
borderline of statistical significance but with no major shift in the standardised beta 
coefficient (β = 0.219, p = 0.050; adjusted R2 for the model = 0.437; p < 0.001). 
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Table 4.2  Haemostatic markers measured across three different conditions in participants with normotensive and hypertensive response to 
exercise 
Characteristics  NRE (n = 44) HRE (n = 20) p value 
 Rest 1129 (871-1386) 1927 (1240-2615) 0.016 
Von Willebrand factor (mU/mL) Exercise 1484 (1143-1825)* 1488 (945-2030) 0.992 
 Post-exercise 1286 (980-1592) 1045 (658-1433)* 0.369 
 Rest 3.59 (3.41-3.78) 3.78 (3.52-4.04) 0.265 
Fibrinogen (g/L) Exercise 3.63 (3.44-3.82) 3.76 (3.49-4.03) 0.448 
 Post-exercise 3.47 (3.27-3.67) 3.80 (3.53-4.08) 0.067 
 Rest 104.8 (51.0-158.5) 130.0 (15.2-244.8) 0.669 
Tissue factor (pg/mL) Exercise 111.1 (55.7-166.5) 126.7 (13.4-239.9) 0.812 
 Post-exercise 88.5 (38.9-138.0)*+ 118.0 (8.3-227.7) 0.629 
 Rest 1.22 (0.94-1.51) 1.22 (0.80-1.65) 0.997 
Thrombin-antithrombin complex (ng/mL) Exercise 1.21 (0.92-1.49) 1.01 (0.62-1.39) 0.438 
 Post-exercise 1.17 (0.89-1.45) 1.08 (0.68-1.48) 0.726 
NRE, normotensive response to exercise; HRE, hypertensive response to exercise. Values represent means (95% confidence interval) 
adjusted for age, sex, body mass index, triglycerides and resting systolic blood pressure. The p values are for the difference between 
NRE and HRE at each of the three time points. *p < 0.05 for the comparison with the rest haemostatic marker within group; +p < 0.05 
for the comparison with the exercise haemostatic marker within group. 
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Figure 4.1 Von Willebrand factor levels at three different conditions 
Von Willebrand factor (vWf) at rest, during exercise and post-exercise in participants with normotensive response to exercise (NRE) and 
hypertensive response to exercise (HRE). There was a significant difference in vWf at rest between groups (*p = 0.016). Error bars represent 
means and standard error of the mean after adjusting for age, sex, body mass index, triglycerides and resting systolic blood pressure. 
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Table 4.3 Haemodynamic variables measured during treadmill exercise stress testing (Bruce 
protocol), and at rest and during moderate intensity exercise at the research clinic in 
participants with normotensive and hypertensive response to exercise 
Characteristics NRE 
(n=44) 
HRE  
(n=20) 
p value 
Treadmill exercise stress testing 
Max. ex brachial systolic BP (mmHg) 172 ± 24 191 ± 23 0.006 
Max. ex brachial diastolic BP (mmHg) 81 ± 11 82 ± 11 0.752 
Max. ex brachial PP (mmHg) 92 ± 20 109 ± 23 0.007 
Max. ex heart rate (bpm) 157 ± 15 149 ± 20 0.106 
Stage 2 ex brachial systolic BP (mmHg) 154 ± 26 174 ± 24 0.004 
Stage 2 ex brachial diastolic BP (mmHg) 77 ± 11 80 ± 11 0.422 
Stage 2 ex brachial PP (mmHg) 77 ± 22 95 ± 22 0.005 
Stage 2 heart rate (bpm) 129 ± 17 129 ± 20 0.992 
Research clinic rest conditions    
Office brachial systolic BP (mmHg) 120 ± 12 128 ± 12 0.021 
Office brachial diastolic BP (mmHg) 73 ± 9 74 ± 8 0.517 
Office brachial PP (mmHg) 47 ± 8 54 ± 9 0.009 
Central systolic BP (mmHg) 110 ± 12 117 ± 13 0.043 
Central diastolic BP (mmHg) 73 ± 9 75 ± 8 0.518 
Central PP (mmHg) 37 ± 9 43 ± 10 0.029 
Aortic pulse wave velocity (m/s) 7.7 ± 1.6 9.0 ± 1.3 0.001 
Brachial pulse wave velocity (m/s) 8.5 ± 1.0 8.2 ± 0.9 0.215 
Heart rate (bpm) 62 ± 10 61 ± 7 0.549 
Cardiac output (L/min) 4.8 ± 1.2 4.8 ± 1.0 0.815 
Stroke volume (mL) 77 ± 14 81 ± 17 0.468 
SVRi (dyne/s/cm
5
) 3086 ± 624 3250 ± 781 0.412 
Research clinic moderate intensity exercise     
Ex brachial systolic BP (mmHg) 150 ± 12 175 ± 8 <0.001 
Ex brachial diastolic BP (mmHg) 76 ± 6 76 ± 7 0.855 
Ex brachial PP (mmHg) 74 ± 12 98 ± 9 <0.001 
Ex central systolic BP (mmHg) 123 ± 9 137 ± 7 <0.001 
Ex central diastolic BP (mmHg) 79 ± 6 79 ± 7 0.723 
Ex central PP (mmHg) 44 ± 8 58 ± 7 <0.001 
Ex heart rate (bpm) 102 ± 9 101 ± 9 0.862 
Ex cardiac output (L/min) 10.3 ± 1.2   10.7 ± 1.8 0.405 
Ex stroke volume (mL) 102 ± 13 106 ± 17 0.409 
Ex SVRi (dyne/s/cm
5
)  1573 ± 231 1725 ± 222 0.019 
Data are mean ± standard deviation ; NRE, normotensive response to exercise; HRE, 
hypertensive response to exercise; max, maximal; ex, exercise; BP, blood pressure; PP, pulse 
pressure; SVRi, systemic vascular resistance index 
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Figure 4.2  Correlations between moderate intensity exercise systolic blood pressure and von 
Willebrand factor. 
Correlations between moderate intensity exercise systolic blood pressure (BP) and (A) rest 
von Willebrand factor (vWf); (B) change in vWf from rest to exercise (ex); and (C) change in 
vWf from rest to post-exercise (post ex).  *VWf and changes in vWf are represented on the 
natural logarithm scale.  
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4.5 Discussion 
An HRE at moderate intensity is associated with increased CV risk.
5
 In a sample of 64 people 
undergoing routine exercise stress testing, we identified an independent relationship between 
resting vWf levels and moderate intensity exercise systolic BP, as well as higher resting vWf 
levels in those with an HRE. Furthermore, participants with an HRE had significantly 
different responses of vWf to moderate exercise compared to people with normal exercise 
systolic BP. Measures of arterial haemodynamics (large artery stiffness and SVRi during 
moderate intensity exercise) were also higher in HRE individuals. These findings implicate 
haemostatic abnormalities as a possible factor contributing to an HRE at moderate intensity. 
The vascular endothelium is involved in production of many vasoactive substances, including 
haemostatic factors that are released with endothelial damage/dysfunction. Our study showed 
that vWf was increased in participants with an HRE, suggesting the presence of endothelial 
dysfunction.
79
 Interestingly, vWf was significantly correlated with the moderate intensity 
exercise systolic BP. This positive association may reflect the interaction between endothelial 
dysfunction and high BP, due to the dysregulation of endothelial vasoactive substances 
(including vWf) and an altered capacity of the endothelium to maintain homeostasis and 
vascular tone. Indeed, the association between endothelial dysfunction and high BP could be 
a failure of the peripheral vasculature to appropriately dilate in order to mitigate pressure 
rises, particularly during exercise. These findings are in agreement with previous studies that 
also found the association between endothelial dysfunction (although measured by different 
methods) and exercise systolic BP. Indeed, in a large community-based population cohort of 
2115 participants from the Framingham Heart Study, flow-mediated vasodilation was 
negatively associated with exercise systolic BP at moderate intensity.
50
 Similarly, a study of 
healthy subjects with high normal BP or mild hypertension showed that reduced endothelial-
dependent vasodilatation (assessed by the same method) was inversely associated with 
exaggerated exercise systolic BP, but only in men.
63
  
vWf facilitates platelet adhesion and aggregation, and also contributes to blood coagulation 
by acting as a carrier for factor VIII. In this current study, the observed elevation of vWF in 
the absence of a significant increase in TAT complexes suggests low grade activation of the 
coagulation system rather than extensive amplification and propagation that would be 
reflected by increased thrombin generation. Nevertheless, increased levels of vWf may be 
clinically significant in patients with an HRE, especially in those with other CV risk 
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factors.
200
 It was also interesting to observe that vWf levels significantly decreased in HRE 
individuals 15 minutes following moderate intensity exercise, despite having elevated 
exercise BP levels. This finding may possibly suggest that moderate intensity exercise could 
act to suppress coagulation and/or platelet activation and potentially have beneficial effects 
that may be more pronounced in those with excessive initial vWf levels (such as HRE 
subjects). Moderate intensity exercise (in contrast to strenuous exercise) has been found to 
suppress agonist-and shear-induced platelet aggregation by reducing vWF binding to platelets 
and down-regulation of platelet activation (GPIIb/IIIa) in sixteen sedentary men.
201
 Another 
possible contributing factor to lower vWf levels in HRE subjects following the exercise may 
be disturbed nitric oxide bioavailability from endothelial dysfunction.
63
 Indeed, the study of 
Jilma et al
202
 showed that vWf levels were significantly attenuated during exercise when 
systemic nitric oxide was blocked. However, further studies are needed to explore these 
postulates. 
A reduction in large central artery compliance could contribute to BP elevation during 
exercise. Indeed, increased aortic stiffness (measured by carotid-to-femoral pulse wave 
velocity) has been shown to be associated with peak exercise systolic BP at maximal intensity 
in 171 untreated essential hypertension subjects.
51
 Similarly, the study by Thanassoulis et al
50
 
found that aortic stiffness (in addition to endothelial dysfunction, as mentioned above) was 
independently associated with moderate intensity exercise systolic BP, measured during the 
second stage of an exercise stress test. Consistent with these data, this current study found 
that aortic stiffness, measured by the same technique as Thanassoulis et al 
50
, was associated 
with the exercise systolic BP at moderate intensity, and was higher in those with an HRE. 
Furthermore, we also found that SVRi during moderate intensity exercise (but not at rest) was 
increased in HRE participants. The combination of increased central artery stiffness with 
increased vascular resistance would reasonably expect to increase exercise BP from the 
ejection of higher cardiac output into a stiff arterial system together with impaired peripheral 
run-off of blood. Interestingly, one study has shown that an excessive rise in systemic 
vascular resistance measured invasively during submaximal or maximal exercise 
independently predicted incident CV events and total mortality.
203
 This tends to support the 
notion that some of the risk attributable to an HRE may be due to altered vascular function 
although we did not find an independent relationship in this current study. 
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Our study was a cross-sectional analysis of data from a selected study population. The 
findings do not establish causality and may not be generalizable to other populations. 
Endothelial function of specific arterial beds, such as the brachial artery, was not measured in 
this study and would have been a valuable addition. Also, different devices were used to 
measure resting and exercise BP. Although both devices have been validated, the use of 
separate machines might have affected the study results. Furthermore, the use of a standard 
formula to estimate heart rate might have underestimated heart rate and the intensity of 
exercise, as per Tanaka et al.
204
 However, it should be noted that the same formula was used 
to determine the heart rate in all study participants (HRE and NRE groups), and the possible 
underestimation of heart rate would not significantly affect the results of this study. Future 
studies may be worth directing attention towards the role of vWf and endothelial dysfunction 
as contributors to an HRE at moderate intensity, as well as therapeutic/exercise interventions 
targeting haemostatic markers and endothelial function with benefit to vascular function and 
BP control. 
In summary, this study has demonstrated that abnormal haemostasis as reflected by higher 
resting vWf, as well as structural and functional vascular abnormalities (such as increased 
aortic stiffness and systemic vascular resistance during exercise) were present in subjects 
with an HRE. Although endothelial dysfunction was not estimated with standard measures in 
this study (e.g. flow-mediated vasodilation), an increased vWf (also a marker of endothelial 
dysfunction) may provide some indications that endothelial dysfunction may be present in 
people with an HRE and may be a contributing factor of an HRE. For the first time, we show 
that resting blood levels of vWf were significantly associated with moderate intensity 
exercise systolic BP, independent of resting brachial systolic BP and other CV risk factors.  
4.6 Contribution of Chapter 4 to thesis aims 
Previously published literature highlights the potential clinical relevance of an HRE at 
moderate intensity. Chapter 4 represents the first comprehensive CV assessment at rest and 
during moderate intensity exercise to explore the haemodynamic and haemostatic correlates 
of an HRE in people with a clinical indication for exercise stress testing. This study showed 
for the first time that haemostatic abnormalities reflecting endothelial dysfunction (increased 
vWf levels) were present in people with an HRE, and were significantly and independently 
correlated with moderate intensity exercise systolic BP. Endothelial function is not only 
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required for appropriate vascular tone and BP, but also for the regulation of normal 
haemostasis. Therefore, endothelial dysfunction may be a platform on which abnormal 
haemostasis might be contributing to an HRE and associated CV complications. These 
findings may have significant clinical relevance in people with an HRE, especially in those 
with other (possibly metabolic) co-morbidities. Furthermore, haemodynamic factors, 
including increased aortic stiffness, appeared to have a minimal role in an HRE at moderate 
intensity, as there were no independent significant associations with exercise systolic BP. On 
the other hand, there were some indications that metabolic factors may be contributing to an 
HRE, evidenced by increased triglyceride levels in people with an HRE, and their 
independent associations with moderate intensity exercise systolic BP. In order to explore 
other metabolic contributors of an HRE in an exploratory and ‘untargeted’ way using 
metabolomics analysis, next chapter (Chapter 5) represents the study that was primarily used 
for the development of methodology regarding metabolomics analysis (utilised in Chapter 5 
and Chapter 6), but it was also a convenient sample to explore the metabolic actions of the 
aldosterone antagonist spironolactone on exercise BP, as well as other haemodynamic 
measures, in people with an HRE.   
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Chapter 5. Spironolactone Reduces Aortic Stiffness via Blood 
Pressure-Dependent Effects of Canrenoate 
 
 
 
 
 
 
 
 
 
 
This thesis chapter has been previously published:  
Nikolic SB, Wilson R, Hare JL, Adams MJ, Edwards LM, Sharman JE. Spironolactone 
reduces aortic stiffness via blood pressure-dependent effects of canrenoate. Metabolomics. 
2014;10:105-113 
 
This chapter represents the first application of the metabolomics analysis in people with a 
hypertensive response of exercise and was primarily used to develop methodology regarding 
metabolomics analysis (also utilised in Chapter 6). However, this study was also a 
convenient sample to explore the metabolic actions of the aldosterone antagonist 
spironolactone on exercise blood pressure and aortic stiffness in people with a hypertensive 
response to exercise. The final published version of this paper (as presented in Chapter 5) 
included the exploration of the underlying metabolic effects of spironolactone on aortic 
stiffness only (a proposed contributor of a hypertensive response to exercise), whereas 
additional analysis and results regarding the spironolactone effects on exercise blood pressure 
are presented in Appendix 3.  
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5.1 Abstract  
Background. Spironolactone is thought to improve aortic stiffness via blood pressure (BP) 
independent (antifibrotic) effects, but the exact mechanism is unknown. We used 
metabolomics and hemodynamic measures to reveal the underlying actions of spironolactone 
in people with a hypertensive response to exercise (HRE).  
Methods. Baseline and follow-up serum samples from 115 participants randomized to three 
months spironolactone (25 mg/day) or placebo were analysed using liquid 
chromatography/mass spectrometry and nuclear magnetic resonance spectroscopy. 
Hemodynamic measures recorded at baseline and follow-up included aortic pulse wave 
velocity (stiffness) and 24 hour ambulatory BP.  
Results. Aortic stiffness was significantly reduced by spironolactone compared with placebo 
(-0.18 ± 0.17 m/s versus 0.30 ± 0.16 m/s; p < 0.05), but this was no longer significant after 
adjustment for the change in daytime systolic BP (p = 0.132). Further, the change in aortic 
stiffness was correlated with the change in daytime and 24 hour systolic BP (p < 0.05). 
Metabolomics detected 42 features that were candidate downstream metabolites of 
spironolactone (no endogenous metabolites), although none were correlated with changes in 
aortic stiffness (p > 0.05 for all). However, the spironolactone metabolite canrenoate was 
associated with the change in daytime systolic BP (r = -0.355, p = 0.017) and 24 hour pulse 
pressure (r = -0.332, p = 0.026). This remained highly significant on multiple regression and 
was independent of age, body mass index and sex.  
Conclusion. Canrenoate appears to be an active metabolite with BP-dependent effects on the 
attenuation of aortic stiffness in people with an HRE. This finding, together with the lack of 
change in endogenous metabolites, suggests that the antifibrotic effects of spironolactone 
could be BP-dependent. 
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5.2 Introduction 
Spironolactone is a diuretic that acts as a competitive aldosterone antagonist at the 
mineralocorticoid receptors of the epithelial cells in the kidneys.
205
 Studies in animals and 
humans have indicated that spironolactone exerts broad metabolic, structural and functional 
effects via mineralocorticoid receptors outside the kidneys, although the details of these 
actions remain unclear.
58-60
 Recently, mineralocorticoid receptors have been implicated in the 
function of the vasculature and it has been suggested that blockade by spironolactone may 
prevent, or lessen, arterial fibrosis and aortic stiffness independent of blood pressure (BP) 
changes.
58, 60
 Indeed, spironolactone has been shown to prevent aortic collagen accumulation, 
improve carotid artery distensibility, and lower aortic stiffness despite no significant changes 
in resting or office BP.
58, 61
 However, some of these studies did not consider the ambulatory 
or central BP-lowering effects of spironolactone, which are likely to be different to 
spironolactone’s effect on resting BP.61 Thus, the magnitude of the association between the 
BP-lowering effect of spironolactone and arterial stiffness might have been underestimated. 
Metabolomics is the systematic profiling of metabolites in biological systems and their 
changes in response to physiological stimuli. It may be used to characterise metabolic 
pathways associated with cardiovascular (CV) diseases and therapy.
206
 Indeed, mapping of 
endogenous metabolites pre- and post-drug treatment, and identifying perturbed metabolic 
pathways, may provide unique information on underlying drug mechanisms of action.
206
 To 
our knowledge, this approach has never been used to characterise the effects of 
spironolactone. Given that this drug undergoes extensive metabolism, and its activity is 
mainly attributed to its breakdown products (e.g. canrenoate and canrenone; Figure 5.1),
207
 
the identification of these products and consequent correlation with arterial/hemodynamic 
changes induced by spironolactone, may shed new light on the underlying physiological 
actions of the drug. This study sought to achieve this by conducting a metabolomic analysis 
of serum from subjects in a convenience sample from our recently completed randomized 
clinical trial where aortic stiffness and BP measures were acquired at baseline and after three 
months of spironolactone treatment in patients with a hypertensive response to exercise 
(HRE).
9
 We hypothesized that metabolite drug responses would be associated with changes 
in aortic stiffness and BP. 
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Figure 5.1  Metabolic pathway of spironolactone 
Metabolic pathway of spironolactone (A) forming two main downstream metabolites: canrenone (B) and canrenoate (C). Spironolactone is 
dethioacetylated to canrenone that further undergoes hydrolysis of its lactone ring to canrenoate. 
74 
 
5.3 Methods 
5.3.1 Study participants  
A total of 115 participants with an HRE were recruited into this randomized placebo-
controlled, double-blind clinical trial (htpp://www.anzctr.org.au; ACTRN12609000835246). 
HRE was defined as resting BP < 140/90 mmHg with a peak exercise BP ≥ 210/110 mmHg 
for men and ≥ 190/105 mmHg for women.30 Exclusion criteria for the principal clinical trial 
were: age over 70 years, a prior history of hypertension or taking antihypertensive 
medications, a history of known coronary artery disease or renal dysfunction (serum 
creatinine > 80 µmol/L), gynecomastia and pregnancy. Eligible participants were selected 
from hospital and community cardiology clinic records of exercise stress tests that were 
conducted in a period between 2004 and 2008. The study was approved by the Human 
Research Ethics Committee of the University of Queensland and all procedures conformed to 
the Declaration of Helsinki. Study participants gave written informed consent prior to 
participation. 
5.3.2 Study protocol 
Study participants attended the clinic at two different occasions. First clinic baseline visit was 
conducted in the morning where fasting blood samples were collected for metabolomics 
analysis (pre-samples) and standard clinical biochemistry. Resulting serum samples were 
stored at -80°C for later analysis. Following this, participants were examined with 
hemodynamic measurements including 24 hour ambulatory BP, office brachial BP, office 
central BP and aortic stiffness. After the baseline visit, participants were randomly assigned 
either 25 mg of spironolactone or placebo daily for three months. Participants and researchers 
were blinded to treatment allocations. Subjects then returned to the clinic for their follow-up 
examination after the three months of treatment. All participants were advised to take their 
last dose of spironolactone on the day of the examination. This maintained the steady-state 
concentration of long half-life metabolites of spironolactone (e.g. canrenoate and canrenone) 
that was achieved after daily drug intake. Blood samples were collected as before (post-
samples) and all hemodynamic measurements were repeated at three months. 
75 
 
5.3.3 Liquid chromatography-mass spectrometry (LC-MS) 
Serum samples were thawed and a 100 µL aliquot of each sample was mixed with 300 µL of 
ice-cold methanol. The sample was then incubated at 4°C for 20 minutes and centrifuged at 
13200 g for 10 minutes. The supernatant was collected and lyophilized in a vacuum 
centrifuge (Labconco, Kansas City, USA) and re-stored at -80°C. The dried samples were 
rehydrated in 100 µL of HPLC-grade water immediately prior to LC-MS analysis. Quality 
control samples were also prepared by pooling 10 µL of 40 random samples (placebo and 
spironolactone) and analysed throughout the LC-MS runs to assess the equipment drift and 
‘batch-to-batch’ variability, as recommended by Dunn et al.124 Samples were analysed using 
an LTQ-Orbitrap XL mass spectrometer (ThermoFisher Scientific, Bremen, Germany) 
controlled by XCalibur v2 software (ThermoFisher Scientific). To prevent systematic bias, 
samples from participants on spironolactone and placebo samples were randomly distributed 
throughout the runs. Each participant’s pre- and post-treatment samples were analysed 
together. Data were acquired in both positive (+) and negative (-) ionization modes. Retention 
times for tandem mass spectrometry (MS/MS) targets were specified according to retention 
time values acquired by LC-MS. Data were processed for peak finding, grouping and 
retention time alignment using XCMS running in the R environment (R 2.14; http://cran.r-
project.org/). 
5.3.4 Nuclear magnetic resonance (NMR) spectroscopy 
Serum samples were thawed and 300 µL was added to 300 µL of D2O in a 1.5 mL Eppendorf 
tube. The mixture was briefly vortexed and then centrifuged at 16606 g for five minutes after 
which 550 µL of the supernatant was transferred to a 5 mm NMR tube for analysis. NMR 
data were acquired on a Bruker Avance III spectrometer operating at 800.13 MHz (Bruker 
Biospin, Karlsruhe, Germany). Data were acquired with a Carr-Purcell-Meiboom-Gill pulse 
sequence with presaturation during the recycle delay (2 s) and a total echo time of 51.2 ms. 
The time domain was 128 k and the sweep width was 20 ppm. Data were Fourier transformed 
with exponential line broadening of 0.5 Hz in the frequency domain. Spectra were phased and 
baselined in Topspin 3.0 (Bruker Biospin, Karlsruhe, Germany) before being imported into 
Matlab (Mathworks, Natick, MA) at full resolution. Resulting spectra were normalised and 
bucketed using probabilistic-quotient normalisation
197
 and adaptive intelligent binning
112
 
respectively, both in Matlab. 
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5.3.5 Aortic stiffness, blood pressure and clinical biochemistry 
Aortic stiffness: ECG-gated sequential applanation tonometry of the carotid and femoral 
arteries using the SphygmoCor system (SphygmoCor 8.1, AtCor Medical, Sydney, NSW) 
was used to measure aortic pulse wave velocity (PWV), a measure of aortic stiffness.
177
 24 
hour ambulatory BP: A validated device  (TM-2430, A&D Mercury, A&D Medical, 
Thebarton, South Australia)
189
 - which was set to take measurements every 30 minutes during 
the day (between 6 am and 10 pm) and every hour during night (between 10 pm and 6 am) - 
recorded 24 hour ambulatory BP.
23
 The mean 24 hour pulse pressure (PP) was calculated as 
the difference between 24 hour systolic and diastolic BP. Office brachial BP: After at least 10 
minutes of rest in a supine position, office brachial BP was measured by trained technician in 
duplicate using a validated manual sphygmomanometer with suitable sized cuff, as per 
recommendations.
4, 198
 The mean of these two readings was used for subsequent analysis. 
Office central BP: A validated and highly reproducible radial applanation tonometry
47, 48
 
using the SphygmoCor system (SphygmoCor 8.1, AtCor Medical, Sydney, NSW) was used 
to measure office central BP. The mean of the office brachial BP measurements, measured 
before the radial applanation tonometry, was used to calibrate the radial pressure waveform. 
Clinical biochemistry: Standard clinical biochemistry included analysis of glucose, 
glycosylated haemoglobin (HbA1c), triglycerides, total, low-density and high-density 
lipoprotein cholesterol, as per routine pathology laboratory procedures. 
5.3.6 Data analysis, statistics and feature annotation  
As previously reported,
194
 we found that principle components analysis (PCA; and its 
variants) was ineffective for identifying differences in the LC-MS data. Thus, as before, we 
used a repeated-measures ANOVA to compare each feature and then corrected the resulting p 
values using the Benjamini and Hochberg False Discovery Rate correction.
194
 Features were 
accepted as being significantly different if the corrected p < 0.05. The LC-MS data were 
hand-checked for artefacts (for example, Fourier-transform ‘shoulders’) before being de-
isotoped and putatively annotated using the Human Metabolome Database (HMDB) and the 
Taverna workflows.
196
 Compounds of interest were further examined by MS/MS to provide 
additional structural information and to confirm annotation, where possible, by comparison 
with MS/MS spectra held in public databases.  
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Post-intervention NMR data were mean-centred and Pareto-scaled, before being analyzed 
using PCA and partial least squares-discriminant analysis (PLSDA), both in PLS Toolbox 
(PLS Toolbox 6.5, Eigenvector Research Inc., Wenatchee, US). Permutation testing was used 
to assess whether PLSDA models were the result of over-fitting; models were considered 
significant if the estimated p < 0.05.  
Data processing of metabolomics data and subsequent statistical analysis were all conducted 
in Matlab. All additional statistical analysis was conducted using SPSS 17.0 (SPSS Inc., 
Chicago, Illinois, USA). Clinical characteristics of study participants are presented as mean 
and standard error of the mean (SEM). Comparisons between placebo and spironolactone 
groups were performed by independent t-tests. Comparisons between categorical variables 
were assessed by chi-squared tests. Changes in hemodynamic variables were adjusted by 
analysis of covariance (ANCOVA) for potential confounders. Metabolomics data, when 
included in an analysis with conventional data, was checked for normality and non-normally 
distributed data was square-root-transformed. Associations between metabolites of interest 
and physiological variables were assessed by linear correlation. Multiple regression was used 
for the predictors of change in physiological parameters after treatment. In all cases, a value 
of p < 0.05 was taken as statistically significant.  
5.4 Results 
5.4.1 Clinical characteristics 
Of the 115 participants included in the clinical trial, 58 were randomized to spironolactone 
treatment and 57 to placebo. Of these, serum samples were available from 92 participants for 
the metabolomics analysis (43 in placebo group and 49 in spironolactone group). Two study 
participants were taking antihypertensive drugs (one in the placebo and one in the 
spironolactone group), but these were not excluded from the metabolomics analysis. Table 
5.1 represents the baseline clinical characteristics of study participants, which was not 
significantly different from the complete study population. 
  
78 
 
Table 5.1  Clinical characteristics of study participants at baseline 
Variable Placebo                    
(n = 43) 
Spironolactone       
(n = 49) 
p value 
Age (years) 55 ± 1 55 ± 1 0.961 
Sex (% male) 55.8 59.2 0.833 
BMI (kg/m
2
) 29.1 ± 0.6 29.2 ± 0.7 0.993 
Type 2 diabetes mellitus (%) 4 (9.3) 9 (18.4) 0.344 
24 hour SBP (mmHg) 133 ± 2 133 ± 1 0.894 
24 hour PP (mmHg) 53 ± 1 54 ± 1 0.288 
Day SBP (mmHg) 137 ± 2 137 ± 1 0.978 
Day PP (mmHg) 54 ± 1 55 ± 1 0.575 
Night SBP (mmHg) 117 ± 2 118 ± 2 0.694 
Night PP (mmHg) 47 ± 1 50 ± 1 0.050 
Office brachial SBP (mmHg) 125 ± 2 126 ± 2 0.724 
Office brachial PP (mmHg) 52 ± 2 52 ± 1 0.802 
Office central SBP (mmHg) 114 ± 2 114 ± 2 0.795 
Office central PP (mmHg) 40 ± 1 39 ± 1 0.954 
Aortic PWV (m/s) 8.2 ± 0.3 8.4 ± 0.3 0.588 
Glucose (mmol/L) 5.7 ± 0.2 5.9 ± 0.3 0.461 
HbA1c (%) 5.9 ± 0.1 6.0 ± 0.2 0.531 
Triglycerides (mmol/L) 1.5 ± 0.2 1.5 ± 0.2 0.790 
Total cholesterol (mmol/L) 5.3 ± 0.1 5.1 ± 0.1 0.368 
LDL cholesterol (mmol/L) 3.3 ± 0.1 3.2 ± 0.1 0.608 
HDL cholesterol (mmol/L) 1.4 ± 0.1 1.4 ± 0.1 0.965 
ACE inhibitors (%) 1 (2.3) 1 (2.0) 1.000 
Statins (%) 9 (20.9) 7 (14.3) 0.573 
BMI, body mass index; SBP, systolic blood pressure; PP, pulse pressure; PWV, pulse wave 
velocity; HbA1c, glycosylated haemoglobin; LDL, low density lipoprotein; HDL, high density 
lipoprotein; ACE, angiotensin converting enzyme; values are mean ± SEM or %; p < 0.05 
was considered significant 
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5.4.2 Metabolomics (LC-MS)  
All data (pre/post and spironolactone/placebo) were combined and pre-processed together 
using XCMS. We identified 7363 common features across the combined mass spectra 
acquired in negative ionization mode and 9185 features from the spectra acquired in positive 
ionization mode. Of these, 42 features (34 from negative and eight from positive ionization 
mode) were significantly different in the spironolactone group compared with placebo 
(p < 0.05 after the Benjamini and Hochberg False Discovery Rate correction). Nine isotopes 
and 17 adducts were subsequently identified and removed, leaving 16 features for further 
investigation. However, we were not able to putatively annotate any of these as being 
endogenous (i.e. non-xenobiotic) metabolites. Since these 16 features were undetectable in 
any but the post-spironolactone group and none could be annotated using any public human 
metabolomics repositories, we concluded that these features were almost certainly 
downstream breakdown products of spironolactone itself. As a result, several were 
immediately identified (from accurate mass and MS/MS) as signals from the most 
commonly-reported breakdown products of spironolactone: canrenoate (CHEBI: 50159; 
357.2071 m/z in negative ion mode) and canrenone (CHEMBL42874: 341.2111 m/z in 
positive ion mode; Figure 5.2).  
 
Figure 5.2  Spironolactone downstream metabolites 
Spironolactone downstream metabolites (A) canrenoate and (B) canrenone measured by LC-
MS (n = 49). 
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5.4.3 Metabolomics (NMR)  
The post-spironolactone and post-placebo groups were normalised and pre-processed 
together. The adaptive intelligent binning algorithm identified 336 spectral regions of 
interest. Yet despite outstanding spectral quality resulting from the high field strengths 
employed, subsequent analysis of the NMR data using both principal component analysis and 
partial least squares-discriminant analysis was unable to identify any significant effect of 
spironolactone treatment (p > 0.05 for all models). 
5.4.4 Hemodynamic response to spironolactone 
As per Table 5.2, the group that received spironolactone for three months had a significant 
reduction in all ambulatory BP values, except for night systolic BP where the reduction was 
of borderline significance. There was a larger decrease in office brachial and central BP in the 
spironolactone treatment group compared to placebo, but these changes were also of 
borderline statistical significance. Aortic PWV decreased significantly in the spironolactone 
group compared with placebo group. However, the reduction in aortic PWV was no longer 
significant after adjustment for the change in daytime systolic BP (p = 0.132).  
Table 5.2  Changes in hemodynamic variables in placebo compared to spironolactone group 
after three months of treatment 
Variable Placebo 
(n = 43) 
Spironolactone 
(n = 49) 
p value 
Δ 24 hour SBP (mmHg) 0.8 ± 1.3 -3.5 ± 1.0 0.010 
Δ 24 hour PP (mmHg) 2.3 ± 1.1 -2.3 ± 0.7 <0.001 
Δ Day SBP (mmHg) 1.1 ± 1.4 -3.3 ± 1.1 0.014 
Δ Day PP (mmHg) 2.6 ± 1.5 -2.0 ± 0.8 0.007 
Δ Night SBP (mmHg) 0.5 ± 1.9 -3.9 ± 1.5 0.067 
Δ Night PP (mmHg) 1.4 ± 1.2 -2.6 ± 0.9 0.010 
Δ Office brachial SBP (mmHg) -0.4 ± 1.3 -3.6 ± 1.2 0.070 
Δ Office brachial PP (mmHg) -0.9 ± 1.3 -1.9 ± 1.0 0.560 
Δ Office central SBP (mmHg) -0.7 ± 1.3 -3.9 ± 1.1 0.063 
Δ Office central PP (mmHg) -1.3 ± 1.1 -2.2 ± 0.8 0.488 
Δ Aortic PWV (m/s) 0.30 ± 0.16 -0.18 ± 0.17 0.047 
SBP, systolic blood pressure; PP, pulse pressure; PWV, pulse wave velocity; values are mean 
± SEM; p < 0.05 was considered significant 
81 
 
5.4.5 Associations between hemodynamic parameters and spironolactone metabolites  
Changes in hemodynamic parameters were correlated with the post-spironolactone signal 
intensity for each of the metabolomic features of interest. There were no significant 
correlations between the change in aortic PWV and any metabolic features, including 
canrenoate and canrenone (p > 0.05 for all). However, canrenoate was associated with the 
change in daytime systolic BP and the change in 24 hour PP (Figure 5.3). On the other hand, 
there were no significant associations between the changes in canrenone and ambulatory BP 
values after treatment (p < 0.05 for all). The change in aortic PWV was significantly related 
to the change in daytime systolic BP and the change in 24 hour systolic BP (Figure 5.4).  
5.4.6 Multiple regression analysis 
The change in daytime systolic BP was significantly correlated with canrenoate (r = -0.355, 
p = 0.017), the change in aortic PWV (r = 0.333, p = 0.024), body mass index (r = -325, 
p = 0.023), change in 24 hour systolic BP (r = 0.875, p < 0.001), change in 24 hour PP 
(r = 0.527, p < 0.001), change in 24 hour diastolic BP (r = 0.583, p < 0.001) and change in 
daytime diastolic BP (r = 0.610, p < 0.001). A multiple regression model for predictors of the 
change in daytime systolic BP was constructed, with the following variables entered as 
covariates; age, sex, body mass index, the use of statins and angiotensin converting enzyme 
inhibitors, canrenoate and the change in aortic PWV. Ambulatory BP variables were not 
included in the model due to collinearity or non-significance. Canrenoate (β = -0.394, 
p = 0.012) and the change in aortic PWV (β = 0.445, p = 0.011) were independent predictors 
of the change in daytime systolic BP (Adjusted R
2 
= 0.212, p = 0.031). A multiple regression 
model for predictors of the change in aortic PWV was also constructed, with the age, sex, 
body mass index, the use of statins and angiotensin converting enzyme inhibitors, canrenoate, 
the change in office brachial systolic BP and the change in daytime systolic BP entered as 
independent variables. The change in daytime systolic BP (β = 0.344, p = 0.029) and female 
gender (β = -0.410, p = 0.006) were independent predictors of the change in aortic PWV 
(Adjusted R
2 
= 0.315, p = 0.006), whereas canrenoate was of borderline significance 
(β = 0.293, p = 0.058) and the change in office brachial systolic BP was not significant 
(β = 0.167, p = 0.230). 
Further data analysis concerning the effects of spironolactone treatment on exercise BP is 
presented in Appendix 3 of the thesis. 
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Figure 5.3  Correlations with the spironolactone metabolite canrenoate 
Correlations with the spironolactone metabolite canrenoate (expressed relative to the group 
mean signal intensity). LEFT: the change in daytime systolic blood pressure (SBP); RIGHT: 
the change in 24 hour pulse pressure (PP), both after three months of spironolactone 
treatment (n = 49). 
 
 
 
Figure 5.4  Correlations with the change in aortic pulse wave velocity 
Correlations with the change in aortic pulse wave velocity (PWV). LEFT: the change in 
daytime systolic blood pressure (SBP); RIGHT: the change in 24 hour pulse pressure (PP), 
both after three months of spironolactone treatment (n = 49). 
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5.5 Discussion 
To our knowledge, this is the first study that has used the combination of metabolomics and 
hemodynamics to examine the underlying physiological actions of spironolactone. The 
principal findings were that: i) spironolactone did not induce any detectable changes in the 
endogenous metabolite profile, ii) the changes in aortic stiffness were due to a reduction in 
ambulatory BP over three months of daily spironolactone treatment and iii) canrenoate may 
be responsible for the ambulatory BP-lowering effect but not for the reduction in aortic 
stiffness. These findings suggest that spironolactone has a BP-dependent effect on the 
attenuation of aortic stiffness, with canrenoate being the major active metabolite. 
Spironolactone has been found to be effective in people with heart failure, a condition 
associated with advanced cardiac fibrosis.
208
 Indeed, in the Randomized Aldactone 
Evaluation Study (RALES), spironolactone significantly reduced mortality by 30 %, together 
with a reduction in cardiac fibrosis (markers of cardiac collagen turnover), compared with 
placebo.
59, 208
 Although the mechanism is not clear, beneficial effects of spironolactone in 
these individuals has been attributed to the antagonising effects of aldosterone on cardiac 
mineralocorticoid receptors, thus preventing the progression of cardiac fibrosis.
59
 Recent 
studies have also confirmed the presence of mineralocorticoid receptors in vascular smooth 
muscle cells, endothelial cells, and fibroblasts.
209-211
 It has been suggested that, irrespective of 
BP control, blocking vascular mineralocorticoid receptors may prevent or attenuate negative 
effects of aldosterone on the structure and function of the vascular wall.
58, 61, 212
 Thus, 
spironolactone treatment has been purported to improve vascular function via BP-
independent, antifibrotic mechanisms.
58, 212
 
We used metabolomics to study metabolites in an unbiased, untargeted manner and 
investigate whether spironolactone causes metabolic perturbations that might explain arterial 
wall effects of spironolactone in individuals with an HRE. Despite using state-of-the-art 
analytical platforms, and subject numbers within recommended ranges to achieve sufficient 
power,
121
 systematic changes in endogenous metabolism were not detected. Confidence in the 
sensitivity of the methods is provided by identification of known xenobiotic metabolites. 
However, it should be noted that our study cohort was reasonably healthy without established 
hypertension at rest and, therefore, we cannot exclude the possibility that significant 
metabolic effects of spironolactone may have only been detectable in individuals with more 
advanced arterial stiffness and sustained hypertension, or those with other (possibly 
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metabolic) co-morbidities. Indeed, under conditions of severe aortic stiffness the effects of 
spironolactone may become BP-independent through mineralocorticoid/antifibrotic 
mechanisms of action, but this need to be tested in other studies. Although previous studies 
report on the possible BP-independent effects of spironolactone within periods less than three 
months, it could also be argued that this was an insufficient treatment period in the current 
work.  
Previous studies
60, 61
 have reported that the effect of spironolactone in reducing arterial 
stiffness was independent of mechanical factors (e.g. decrease in pressure load). Even if one 
accepts the possibility that spironolactone has a BP-independent effect on the arterial wall (at 
least in individuals with more advanced arterial stiffness, as suggested above), overall BP-
dependent effects of spironolactone on arterial function could have been more thoroughly 
estimated by taking into account all measures of BP that spironolactone is known to affect 
(i.e. brachial, central and ambulatory BP). For example, treatment with spironolactone for 40 
weeks reduced measures of arterial stiffness, which remained significant after correcting for 
the reduction in mean office BP, and, thus, interpreted as a BP-independent effect of 
spironolactone. 
60
 However, the authors also reported a significant reduction in ambulatory 
BP but this was not statistically accounted for.
60
 Mahmud et al
61
 in a yet smaller study 
(n=24), reported that the change in aortic PWV after spironolactone treatment was no longer 
significant after correcting for resting mean BP, again suggesting a BP-independent effect, 
but no account was made for possible changes in ambulatory BP. On the other hand, lack of a 
change in aortic PWV observed in hypertensive people after six months of spironolactone 
treatment could also be explained by the lack of change in ambulatory BP values.
213
 Taken all 
together, the effect of the change in BP induced by spironolactone treatment on arterial 
properties in previous studies might have been underestimated.  
Our study supports the notion that the overall BP reduction induced by spironolactone could 
have a significant beneficial effect on arterial physiology, producing an effect that is mostly, 
if not entirely, BP-dependent. Indeed, we found that spironolactone significantly reduced 
aortic PWV, but this reduction was no longer significant when corrected for the reduction in 
ambulatory BP, despite the absence of a significant change in resting office brachial or 
central BP. Importantly, the change in daytime systolic BP was a significant predictor of the 
change in aortic PWV on multiple regression analysis independently of the change in resting 
office brachial BP. As spironolactone has a very short half-life once it is absorbed, major 
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effects of spironolactone are mainly attributed to its active metabolites with a longer half-life 
(up to 22 hours), such as canrenoate and canrenone.
207
 Notably, the metabolite canrenoate 
independently correlated with the change in ambulatory BP suggesting that this is an active 
metabolite of spironolactone with regard to its BP-lowering effect.  
In conclusion, spironolactone seems to improve aortic stiffness via BP-dependent effects.  In 
this current study, we show that in people with an HRE, spironolactone had no significant 
metabolic effects, and all improvements in aortic stiffness were related to ambulatory BP 
reduction by spironolactone. These findings, together with the association of canrenoate with 
ambulatory BP reduction, suggest that the reduction in aortic stiffness by spironolactone was 
due to BP-dependent, rather than the BP-independent or antifibrotic, effects of 
spironolactone. This new information highlights the importance of using out-of-office BP 
measures when assessing the clinical, and so-called BP-independent, effects of 
antihypertensive medications such as spironolactone.  
5.6 Contribution of chapter 5 to thesis aims 
Chapter 5 represents the first application of the metabolomics analysis in people with an 
HRE. This study was primarily used to develop a methodology regarding metabolomics 
analysis, but it was also a convenient sample to explore the metabolic actions of the 
aldosterone antagonist spironolactone on exercise BP and aortic stiffness in people with an 
HRE. Utilising the metabolomics technique, this study showed that spironolactone did not 
have any significant endogenous metabolic effects in people with an HRE, but reduced the 
exercise BP, as well as aortic stiffness, by BP-lowering effects. Importantly, Chapter 5 
further supports the results from Chapter 4 that vascular haemodynamic factors, such as 
increased aortic stiffness, are less relevant to exercise BP than what is widely thought, given 
the lack of a significant relationship between the reductions in aortic stiffness and exercise 
BP by spironolactone treatment. Whilst this study itself represents an important contribution 
to knowledge surrounding treatment strategies to improve an HRE, this study also 
demonstrates how the application of metabolomics combined with haemodynamic measures 
could be a powerful method to characterise metabolic pathways associated with CV diseases.  
Once the technique was developed, metabolomics analysis was used to explore the metabolic 
factors that might be contributing to an HRE in a population with the high prevalence of an 
HRE, such as those with type 2 diabetes mellitus (presented in Chapter 6).  
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Chapter 6. Serum Metabolic Profile Predicts Adverse 
Central Haemodynamics in Patients with Type 2 Diabetes 
Mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the time of thesis submission, this chapter is under peer review in Acta Diabetologica. 
Sonja B. Nikolic, Lindsay M. Edwards, Yuliya V. Karpievitch, Richard Wilson, James 
Horne, Murray J. Adams, James E. Sharman 
 
This chapter reports on possible metabolic factors that may be contributing to a hypertensive 
response to exercise at moderate intensity in participants with type 2 diabetes mellitus (a 
population with the high prevalence of a hypertensive response to exercise). This was 
achieved by exploring metabolic perturbations (utilising untargeted metabolomics analysis) 
that were related to both peripheral and central haemodynamic variables recorded during 
resting, as well as exercise conditions.  
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6.1 Abstract  
Background. People with type 2 diabetes mellitus (T2DM) have abnormal peripheral and 
central haemodynamics at rest and during exercise, probably due to metabolic perturbations, 
but mechanisms are unknown. We used untargeted metabolomics to determine the 
relationships between metabolic perturbations and haemodynamics (peripheral and central) 
measured at rest and during exercise.  
Methods. Serum samples from 39 participants with T2DM (62 ± 9 years; 46% male) and 39 
controls (52 ± 10 years; 51% male) were analysed by liquid chromatography-mass 
spectrometry, nuclear magnetic resonance spectroscopy and principal component analysis. 
Scores on principal components (PC) were used to assess relationships with haemodynamics 
including peripheral and central BP, central augmentation index (AIx) and central 
augmentation pressure (AP).  
Results. Participants with T2DM had higher resting and exercise haemodynamics (peripheral 
and central BP, central AIx and central AP) compared to controls (p < 0.05). PC comprised of 
a signature metabolic pattern of disordered carbohydrate metabolism in T2DM was 
independently associated with resting and exercise central AIx and central AP (p < 0.05). 
Glucose alone independently predicted central BP, rest and exercise central AIx and exercise 
AP (p < 0.05).  
Conclusion. Serum metabolic profile was associated with resting and exercise central, but 
not peripheral, haemodynamics in T2DM participants, suggesting that metabolic irregularities 
may explain abnormal central haemodynamics in T2DM patients.  
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6.2 Introduction 
Type 2 diabetes mellitus (T2DM) is associated with increased risk of cardiovascular (CV) 
morbidity and mortality.
214
 High brachial blood pressure (BP) is common in T2DM, affecting 
up to 40% of newly diagnosed T2DM patients and significantly contributing to CV 
complications.
162
 T2DM is also associated with premature vascular aging and arterial 
structural remodelling, leading to increased arterial stiffness.
92
 However, T2DM has a greater 
impact on central arterial stiffness - and central BP indices - than the stiffness of peripheral 
arterial segments (measured by pulse wave velocity, PWV).
215
 This is an important 
observation, as central arterial stiffness (or aortic PWV) and central BP indices such as 
augmentation index (AIx) are significant independent predictors of CV risk.
12
  
Interestingly, increased central BP (including central systolic BP and AIx) are independent 
predictors of the onset of T2DM, even after correcting for mean BP and baseline glucose 
concentrations.
216
 However, these early CV changes are not always apparent when subjects 
are tested under resting conditions. Indeed, the stress of exercise may reveal BP abnormalities 
that fail to be detected by conventional BP screening.
6
 People with T2DM who are 
normotensive at rest have a higher prevalence of exercise hypertension both peripherally and 
centrally (also referred as a hypertensive response to exercise [HRE]) than age-matched 
controls.
11
 An HRE at moderate intensity has been associated with an increased risk of CV 
events and mortality when compared to those having a normotensive BP response to 
exercise.
5
 The pathophysiological mechanisms underlying abnormal peripheral and central 
haemodynamics at rest and during exercise in T2DM are yet to be elucidated.  
The pathogenesis of T2DM is complex, involving genetic, environmental and lifestyle factors 
such as diet, lack of physical activity and obesity. Together, these lead to progressive decline 
in metabolic control and ultimately diabetes.
163
 These metabolic disturbances may also 
adversely impact on central arterial haemodynamics and contribute to CV complications,
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but the exact mechanisms are unclear. Metabolomics (the comprehensive analysis of low-
molecular weight molecules in biological systems) has been increasingly used to evaluate 
perturbations associated with T2DM and have revealed alterations in the metabolism of 
carbohydrates, lipids, amino acids and bile acids.
164
  Understanding how modification of the 
metabolic profile may influence peripheral or central haemodynamics (at rest and during 
exercise) could provide mechanistic insights of disease progression in people with T2DM.  
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In this study, we used untargeted metabolomics analysis and pattern recognition (principal 
component analysis; PCA) with the aim of identifying metabolic perturbations in people with 
T2DM compared with healthy non-diabetics. We aimed to determine the relationships 
between metabolic patterns (principal components; PC) and both peripheral and central 
haemodynamics recorded during resting and exercise conditions. Given the central 
haemodynamic disturbances in patients with T2DM, and also that exercise provides a means 
to reveal haemodynamic irregularity that may be obscured at rest, we hypothesised that 
metabolomic profiles would be more closely associated with central haemodynamics (and 
exercise) than with peripheral haemodynamics.  
6.3 Methods  
6.3.1 Study participants  
Forty participants with T2DM and 40 sex-matched non-diabetic controls were recruited for 
this study through local community advertisements. Participants were excluded if they were 
below 18 years of age, pregnant or had a clinical history of cardiovascular complications 
including myocardial infarction, stroke or sustained arrhythmia. Of 80 participants, two 
participants were additionally excluded due to a missing serum sample (control group) and 
haemodynamic data (diabetic group). T2DM was diagnosed by the participants’ physician 
according to the accepted clinical criteria for hyperglycemia (fasting or two hours post 
glucose load).
217
 The study was approved by the Human Research Ethics Committee of the 
University of Tasmania. All procedures were performed in accordance with the Declaration 
of Helsinki and all participants provided informed consent.   
6.3.2 Study protocol 
Resting serum blood samples were acquired in the morning after over-night fasting for 
metabolomics analysis and clinical chemistry measures, and participants were fitted with an 
ambulatory BP device to measure 24 hour BP. On another occasion scheduled within seven 
days (also in the morning), participants were examined for peripheral and central 
haemodynamics at rest and during exercise in a quiet and temperature-controlled room. 
Participants refrained from consuming heavy meals and caffeine or smoking for at least three 
hours prior to examination and avoided exercise on the day of examination. Brachial BP was 
measured after 10 minutes of rest on a bed in semi-recumbent position, followed by 
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measurements of central BP, AIx, augmentation pressure (AP), aortic stiffness and systemic 
vascular resistance index (SVRi). When resting measures were completed, participants were 
asked to perform moderate intensity semi-recumbent cycling exercise (60% of age predicted 
maximal heart rate) on a bicycle ergometer positioned on the bed (Rehab Trainer 881, 
MONARK Exercise110 AB, Vansbro, Sweden), and all measures were repeated during 
exercise, as previously described.
188
 
6.3.3 Clinical chemistry  
Serum samples were analysed using standard laboratory procedures to determine glucose, 
glycated haemoglobin (HbA1C), insulin, triglycerides, total, low-density lipoprotein (LDL) 
and high-density lipoprotein (HDL). 
6.3.4 Haemodynamic variables   
Peripheral haemodynamics. Brachial BP was measured in duplicate by a trained non 
clinician using a validated semi-automated device (Omron HEM-907; OMRON Europe B.V. 
(OMCE), Hoofddorp, The Netherlands),
183
 in accordance with guidelines.
4
 Pulse pressure 
(PP) was defined as the difference between systolic and diastolic BP defined Brachial BP 
during exercise was acquired in duplicate using a validated mercury-free sphygmomanometer 
(UM-101B, A&D Medical, Thebarton, South Australia).
184
 An HRE was defined as exercise 
peripheral systolic BP ≥ 170 mmHg for men and ≥ 160 mmHg for women (or the highest 
tertile of the study population, as previously described).
199
 Ambulatory BP was measured 
every 20 minutes during the day and every 30 minutes during the night using a TM-2430 
monitor (A&D Medical, Sydney, Australia). Cardioimpedance was used to measure SVRi 
(Physio Flow; Manatec Biomedical; Macheren, France).
193
 Central haemodynamics. 
Duplicate measures of central BP were recorded at rest and during exercise using validated 
and reproducible radial applanation tonometry (SphygmoCor 8.1, AtCor Medical, Sydney, 
NSW).
47, 48
 The pressure waveforms were calibrated using the brachial systolic and diastolic 
BP values measured prior to applanation tonometry. AP was calculated as the difference 
between the second and first systolic peak of the central pressure waveform, and expressed as 
a percentage of the PP for definition of AIx (also normalised to heart rate of 75 bpm). Resting 
and exercise aortic stiffness was measured by pulse wave velocity (PWV) and applanation 
tonometry (SphygmoCor 8.1, AtCor Medical, Sydney, NSW).
177
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6.3.5 Metabolomics analysis  
Liquid chromatography-mass spectrometry (LC-MS) - Collected blood samples for 
metabolomics analysis were allowed to clot at room temperature for 30 minutes before being 
centrifuged at 3000 rpm for 15 minutes. Serum was transferred into aliquot tubes and stored 
at -80°C until analysis. Samples were thawed and a 100 µL aliquot of each sample was mixed 
with 300 µL of ice-cold methanol, incubated at 4°C for 20 minutes and centrifuged at 13200 
g for 10 minutes. The supernatant was lyophilized in a vacuum centrifuge (Labconco, Kansas 
City, USA) and re-stored at -80°C. The dried samples were reconstituted in 100 µL of HPLC-
grade water prior to LC-MS analysis. Samples were vortexed and centrifuged for 15 minutes, 
and supernatant was transferred to vials.
10
 Quality control (QC) samples were prepared by 
mixing 10 µL aliquots taken from each study sample and analysed throughout the LC-MS 
runs to ensure analytical consistency and correct for systematic drifts (four study samples 
were bracketed by two QCs). Samples from participants with T2DM were matched with 
samples from non-diabetic participants by age, sex, and anthropometric measures and were 
analysed together to protect against systematic bias. An LTQ-OrbitrapXL mass spectrometer 
(ThermoFisher Scientific, Bremen, Germany) controlled by XCalibur v2 software 
(ThermoFisher Scientific) was used for sample analysis. Chromatographic separation was 
performed on a Waters Nova-Pak 4.0 µm C18 column (3.91x150 mm) with an injection 
volume of 10 µL. The mobile phases used for the sample elution were A) 0.1% formic acid in 
water and B) 0.1% formic acid in methanol, with a flow rate of 0.8 mL/minute. Both positive 
(PIMS) and negative (NIMS) ionization modes were used for data acquisition. XCMS 
software running in R (R 2.14; http://cran.r-project.org/) was used for data processing - peak 
finding, grouping and retention time alignment. The parameters for deconvolution were: 
method='centWave', ppm=3, peakwidth=5-30, snthresh=6, mzdiff=0.01; and for retention 
time correction: method="obiwarp" and profStep=0.1. A singular value decomposition-based 
method (EigenMS) was used for data normalisation. 
Proton nuclear magnetic resonance (
1
H NMR) spectroscopy – A 500 µL aliquot of serum 
was mixed with 1 mL of methanol (2:1 v/v with original sample), incubated in a -20°C 
freezer for 20 minutes and centrifuged for 10 minutes at 13,200 g. Supernatants were dried in 
a vacuum centrifuge overnight (Labconco, Kansas City, USA), re-suspended in 700 µL NMR 
buffer (2 mM 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt in D2O) and stored at -
80°C until the analysis. 
1
H NMR spectra were acquired using an Agilent/Varian Inova 
92 
 
400 MHz wide bore spectrometer (Varian Medical Systems, Palo Alto, CA, USA), in a 5mm 
ID-PFG probe, as described previously.
218
 Briefly, spectra were acquired with 90° pulse 
excitation, sweep width of 4,299 ppm and relaxation delay of 2 seconds at 25°C. A total of 
128 transients were collected into 32000 complex data points. The water resonance was set to 
the centre of the sweep width on the transmitter offset and attenuated using a pre-saturation 
pulse of 2 seconds during the relaxation delay and the mixing time (100 ms) of the NOESY 
pulse sequence. Data were Fourier-transformed, probalistic-quotient normalised and ‘binned’ 
using an adaptive-intelligent algorithm described elsewhere.
112
  
6.3.6 Data analysis, statistics and feature annotation  
The 
1
H NMR and LC-MS data were mean-centred and Pareto-scaled before using PCA to 
dimensionally reduce the data using PLS Toolbox 6.5 (Eigenvector Research Inc., 
Wenatchee, US). Visual inspection of a ‘scree’ plot of captured variance versus number of 
components was used to identify the number of PCs comprising each model (prior to any 
further analysis). Plots of scores on each PC were visually inspected. Those that appeared to 
separate the groups were compared using an independent t-test. Loading coefficients were 
used to identify metabolites that significantly contributed to discriminatory PCs. In addition, 
individual metabolites were compared across groups by independent t-test with significance 
cut-off p = 0.05 after Benjamini-Hochberg multiple testing adjustment.
195
 The LC-MS data 
were checked for artefacts, de-isotoped and putatively annotated using online databases and 
the Taverna workflows.
196
 Unambiguous identification of LC-MS metabolites was confirmed 
by tandem mass spectrometry (MS/MS), 
1
H NMR spectroscopy and online databases. All 
identified metabolites listed in results are accompanied by the METLIN identification (MID) 
number.  
The rest of the standard statistical analyses were conducted using SPSS 20.0 (IBM SPSS 
Statistics for Windows, Armonk, NY: IBM Corp). Clinical characteristics of study 
participants were presented as mean and standard deviation. Comparisons between 
participants with T2DM and non-diabetic controls were performed by independent t-tests, 
whereas comparisons between categorical variables were assessed by chi-squared tests. 
Analysis of covariance was used to explore the difference in aortic PWV between groups 
while adjusting for resting peripheral BP. Associations between PCs, individual identified 
metabolites and physiological variables were assessed by Pearson correlations. Multiple 
linear regression was used to assess the independent associations between PCs and 
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haemodynamic variables, while correcting for age, sex, body mass index, the use of 
antihypertensive medications and statins. A p-value of 0.05 was used as a significance cut-
off.  
6.4 Results 
6.4.1 Clinical characteristics  
Table 6.1 represents the clinical characteristics of study participants. There were no 
differences in sex between groups, but participants with T2DM were older, had higher waist-
to-hip ratio, body mass index, and were taking more medications (statins and 
antihypertensives) compared to non-diabetic controls. As expected, T2DM participants had 
significantly higher fasting serum glucose, HbA1C, triglycerides and insulin concentrations 
than controls. However, total cholesterol, HDL and LDL cholesterol were significantly lower 
in participants with T2DM, probably due to lipid lowering medications. 
Table 6.1  Clinical characteristics of study participants 
Characteristics Control           
(n = 39) 
T2DM                    
(n = 39) 
p value 
Age (years) 52 ± 10 62 ± 9 <0.001 
Sex, male (%) 46 51 0.821 
Body mass index (kg/m
2
) 24.7 ± 3.1 31.1 ± 5.5 <0.001 
Antihypertensive medications (%) 0 61 <0.001 
Statins (%)  0 64 <0.001 
Diabetic medications (%) 0 67 <0.001 
Glucose (mmol/L) 4.7 ± 0.4 7.6 ± 1.8 <0.001 
 HbA1C (%) 5.5 ± 0.4 7.2 ± 0.8 <0.001 
Insulin (mU/L) 2.4 ± 4.6 10.3 ± 8.8 <0.001 
Triglycerides (mmol/L) 1.0 ± 0.5 1.5 ± 0.7 <0.001 
Total cholesterol (mmol/L) 5.4 ± 1.0 4.4 ± 1.0 <0.001 
HDL cholesterol (mmol/L) 1.7± 0.4 1.3 ± 0.4 <0.001 
LDL cholesterol (mmol/L) 3.3 ± 0.9 2.7 ± 0.8 <0.001 
Glycated haemoglobin HDL, high density lipoprotein; LDL, low density lipoprotein. 
6.4.2 Haemodynamic variables  
Table 6.2 summarises the peripheral and central haemodynamic variables measured at rest 
and during exercise.  
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Table 6.2  Peripheral and central haemodynamic variables measured at rest and during 
exercise in participants with type 2 diabetes mellitus compared with non-diabetic controls 
Characteristics Control (n = 39) T2DM (n = 39) p value 
Peripheral haemodynamics    
Brachial systolic BP (mmHg) 114 ± 9 125 ± 13 <0.001 
Brachial pulse pressure (mmHg) 49 ± 4 56 ± 11 <0.001 
Brachial diastolic BP (mmHg)  65 ± 6 69 ± 8 0.011 
SVRi (dyne/s/cm
5
) 2780 ± 361 2750 ± 471 0.754 
Ex brachial systolic BP (mmHg) 135 ± 14 156 ± 17 <0.001 
Ex brachial pulse pressure (mmHg) 62 ± 11 79 ± 15 <0.001 
Ex brachial diastolic BP (mmHg) 73 ± 8 78 ± 8 0.017 
Ex SVRi (dyne/s/cm
5
) 1843 ± 323 2028 ± 352 0.019 
24h systolic BP (mmHg) 130 ± 12 135 ± 13 0.095 
24h pulse pressure (mmHg) 51 ± 12 59 ± 10 <0.001 
Daytime systolic BP (mmHg) 136 ± 13 139 ± 15 0.331 
Daytime pulse pressure (mmHg) 52 ± 8 61 ± 10 <0.001 
Night systolic BP (mmHg) 113 ± 11 121 ± 13 0.002 
Night pulse pressure (mmHg) 47 ± 7 54 ± 10 <0.001 
Central haemodynamics    
Central systolic BP (mmHg) 102 ± 9 115 ± 12 <0.001 
Central pulse pressure (mmHg) 36 ± 5 45 ± 9 <0.001 
Central diastolic BP (mmHg) 66 ± 6 70 ± 8 0.013 
Augmentation pressure (mmHg) 8 ± 5 13 ± 5 <0.001 
Augmentation index (%) 13 ± 11 23 ± 6 <0.001 
Aortic pulse wave velocity (m/s) 6.4 ± 1.4 8.0 ± 2.1 <0.001 
Ex central systolic BP (mmHg) 114 ± 12 133 ± 14 <0.001 
Ex central pulse pressure (mmHg) 39 ± 7 53 ± 12 <0.001 
Ex central diastolic BP (mmHg) 75 ± 9 79 ± 9 0.010 
Ex augmentation pressure (mmHg) 8 ± 5 13 ± 5 <0.001 
Ex augmentation index (%) 13 ± 13 25 ± 8 <0.001 
Ex aortic pulse wave velocity (m/s) 7.1 ± 1.4 9.6 ± 2.0 <0.001 
BP, blood pressure; SVRi, systemic vascular resistance index; ex, exercise. 
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Peripheral haemodynamics. Patients with T2DM had higher resting and exercise brachial BP 
compared to non-diabetic controls (p < 0.001). The prevalence of an HRE in T2DM group 
was 31%, and in non-diabetic controls 5%. There were no significant differences in SVRi 
between groups at rest, but during exercise, SVRi was significantly higher in participants 
with T2DM. Ambulatory BP variables were also significantly higher in participants with 
T2DM, except for 24 hour systolic BP and daytime systolic BP. Central haemodynamics. 
Patients with T2DM had higher resting and exercise central BP, AP and AIx compared to 
non-diabetic controls. Resting aortic PWV was also significantly increased, even after 
correcting for the brachial systolic BP (p = 0.029). The change in brachial systolic BP from 
rest to exercise was significantly higher in participants with T2DM compared to non-diabetic 
controls (31 ± 13 mmHg vs. 21 ± 13 mmHg; p = 0.001), and similar for the change in central 
systolic BP (18 ± 12 mmHg vs. 12 ± 11 mmHg; p = 0.026). 
6.4.3 Metabolomics analysis 
The metabolic profiles of participants with T2DM acquired by LC-MS were compared to 
those of non-diabetic controls. PCA models were built for both NIMS and PIMS data. For the 
NIMS, a six-component PCA model accounted for 62% of the total variance. NIMS PC1 
(27% of variance explained; Figure 6.1) and NIMS PC3 (8% of variance explained) gave 
good discrimination between groups (p < 0.001 and p < 0.002, respectively). Examination of 
the loading coefficients revealed metabolites that significantly contributed to NIMS PC1 and 
included glucose (MID 133), fructose (MID 135), lactate (MID 63094), α-N-phenylacetyl-L-
glutamine (MID 58397), glycochenodeoxycholic acid 3-glucuronide and 2-hydroxy-3-(4-
methoxyethylphenoxy)-propanoic acid (MID 1255). The most significant contributor to 
NIMS PC3 was inosine (MID 84), and the relative difference of inosine in T2DM 
participants relative to non-diabetic controls is presented in Figure 6.2. Also, there were no 
significant differences in inosine levels between T2DM participants that were taking 
antihypertensive medications and/or statins compared to those that were not using the 
medications (p > 0.05). For the PIMS data, a three-component PCA model was selected and 
accounted for 79% of the total variance in the data. PIMS PC1 (64% of total variance) gave 
good separation between groups (p < 0.001). Loading coefficients showed that amino acids 
including tyrosine (MID 34), proline (MID 29) and leucine (MID 24) were the significant 
contributors to PIMS PC1. The 
1
H NMR metabolic profiles showed metabolic patterns that 
were similar and complementary to the metabolic profiles acquired using LC-MS. For the 
1
H 
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NMR data, a three-component PCA accounted for 65% of the total variance. NMR PC1 (33% 
of variance explained) and NMR PC2 (21% of variance explained) produced good 
discrimination between groups (p < 0.001 for both). Major NMR PC1 contributors were 
again glucose (MID 133), fructose (MID 135) and lactate (MID 63094), whereas significant 
contributors to NMR PC2 were creatinine (MID 8) and 3-hydroxybutyric acid (MID 85159). 
All metabolites presented were increased in T2DM participants, except for inosine and 
creatinine that were decreased. Identified metabolites were summarised in Table 6.3. 
    
 
Figure 6.1 Score plot 
The score plot from the principal component analysis of negative ion mass spectrometry 
spectra of serum from participants with type 2 diabetes mellitus (T2DM) and non-diabetic 
controls; groups are different on PC1 (p < 0.001). Metabolites that significantly contributed 
to negative ion mass spectrometry spectra  principal component 1 included glucose, fructose, 
lactate, α-N-phenylacetyl-L-glutamine, glycochenodeoxycholic acid 3-glucuronide and 2-
hydroxy-3-(4-methoxyethylphenoxy)-propanoic acid. 
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Figure 6.2  Difference in inosine in participants with type 2 diabetes mellitus (T2DM) 
relative to non-diabetic controls, measured in arbitrary units (a.u.). 
Table 6.3 Summary of identified serum metabolites with significantly different 
concentrations in participants with type 2 diabetes mellitus versus non-diabetic controls 
Metabolite Formula Platform *p 
Glucose C6H12O6 NIMS/NMR 3×10
-13
 
Fructose C6H12O6 NIMS/NMR 4×10
-7
 
Lactate C3H6O3 NIMS/NMR 4×10
-5
 
α-N-Phenylacetyl-L-glutamine C13H16N2O4 NIMS 8×10
-4
 
Glycochenodeoxycholic acid 3-glucuronide C32H51NO11 NIMS 2×10
-6
 
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic 
acid 
C12H16O5 NIMS 4×10
-4
 
Inosine C10H12N4O5 NIMS 4×10
-3
 
Tyrosine C9H11NO3 PIMS 1×10
-4
 
Proline C5H9NO2 PIMS 3×10
-4
 
Leucine C6H13NO2 PIMS 8×10
-6
 
Creatinine C4N7H3O  NMR 1×10
-4
 
3-Hydroxybutyric acid C4H8O3 NMR 1×10
-2
 
NIMS, negative ion mass spectrometry; NMR, nuclear magnetic resonance; PIMS, positive 
ion mass spectrometry; *p value after Benjamini and Hochberg correction. Inosine and 
creatinine were decreased, whereas all other metabolites were increased in participants with 
T2DM compared to non-diabetic controls 
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6.4.4 Associations between metabolomics principal components and haemodynamic 
variables.  
Figure 6.3 illustrates the correlations between PCs (Pearson’s r coefficient, absolute values), 
identified metabolites and peripheral and central haemodynamic variables. Among all PCs, 
NIMS PC1 was the strongest correlate of peripheral and central haemodynamics being the 
highest for rest and exercise central systolic BP, AP and AIx, as well as for exercise brachial 
systolic BP, 24 hour and daytime PP (all r > 0.400). Also, mean univariable correlations of 
NIMS PC1 were highest for exercise central haemodynamics (r = 0.457), followed by rest 
central haemodynamics (r = 0.405), exercise peripheral haemodynamics (r = 0.395), and the 
lowest were for rest peripheral haemodynamics (r = 0.225). Table 6.4 shows the associations 
of NIMS PC1 on multiple regression analysis with individual peripheral and central 
haemodynamics after adjusting for age, sex and body mass index, the use of antihypertensive 
medications and statins. NIMS PC1was significantly associated with exercise SVRi, 24 hour 
and daytime PP. Among central haemodynamics, NIMS PC1 was significantly associated 
with central rest and exercise AP and AIx. When the same regression models were 
constructed with the addition of statins, the results did not change significantly. 
NIMS PC3 was significantly inversely associated with brachial resting (β = -0.231, p = 0.032) 
and exercise (β = -0.212, p = 0.033) systolic BP, even after correcting for age, sex, body mass 
index, the use of antihypertensive medications and statins. NMR PC2 scores were 
significantly, inversely associated with exercise brachial systolic BP and PP, 24 hour and 
daytime PP. Among central haemodynamics, NMR PC2 scores were negatively associated 
with central both resting and exercise BP, exercise central PP, and resting AP and AIx (Table 
6.5) after correction for age, sex, body mass index,  the use of antihypertensive medications 
and statins. 
Among individual metabolites, glucose was the strongest independent predictor of central rest 
systolic BP (β = 0.274, p = 0.032), exercise AP (β = 0.233, p = 0.016) and rest and exercise 
AIx (β = 0.254, p = 0.019 and β = 0.272, p = 0.007; respectively) after correcting for age, sex, 
body mass index, the use of antihypertensive medications and statins.  
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Figure 6.3  Heat plot 
Correlations (Pearson’s r coefficient, absolute values) between principal components, 
identified metabolites and peripheral and central haemodynamic variables measured at rest 
and during exercise. PC, principal component; NIMS, negative ion mass spectrometry; PIMS, 
positive ion mass spectrometry; NMR, nuclear magnetic resonance; BP, blood pressure; PP, 
pulse pressure, AP, augmentation pressure; AIx, augmentation index; PWV, pulse wave 
velocity. Among all PCs, NIMS PC1 was the strongest correlate of peripheral and central 
haemodynamics (highlighted by rectangular box) being the highest for rest and exercise 
central systolic BP, AP and AIx, as well as for exercise brachial systolic BP, 24 hour and 
daytime PP (all r > 0.400).  
100 
 
Table 6.4  Multiple regression analysis assessing the associations of negative ion mass 
spectrometry principal component 1 (NIMS PC1) with peripheral and central haemodynamic 
variables 
Dependent variable Standardized β p value Adjusted R2 
Peripheral haemodynamics    
Brachial systolic BP 0.118 0.399 0.202 
Brachial pulse pressure  0.056 0.677 0.270 
SVRi 0.110 0.490 0.067 
Ex brachial systolic BP 0.102 0.430 0.313 
Ex brachial pulse pressure 0.019 0.875 0.402 
Ex SVRi 0.303 0.041 0.140 
24h pulse pressure 0.389 0.009 0.156 
Daytime pulse pressure  0.401 0.007 0.140 
Central haemodynamics    
Central systolic BP  0.241 0.085 0.210 
Central pulse pressure  0.108 0.392 0.350 
Augmentation pressure  0.276 0.022 0.428 
Augmentation index  0.275 0.020 0.462 
Aortic pulse wave velocity 0.085 0.524 0.294 
Ex central systolic BP  0.158 0.218 0.335 
Ex central pulse pressure 0.085 0.470 0.434 
Ex augmentation pressure  0.243 0.029 0.510 
Ex augmentation index  0.270 0.015 0.535 
BP, blood pressure; SVRi, systemic vascular resistance index; ex, exercise; Adjusted for age, 
sex, body mass index, the use of antihypertensive medications and statins 
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Table 6.5  Multiple regression analysis assessing the associations of nuclear magnetic 
resonance principal component 2 (NMR PC2) with peripheral and central haemodynamic 
variables 
Dependent variable Standardized β p value Adjusted R2 
Peripheral haemodynamics    
Brachial systolic BP -0.214 0.055 0.236 
Brachial pulse pressure -0.111 0.299 0.280 
SVRi 0.031 0.808 0.022 
Ex brachial systolic BP -0.289 0.005 0.384 
Ex brachial pulse pressure -0.203 0.034 0.439 
Ex SVRi -0.079 0.512 0.091 
24hour pulse pressure -0.280 0.020 0.138 
Daytime pulse pressure  -0.252 0.037 0.102 
Central haemodynamics    
Central systolic BP  -0.240 0.033 0.228 
Central pulse pressure -0.188 0.063 0.375 
Augmentation pressure  -0.235 0.015 0.433 
Augmentation index  -0.202 0.036 0.454 
Aortic pulse wave velocity -0.103 0.338 0.300 
Ex central systolic BP  -0.280 0.006 0.392 
Ex central pulse pressure -0.209 0.025 0.470 
Ex augmentation pressure -0.123 0.176 0.488 
Ex augmentation index -0.125 0.170 0.505 
BP, blood pressure; ex, exercise; Adjusted for age, sex, body mass index, the use 
of antihypertensive medications and statins 
6.5 Discussion 
To our knowledge, this is the first study that has used untargeted metabolomics to investigate 
the relationships between resting serum metabolic profile and underlying haemodynamic 
abnormalities in T2DM measured at rest and during exercise. We have found that a PC 
consisting of common metabolites of impaired carbohydrate metabolism was more strongly 
associated with increased central (and exercise) haemodynamics than with peripheral 
102 
 
haemodynamics, suggesting that the metabolic irregularities in glucose metabolism, the 
hallmark of T2DM, may be mechanistically involved in abnormal central haemodynamics. 
Furthermore, inosine was decreased in T2DM participants (implicated as an anti-
inflammatory agent), and inversely associated with the increased BP values (rest and 
exercise), this finding suggests a possible role of inflammation as a contributing factor in 
hypertension development and exaggerated exercise BP.  
The PCA of NIMS data (PC1) identified major contributors to the separation between T2DM 
participants and non-diabetic controls including expected markers of dysfunctional 
carbohydrate metabolism. Increased lactate, as a variable within this PC, suggests not only 
‘overflow metabolism’ but may also signify a systemic decrease in oxidative capacity in 
insulin-resistant skeletal muscle
219
 or adipose tissue.
220
 This signature metabolic pattern 
underlying T2DM was significantly associated with central BP indices (rest and exercise AP 
and AIx; markers of left ventricular [LV] afterload). Also, glucose levels alone independently 
predicted rest central systolic BP, exercise AP and rest and exercise AIx. These observations 
suggest that disordered carbohydrate metabolism may be directly involved in haemodynamic 
abnormalities in diabetics. The underlying mechanisms for closer association with central 
haemodynamics may be due to formation of advanced glycation end-products by non-
enzymatic crosslinks between sugars and amino acids. This occurs preferentially in central 
elastic arterial walls compared to more muscular peripheral arteries, causing alterations in 
elastin and collagen fibres, and increased large artery stiffness. Indeed, high concentrations of 
advanced glycation end-products have been found in post-mortem aorta samples from 
diabetic patients compared to non-diabetic controls and were significantly correlated with the 
aortic stiffness.
94
 Central BP is pathophysiologically more important than brachial BP 
because it closely represents the pressure to which the vital organs (heart, brain and kidneys) 
are exposed. Hence central BP more strongly relates to CV events than brachial BP.
12
 
However, the present study was cross-sectional in nature and we cannot demonstrate 
causality. Also, we cannot exclude the possibility that the metabolic triad of glucose, fructose 
and lactate is simply a surrogate for disease severity with which central haemodynamic 
dysfunction and other pathogenic variables may correlate. NIMS PC1was also significantly 
associated with exercise (but not resting) SVRi, which was significantly increased in T2DM 
participants, suggesting that the changes of peripheral vasculature may be evident during 
physiological stress, such as exercise.  
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We observed decreased levels of inosine (a major contributor of NIMS PC3) in participants 
with T2DM. Inosine is a naturally occurring purine formed from the conversion of adenosine 
by adenosine deaminase and it has been shown to be an anti-inflammatory agent.
221
 
Treatment with inosine had a protective effect against the development of diabetes in two 
murine models of diabetes (streptozotocin-induced diabetes and spontaneous non-obese 
diabetic mouse model) by decreasing pancreatic leukocyte infiltration and oxidative stress.
222
 
Since inosine was decreased in T2DM participants in our study, and inversely associated with 
the increased rest and exercise BP values, this finding suggests a possible role of 
inflammation as a contributing factor in hypertension development and exaggerated exercise 
BP. Indeed, C-reactive protein (a sensitive marker of inflammation) was independently 
associated with insulin sensitivity and systolic BP in a large, population-based study,
223
 as 
well as with exercise systolic BP during moderate intensity cycling in healthy men and 
women.
224
 Inflammation may be a triggering factor for insulin resistance leading to T2DM, 
but also the cause of vascular endothelial dysfunction (altered vasodilator/vasoconstrictor 
balance) and consequent BP regulation.
168
 Further studies are warranted to establish whether 
inosine supplementation exerts anti-inflammatory effects with benefit to vascular function 
and BP control. 
Consistent with previous studies which reported increased amino acid levels in T2DM 
individuals,
35, 36
 the PCA of PIMS in the current study also revealed higher levels of amino 
acids including leucine, tyrosine and proline that discriminated T2DM participants from non-
diabetic controls. However, increased levels of amino acids, and in particular branched-chain 
amino acids (identified as modulators of insulin secretion),
225
 may promote insulin resistance 
even in non-diabetic individuals most likely via disturbance of skeletal muscle insulin 
signalling.
226
 A recent metabolomics study in the Framingham Offspring cohort has showed 
that the amino acids isoleucine, leucine, valine, tyrosine and phenylalanine were increased 12 
years before the onset of T2DM and were significantly associated with the future incidence of 
T2DM.
165
 Importantly, increased levels of three amino acids (isoleucine, tyrosine and 
phenylalanine) were also significantly associated with the future development of CV disease, 
independently of standard CV disease and diabetes risk factors (including measures of insulin 
resistance), suggesting that disturbed amino acid metabolism may represent a novel link 
between CV disease development and T2DM. A cross-sectional analysis in individuals free 
of CV disease reported that each increase in the score of the same three amino acids was 
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associated with higher risk of having subclinical carotid atherosclerosis, as well as with 
approximately 80% increased risk of exercise-induced myocardial ischemia in individuals 
referred for diagnostic exercise stress testing.
166
 Also, amino acids levels were significantly 
associated with the presence of coronary artery disease in individuals undergoing 
catheterization.
227
 Overall, these findings may suggest that the association between amino 
acids and the development of CV disease may be mediated by irregularities in vascular 
function, although further studies are required to investigate causal mechanisms.  
Although lipid metabolism may also play a significant role in the development of 
haemodynamic abnormalities, metabolomics analysis in this study failed to detect any lipid-
related metabolites, as many study participants were on lipid-lowering medications as part of 
their standard BP management. Therefore, future studies including people with newly 
diagnosed T2DM that are still free from lipid-lowering medications may provide additional 
information regarding metabolic disorders and their connections to abnormal haemodynamic 
variables. Also, resting and exercise BP were measured by different devices; however, both 
devices have been validated according to the standard criteria for BP measurements and 
shown to be highly reproducible. The use of different devices might have affected the study 
results, including the noticed increase in diastolic BP during exercise.
183, 184
 
In conclusion, our findings show that a signature metabolic pattern of disordered 
carbohydrate metabolism was independently associated with central haemodynamics in 
patients with T2DM under resting and exercise conditions. Furthermore, decreased inosine 
levels in subjects with T2DM and inverse correlation with BP values (rest and exercise) 
suggest that inflammation may contribute to haemodynamic abnormalities in T2DM and 
potentially offer a novel therapeutic route.  
6.6 Contribution of chapter 6 to thesis aims  
People with T2DM have a higher prevalence of an HRE compared to those without T2DM, 
but the underlying mechanisms are unknown. Chapter 6 represents the first study that used 
the combination of untargeted metabolomics analysis, along with the haemodynamic 
measures, to help explaining possible metabolic factors that may be contributing to an HRE 
at moderate intensity in people with T2DM. This study showed that a signature metabolic 
pattern of disordered carbohydrate metabolism in T2DM (including increased levels of 
glucose, fructose and lactate) was independently associated with the exercise central BP 
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haemodynamic indices, suggesting that impaired carbohydrate metabolism may be a possible 
metabolic mechanism explaining central (but not peripheral) exercise hypertension. These 
findings are aligned with the observations from previous studies reporting that T2DM has a 
greater impact on central, rather than peripheral, arterial segments. Given the independent 
prognostic value of central BP measures and their higher pathophysiological significance 
compared to peripheral BP variables, these findings have clinical relevance. On the other 
hand, utilisation of exploratory metabolomics analysis has provided some evidence for the 
role of inflammation as a contributing factor of abnormal peripheral BP and an HRE in 
people with T2DM.  
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Chapter 7. Summary and Future Directions 
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Hypertension is a leading risk factor for global disease burden,
3
 affecting approximately one 
billion individuals worldwide, with this number expected to rise.
15
 Resting office blood 
pressure (BP) is used for the diagnosis of hypertension;
4
 however, despite apparently normal 
BP at rest, some individuals experience a hypertensive response to exercise (HRE). An HRE 
at moderate intensity (akin to the condition experienced during normal daily life activities) is 
associated with an increased risk for adverse cardiovascular (CV) events.
5
 It may provide 
better representation of an individual’s true BP when compared to their resting office BP,6 
but, little is known about the underlying pathophysiological contributors of an HRE. 
Therefore, this research program represented the first comprehensive CV examination of 
people with an HRE at moderate intensity and broad exploration of haemodynamic and 
biochemical (haemostatic and metabolic) correlates of an HRE.    
Chapter 4 makes an important contribution to the understanding of haemodynamic and 
haemostatic correlates of an HRE at moderate intensity in people with apparently normal 
resting office BP. This study demonstrated that a haemostatic marker, von Willebrand factor 
(vWf),
79
 was significantly increased in people with an HRE and positively associated with 
moderate intensity exercise systolic BP. Although endothelial dysfunction was not estimated 
with standard measures in this study (e.g. flow-mediated vasodilation), an increased vWf 
(also a marker of endothelial dysfunction) may provide some indications that endothelial 
dysfunction may be present in people with an HRE and may be a contributing factor of an 
HRE. Indeed, the association between vWf and moderate intensity exercise systolic BP may 
be a reflection of the relationship between endothelial dysfunction and high exercise BP, due 
to the altered capacity of the endothelium to appropriately dilate in order to mitigate pressure 
rises (particularly during exercise) and maintain normal vascular tone. Future studies may 
direct attention towards establishing the role of endothelial in an HRE at moderate intensity. 
Despite being a marker of endothelial dysfunction, vWf is also a haemostatic contributor to 
blood coagulation, thrombosis and possible CV events, which may possibly explain the link 
between an increased CV risk and an HRE. Indeed, increased shear pressure (or in the case of 
an HRE, a greater ambulatory cyclic BP load over time) would have a pronounced effects on 
vascular breakdown and increased pro-coagulation capacity, leading to the initiation of the 
coagulation cascade and an increase in thrombin generation. However, in this study 
population, a vWF was increased in the absence of a significant rise in other haemostatic 
(pro-coagulant) markers, which included tissue factor, thrombin-antithrombin complex and 
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fibrinogen. These findings suggest that apparently healthy people with an HRE experience a 
low grade (rather than exaggerated) activation of the coagulation system. Nevertheless, this 
finding has potential clinical significance, especially in those who also have other CV risk 
factors that could possibly act as promoters of blood coagulation.  
Interestingly, people with an HRE had a significantly different response in vWf following 
moderate intensity exercise compared with those with a normal BP response (having lower 
vWf levels compared to baseline), despite having elevated exercise BP levels. Although a 
limited number of studies have examined the influence of moderate intensity exercise (in 
contrast to strenuous exercise) on haemostatic markers, our study is in agreement with the 
study of Wang et al
201
 who also demonstrated that moderate intensity exercise suppresses 
platelet activation and coagulation in sedentary men (sedentary behaviour significantly 
associated with increased CV risk).
228
 It appears that moderate intensity exercise in HRE 
subjects could potentially have beneficial effects that may be more pronounced in those with 
excessive initial vWf levels and potently decrease the risk for, at least pro-thrombotic, CV 
events. However, future studies should investigate these potential beneficial effects of 
moderate intensity exercise in this population.  
This study also included the collection of serum samples for exploring metabolic correlates of 
an HRE at moderate intensity, as an HRE is also found to be associated with various 
metabolic CV risk factors including increased total cholesterol and triglyceride levels.  
Therefore, future steps will include the metabolomics analysis of these serum samples 
(collected at rest and following the exercise) in people with an HRE and their matched 
controls to investigate the metabolic correlates of an HRE, as well as their changes induced 
by moderate intensity exercise. Due to the complexity of the metabolomics analysis, this 
study will be pursued following the completion of this thesis.    
Current beliefs ascribe abnormalities in haemodynamic components, in particular aortic 
stiffness, to play a significant role in an HRE, as increased aortic stiffness may fail to buffer 
the rise in BP occurring with increased cardiac output and blood flow during exercise.
50
 
However, the results of this study outlined a less crucial role of aortic stiffness in the 
development of an HRE. Indeed, although aortic stiffness was increased in people with an 
HRE, an independent relationship with exercise systolic BP at moderate intensity was not 
observed. The lack of an independent association between arterial stiffness and an HRE may 
suggest that the endothelial dysfunction may play a key role in an HRE, given that arterial 
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stiffness is closely regulated by the endothelial function and nitric oxide bioavailability.
66-69
 
Therefore, future studies should explore whether therapeutic intervention targeting 
endothelial dysfunction and nitric oxide bioavailability may potentially prove to have benefits 
to vascular function and BP control in an HRE population.  
It should be noted, however, that this study included reasonably healthy subjects with an 
HRE at moderate intensity without an established hypertension at rest, compared to previous 
studies that included mostly hypertensive individuals.
51
 Therefore, the possibility that more 
advanced arterial stiffness (noticed in people with already established essential hypertension) 
may have a greater influence on exercise hypertension cannot be excluded. Also, the findings 
were limited to a small population of people with an HRE, and further verification of these 
results in a larger sample cohort is needed. Furthermore, the findings of this study also lend 
some support that physiological stress, such as exercise, may represent a useful tool to reveal 
underlying CV abnormalities that are not evident at rest. This is evidenced by finding that 
systemic vascular resistance was increased in people with an HRE only when measured 
during exercise conditions, but not at rest. 
Chapter 5 represents the first study that used the metabolomics analysis, along with 
haemodynamic measures, in people with an HRE, primarily for developing metabolomics 
analysis, as well as to explore metabolic actions of spironolactone on exercise BP and aortic 
stiffness. The results of Chapter 5 further supported that aortic stiffness may not be as 
relevant to an HRE as is widely believed. Indeed, spironolactone reduced exercise systolic 
BP and aortic stiffness by purely BP-dependent effects, and there was a lack of a significant 
relationship between the reduction in exercise BP and the decrease in aortic stiffness by 
spironolactone treatment. Another important observation of this study was that the reduction 
in exercise systolic BP by spironolactone treatment was not independent of the use of statins, 
angiotensin converting enzyme inhibitors and other CV risk factors, suggesting that other 
metabolic mechanisms (possibly those involved with the statins or angiotensin converting 
enzyme inhibitors treatment) may be involved in the development of an HRE. Thus, future 
studies exploring the metabolic effects of statins and/or angiotensin converting enzyme 
inhibitors treatment in people with an HRE using metabolomics techniques would represent a 
significant advancement to the understanding of possible underlying mechanisms associated 
with an HRE. Nevertheless, this study itself represents an important scientific contribution, as 
it shows for the first time how metabolomics analysis when combined with extensive 
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haemodynamic examination (including aortic stiffness and exercise BP measures) could help 
uncover important mechanistic insights of different conditions (including an HRE) and 
discovering possible treatment strategies.  
Investigations of the metabolic correlates of an HRE at moderate intensity (including 
peripheral and central) were investigated in Chapter 6 in people with a high prevalence of an 
HRE, such as those with type 2 diabetes mellitus (T2DM).
11
 Using a combination of the 
metabolomics and haemodynamic analysis, the results suggested that metabolites associated 
with the disordered carbohydrate metabolism in T2DM, might have a greater impact on 
central (rather than peripheral) exercise BP and an HRE. Although this study cannot 
demonstrate causality due to its cross-sectional nature, this closer association with central BP 
may potentially be due to the formation of advanced glycation end-products preferably in the 
central elastic arterial walls compared to the more muscular peripheral arteries, causing 
alterations in elastin and collagen fibres. Also, altered carbohydrate metabolism may also 
cause an increased production of oxidative reactive species that may lead to further damage 
of vascular structure and function.  
The findings that metabolic impairments underlying T2DM have a greater impact on the 
preferably central arterial system may be clinically significant, given that central BP indices 
(including the augmentation index [AIx]) more strongly relate to CV events than peripheral,
12
 
and that the central BP reflects the pressure to which the vital organs (heart, kidneys and 
brain) are directly exposed. These findings may further highlight the importance of including 
central BP measurements (resting and ambulatory) when evaluating someone’s BP control, 
especially in those with T2DM. However, central BP is still not established in routine clinical 
practise, but given that central BP cannot be truly represented by conventional BP measured 
at the periphery (brachial artery),
36
 and ‘true’ BP treatment may not be guided from 
peripheral BP measurements, there is a need for standardization of central BP measurement 
techniques and introducing the measurement of central BP into clinical practise.  
The pathophysiology of an HRE seems to be multifactorial, where inflammatory factors may 
also contribute to its development and associated complications. Indeed, the utilisation of 
exploratory metabolomics analysis found that the metabolic pattern with the decreased 
inosine levels (identified as anti-inflammatory metabolite)
221
 in T2DM participants were 
inversely and independently associated with peripheral exercise BP. Inflammation may 
possibly cause a vasodilator/vasoconstrictor imbalance in the vascular endothelial, leading to 
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endothelial dysfunction and BP deregulation.
168
 Further studies are needed to establish the 
role of inosine and inflammation in people with an HRE, and whether inosine 
supplementation exerts anti-inflammatory effects with benefits to vascular function and an 
HRE. Although lipid metabolism may also play a significant role in the development of an 
HRE, it is worth noting that metabolomics analysis in this study population (people with 
advanced T2DM) failed to detect any lipid-related metabolites and their associations with an 
HRE, as many study participants were on lipid-lowering medications as part of their standard 
BP management. Therefore, future studies including people with newly diagnosed T2DM 
that are still free from lipid-lowering medications may provide additional information 
regarding metabolic disorders and their connections to an HRE. However, an additional 
metabolomics analysis of serum samples from Chapter 4 should provide more evidence for 
the role of lipid metabolism in non-diabetic people with an HRE.  
Chapter 2 – Review of Literature - Part II represents the first comprehensive review of the 
literature explaining the clinical application of metabolomics analysis in hypertension 
research, as well as the basic principles and challenges of metabolomics. This review article 
will especially help the non-experts in this field to better understand and interpret studies 
utilising metabolomics techniques. In addition, the research program contained in this thesis 
demonstrates how metabolomics analysis could be used for exploring new insights into the 
underlying pathophysiological processes associated with high BP. In the future, methodology 
regarding the metabolomics analysis developed in these studies (including the normalisation 
method presented in Appendix 2) could be applied to further understand the 
pathophysiological mechanisms, not only in people with an HRE, but also in other diseases. 
Also, the findings in Appendix 1 reporting the clinical significance of measuring BP a few 
minutes after the recommended five minutes of rest,
4
 may have relevance to an appropriate 
diagnosis of hypertension and the design of future clinical trials. 
Overall, this research further supported evidence that an HRE at moderate intensity, 
irrespective of normal resting BP, represents a clinically important entity. Vascular 
abnormalities were present in people with an HRE, reflected by an increased aortic stiffness, 
but these do not explain an HRE independent of resting BP and other CV risk factors. 
Importantly, abnormal blood biochemistry including haemostatic irregularities (also 
reflecting endothelial dysfunction), increased metabolic markers related to carbohydrate 
metabolism and inflammation in T2DM, explain an HRE independent of resting BP and other 
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CV risk factors. Taken altogether, this thesis provides novel information, and represents a 
significant advancement to the understanding of the pathophysiology of an HRE at moderate 
intensity.  
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Appendix 1  
 
Waiting a Few Extra Minutes Before Measuring Blood Pressure 
Has Potentially Important Clinical and Research Ramifications 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis section has been previously published: 
Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few extra 
minutes before measuring blood pressure has potentially important clinical and research 
ramifications. Journal of human hypertension. 2014;28:56-61 
 
In Appendix 1, a retrospective analysis of data was conducted to define the appropriate timing 
(protocol) for resting blood pressure measurements used in all studies that comprise this 
thesis. Importantly, the findings of this study have also relevance for the appropriate 
diagnosis of hypertension, as well as the design of research studies in which resting office 
blood pressure is measured.  
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A1.1 Abstract 
Background. Office blood pressure (BP) is recommended to be measured after five minutes 
of seated rest, but it may decrease for 10 minutes. This study aimed to determine the change 
(and its clinical relevance) in brachial and central BP from five to 10 minutes of seated rest. 
Methods. Office brachial and central BP (measured after five and 10 minutes), left 
ventricular (LV) mass index, seven-day home and ambulatory BP were measured in 250 
participants with treated hypertension.  
Results. Office brachial and central BP were significantly lower at 10 compared with five 
minutes BP (p < 0.001). Seven-day home systolic BP was significantly lower than office 
systolic BP measured at five minutes (p < 0.001), but was similar to office systolic BP at 10 
minutes (p = 0.511). From five to 10 minutes, the percentage of participants with controlled 
BP increased and the percentage of participants with high central pulse pressure (PP) 
decreased (p < 0.001). Moreover, brachial and central PP were significantly correlated with 
LV mass index measured at 10 (r = 0.171, p = 0.006 and r = 0.139, p = 0.027, respectively), 
but not at five minutes (r = 0.115, p = 0.068 and r = 0.084, p = 0.185, respectively).  
Conclusion. Blood pressure recorded after 10 minutes is more representative of true BP 
control. These findings have relevance to appropriate diagnosis of hypertension and design of 
clinical trials.  
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A1.2 Introduction 
Current guidelines for the management of hypertension recommend that office brachial blood 
pressure (BP) should be optimally measured after five minutes of seated rest.
4, 198
 However, 
brachial BP may decrease for up to 10 minutes of seated rest, after which reaching a plateau 
level.
185, 186
 Furthermore, office brachial BP averaged over 10 minutes seated rest in the 
absence of an observer has been shown to closely relate to out-of-office BP (daytime 
ambulatory BP).
229
 This is an important finding because out-of-office BP measures (e.g. 
seven-day home BP and daytime ambulatory BP) have been shown to be stronger predictors 
of cardiovascular (CV) risk when compared with office BP values.
230, 231
 Consequently, 
office brachial BP measured after the recommended five minutes rest period may not be a 
good representative of true BP, and using this as the sole method to assess BP control may 
result in misclassification or inappropriate management of some individuals.
232
 The first aim 
of this study was to determine the change in seated brachial BP when measured after five and 
10 minutes of seated rest. This study also sought to determine the clinical relevance of the 
change in brachial BP over time by assessing: 1) the change in BP classification; 2) the 
comparison with out-of-office BP and; 3) associations with BP-related end-organ damage 
(left ventricular [LV] mass). 
Central BP may be significantly different from the brachial BP measured at the same time.
39
 
However, central BP is pathophysiologically more important than brachial BP with respect to 
CV disease and has a stronger relation to LV mass than brachial BP.
233
 In recent years, large 
longitudinal studies have indicated that central BP has more power for predicting future CV 
events and mortality when compared with brachial BP.
12
 Furthermore, central BP may also 
change differently from brachial BP in response to physiological stimuli (e.g. posture, 
medications and exercise).
44, 234
 To our knowledge, there have been no studies examining 
how central BP acutely changes over five compared with 10 minutes, and this was an 
additional aim of this study. As with the change in brachial BP over time, we also sought to 
determine the clinical relevance of central BP changes after five compared with 10 minutes of 
seated rest.  
A1.3 Methods 
A1.3.1 Study population 
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Data was analysed from baseline examination of 250 participants, aged 18 to 75 years, with 
treated essential hypertension who were enrolled in the BP GUIDE study 
(http://www.anzctr.org.au; ACTRN12608000041358). See Table A1.1 for participant 
characteristics. Exclusion criteria included taking more than three antihypertensive 
medications or office BP > 180/100 mmHg, a history of coronary artery or renal disease, 
secondary hypertension, aortic valve stenosis or obstructive atherosclerosis at the upper limb 
(difference of > 20 mmHg in systolic BP between both arms), severe LV hypertrophy (LV 
mass index, indexed to height
2.7
, in women ≥ 59g/m2.7 and men ≥ 64 g/m2.7 measured by 
echocardiography) and pregnant females. The study was approved by the local Human 
Research Ethics Committees of attending study sites. All participants gave informed consent 
and all the procedures were performed in accordance with the Declaration of Helsinki (2000).   
Table A1.1 Characteristics of study participants 
Variable Mean ± SD or % 
Age (years) 64 ± 8 
Gender (% male) 52 
Body mass index (kg/m
2
) 29.3 ± 4.8 
Waist-to-hip ratio 0.94 ± 0.51 
Left ventricular mass index (g/m
2.7
) 32.7 ± 8.9 
Heart rate (bpm) 68 ± 10 
Diabetes (%) 7.6 
Glucose (mmol/L) 5.9 ± 6.1 
Total cholesterol (mmol/L) 5.13 ± 1.02 
Low density lipoprotein (mmol/L) 3.04 ± 0.94 
High density lipoprotein (mmol/L) 1.39 ± 0.47 
Triglycerides (mmol/L) 1.65 ± 1.11 
Medications   
Angiotensin converting enzyme inhibitors (%) 30 
Angiotensin receptor inhibitors (%) 63 
Beta blockers (%) 9 
Statins (%) 30 
Diuretics (%) 36 
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A1.3.2 Protocol  
Study participants attended the research clinic at only one occasion in the morning where all 
measurements were acquired. Participants were asked to avoid exercise on the day of 
examination, as well as caffeine-containing beverages, heavy meals and smoking at least 
three hours prior to the visit. All BP measures were recorded by a trained (non-clinician) 
research technician in a quiet, temperature-controlled room. Brachial BP was recorded as the 
average of duplicate measures taken one minute apart after five minutes of seated rest, as per 
recommendations. Duplicate measures of central BP were then recorded and calibrated to the 
averaged brachial BP obtained previously (approximately five minutes of seated rest). 
Tonometric measures took approximately two to four minutes. Following this, two measures 
of brachial BP recorded one minute apart were acquired again, and the average values were 
used to recalibrate the central BP (approximately 10 minutes of seated rest). After acquiring 
the BP measures, a blood sample was collected for standard clinical biochemistry and two-
dimensional echocardiography measures of LV mass were recorded. At the end of the clinic 
visit, each participant was fitted with a 24 hour ambulatory BP device. They were also 
provided with a BP device for seven-day home BP monitoring together with instructions on 
how to measure this, commencing on the day after the clinical visit. 
A1.3.3 Office brachial BP 
Upper arm BP was recorded using a validated semi-automated oscillometric device (Omron 
HEM-907; OMRON Europe B.V. (OMCE), Hoofddorp, The Netherlands).
183
 Blood pressure 
was measured in accordance with guidelines, using an appropriately sized cuff with the arm 
supported at heart level.
4, 198
 Participants were seated quietly in a chair with feet flat on the 
floor and back supported.
4, 198
 Uncontrolled BP was defined as ≥ 140/90 mmHg as per 
accepted criteria.
198
 Brachial pulse pressure (PP) was calculated as the difference between 
brachial systolic and diastolic BP. 
A1.3.4 Office central BP  
Seated central BP was measured by radial applanation tonometry using validated and highly 
reproducible generalized transfer function (SphygmoCor 8.1; AtCor Medical, Sydney, 
Australia).
47, 48
 Central BP was calibrated by two methods: calibration 1) with the brachial 
systolic and diastolic BP; and calibration 2) with mean (1/3 PP + diastolic BP) and diastolic 
BP; and both were used for the analysis. Central PP was calculated as the difference between 
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central systolic and diastolic BP. The Strong Heart Study 
235
 showed that central 
PP ≥ 50 mmHg independently predicted adverse CV outcomes. Accordingly, for the purpose 
of this study, we defined high central PP as ≥ 50 mmHg. 
A1.3.5 Home BP  
Seven-day home BP was self-measured using a validated oscillometric device (UA-767, 
A&D Mercury, A&D Medical, Thebarton, South Australia).
190
 Participants were instructed to 
take BP measures in a warm and quite room after at least five minutes of seated rest in a chair 
enabling back support, with feet flat on the ground and the arm with the cuff supported at 
heart level. Home BP was measured in duplicate in the morning (between 6am and 10am), 
midday and evening (between 6pm and 10pm). The first of two BP measurements was 
discarded and the second BP was recorded and used for analysis. Home BP was compared 
with office BP values to identify individuals with white coat hypertension (increased office 
and normal home BP) and masked hypertension (normal office and increased home BP). 
Raised home BP was defined as ≥ 135/85 mmHg.191 
A1.3.6 24 hour ambulatory BP  
A validated device (TM-2430, A&D Mercury, A&D Medical, Thebarton, South Australia)
189
 
was used for ambulatory BP monitoring. Participants were advised to maintain routine daily 
life activities and the device was set to record BP every 30 minutes during the day (6am to 
10pm) and every hour during the night (10pm to 6am).
23
 Daytime BP was also compared 
with office BP values to identify individuals with white coat and masked hypertension. 
Raised daytime BP was defined as ≥ 135/85 mmHg.23 
A1.3.7 Echocardiography 
LV mass was measured by two-dimensional echocardiography (Vivid 7; GE Medical 
Systems, Milwaukee, WI), calculated by method of Devereux
236
 and indexed to height 
2.7 
(LV 
mass index).
 
 
A1.3.8 Blood biochemistry 
A fasted or non-fasted blood sample was drawn to determine total, low-density and high-
density lipoprotein cholesterol, glucose and triglycerides. Blood was analysed as per standard 
hospital pathology laboratory procedures.  
A1.3.9 Statistical analysis 
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Statistical analyses were performed using SPSS for windows software version 17.0 (SPSS 
Inc., Chicago, Illinois, USA). Comparison of BP variables measured at five and 10 minutes 
were determined by independent t-tests. Between-group categorical variables were assessed 
by the chi-squared test. Correlations between continuous variables were assessed by 
Pearson’s correlation. Difference in the strengths of associations between central and brachial 
PP with LV mass index were compared by calculation of Z statistic scores. Multiple 
regression was used to identify predictors of the change in brachial systolic BP from five to 
10 minutes seated rest. A value of p < 0.05 was taken as statistically significant. 
A1.4 Results 
A1.4.1 BP changes over time  
There were no significant differences in central BP values when calibrated using brachial 
systolic and diastolic BP compared with calibration using mean and diastolic BP. As shown 
in Table A1.2, both brachial and central BPs measured at 10 minutes were significantly lower 
than the BP values recorded at five minutes. Brachial PP was also significantly lower after 10 
minutes compared with five minutes of seated rest. Central PP also declined over time, but 
this was of borderline significance.  
Table A1.2 Blood pressure values measured at five and 10 minutes of seated rest  
BP variable (mmHg) 5 minutes 10 minutes Change p value 
Brachial SBP 131.3 ± 14.0 127.1 ± 13.5 -4.2 ± 6.3 <0.001 
Brachial DBP 77.1 ± 9.7 75.4 ± 9.6 -1.8 ± 4.2 0.041 
Brachial PP 54.2 ± 11.3 51.7 ± 11.2 -2.5 ± 5.8 0.015 
Central SBP (calibration 1) 119.1±13.7 115.5 ± 13.1 -3.7 ± 5.4 0.002 
Central DBP (calibration 1) 78.1 ± 9.8 76.3 ± 9.7 -1.8 ± 4.1 0.035 
Central PP (calibration 1) 41.0 ± 10.7 39.2 ± 10.4 -1.8 ± 4.4 0.054 
Central SBP (calibration 2) 118.8 ± 13.1 115.2 ± 12.6 -3.6 ± 5.5 0.003 
Central PP (calibration 2) 40.7 ± 10.7 38.9 ± 10.7 -1.7 ± 4.5 0.080 
SBP, systolic blood pressure; DBP, diastolic BP; Calibration 1 – calibration by systolic 
and diastolic BP; calibration 2 – calibration by mean and diastolic BP 
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A1.4.2 Clinical relevance of the change in BP 
Figure A1.1 shows the change in the distribution of participants with uncontrolled BP after 
five and 10 minutes of seated rest. There was a significant decrease over time in the number 
of participants regarded as having uncontrolled BP (from n = 72 to n = 49; p < 0.001). Also, 
when seven-day home BP was used to identify participants with white coat or masked 
hypertension, in the time period from five to 10 minutes of seated rest, there were 6% 
(n = 15) fewer participants classified as having white coat hypertension and 4% (n = 10) 
more participants classified as having masked hypertension (Figure A1.2). Furthermore, 
when we used daytime BP to identify these individuals, there were 4% (n = 10) less 
participants classified as having white coat hypertension and 8% (n = 19) more participants 
classified as having masked hypertension.  
The change in the percentage of participants with high central PP after five and 10 minutes of 
seated rest is presented in Figure A1.3. There was a significant decrease of 6.4% (n=16) in 
the number of participants with high central PP (p < 0.001) at 10 minutes compared with five 
minutes BP classification. When central PP calibrated with mean and diastolic BP was used, 
a significant decrease of 4.9% (n = 13) in the number of participants with high central PP 
(p < 0.001) was noticed. 
 
Figure A1.1 Percentage of study participants with uncontrolled blood pressure when 
measured after five minutes and 10 minutes of seated rest; *p < 0.001 and n = 250. From five 
to 10 minutes, there was a significant decrease in the percentage of individuals regarded as 
having uncontrolled blood pressure. 
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Figure A1.2 Percentage of study participants with white coat hypertension and masked 
hypertension when home BP was compared with five and 10 minutes brachial BP. From five 
to 10 minutes, there was a significant decrease (39 vs. 24; p < 0.001) in the number of 
participants who were classified as having white coat hypertension and a significant increase 
(35 vs. 45; p < 0.001) in the number of participants who were identified as having masked 
hypertension.  
 
Figure A1.3 Percentage of study participants with high central pulse pressure when measured 
after five and 10 minutes of seated rest; *p < 0.001 and n = 250. Note a significant decrease 
in the percentage of participants with high central PP at 10 minutes compared with five 
minutes.    
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Table A1.3 shows the correspondence between out-of-office BPs and the BPs recorded at 
different times. Brachial systolic BP values measured after five and 10 minutes rest were 
significantly lower than daytime ambulatory systolic BP. However, the brachial systolic BP 
at 10 minutes was similar to seven-day home systolic BP. On the other hand, brachial systolic 
BP measured at five minutes was significantly higher than seven-day home systolic BP. The 
average number of blood pressure readings taken over the 24 hour period for the study 
population was 41.7. From these, 1.5 readings (on average) were excluded due to 
measurement error, leaving 96.4% valid readings. 
Table A1.4 shows the correlations between LV mass index and PP values. Brachial PP 
measured at 10 minutes seated rest was significantly correlated with LV mass index, whereas 
brachial PP measured at five minutes did not correlate with LV mass index. Similarly, ten 
minutes central PP (calibrated by both methods) was significantly correlated with LV mass 
index, whereas there was no significant correlation between five minutes central PP and LV 
mass index. The correlations between central systolic BP and PP with LV mass index (at both 
times) were slightly improved when calibration 2 was used and compared with calibration 1 
method, but the difference in slopes were not of statistical significance (p > 0.05 for all). 
Similarly, the slope of relationships between central PP and brachial PP (at 10 minutes) with 
the LV mass index were not significantly different (calibration 1 central PP vs. brachial PP, 
Z = 0.520, p = 0.607 and calibration 2 central PP vs. brachial PP, Z = 0.340, p = 0.734).   
Neither brachial nor central systolic BPs were correlated with LV mass index at either time 
points, whereas brachial and central diastolic BPs were significantly correlated only when 
measured at 10 minutes (r = -0.173, p = 0.006 and r = -0.171, p = 0.006), similar to PP. On 
the other hand, LV mass index was significantly correlated with seven-day home systolic BP 
(r = 0.140, p = 0.027), seven-day home PP (r = 0.145, p = 0.022), mean 24 hour systolic BP 
(r = 0.175, p = 0.005) and mean 24 hour PP (r = 0.259, p < 0.001).  
The change in brachial systolic BP from five to 10 minutes was significantly correlated with 
the use of angiotensin converting enzyme inhibitors (ACEi; r = 0.212, p < 0.001), brachial 
systolic BP at five minutes (r = 0.302, p < 0.001), brachial PP at five minutes (r = 0.282, 
p < 0.001), central systolic BP at five minutes (r = 0.279, p < 0.001) and central PP at five 
minutes (r = 0.260, p < 0.001). Due to significant collinearity between BP variables, only the 
use of ACEi and brachial systolic BP at five minutes were entered into a multiple regression 
model as independent predictors of the change in brachial systolic BP over time. The use of 
123 
 
ACEi (β = 0.161, p = 0.008) and brachial systolic BP at five minutes (β = 0.273, p < 0.001) 
were significant predictors of the change in brachial BP, but this was not a strong model 
(Adjusted R
2 
= 0.109, p < 0.001). 
Table A1.3 Daytime ambulatory and home systolic blood pressure and their differences from 
office blood pressure measured after five and 10 minutes of seated rest 
BP variable BP 
(mmHg) 
Mean difference 
from 5 mins BP 
p value Mean difference 
from 10 mins BP 
p value 
Daytime SBP 135.3 ± 11.7 -3.9 ± 14.1 < 0.001 -8.2 ± 13.5 < 0.001 
Home SBP 127.7 ± 12.3 3.7 ± 14.6 < 0.001 -0.6 ± 13.7 0.511 
Data are mean ± standard deviation. BP, blood pressure; SBP, systolic blood pressure 
 
Table A1.4 The correlation coefficients of left ventricular mass index with brachial and 
central BP values at five and 10 minutes of seated rest 
 5 minutes 10 minutes 
BP variable r value p value r value p value 
Brachial  SBP 0.012 0.851 0.020 0.752 
Brachial DBP -0.118 0.061 -0.172 0.006 
Brachial  PP 0.115 0.068 0.171 0.006 
Central SBP (calibration 1) 0.017 0.789 0.016 0.803 
Central PP (calibration 1) 0.084 0.185 0.139 0.027 
Central SBP (calibration 2) 0.011 0.862 0.012 0.876 
Central PP (calibration 2) 0.120 0.057 0.165 0.009 
SBP, systolic blood pressure; DBP, diastolic BP; PP, pulse pressure; calibration 1 
– calibration by systolic and diastolic BP; calibration 2 – calibration by mean and 
diastolic BP 
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Discussion 
Office brachial BP is recommended to be measured after five minutes of seated rest.
198
 The 
principal findings of this study were, firstly, that significant falls in office brachial and central 
BP were observed in the time period from five to 10 minutes of seated rest. Secondly, this 
drop in BP over time would have resulted in significant reclassification of BP control, and 
this was evident for both brachial and central BP values. Thirdly, we observed similar values 
for out-of-office systolic BP and the brachial systolic BP recorded after 10 minutes, but not 
after the recommended five minutes of seated rest. Finally, evidence of end-organ damage 
was correlated with the BP (brachial and central) values recorded after 10 minutes, but not 
five minutes of seated rest. Thus, waiting a few minutes longer than the recommended five 
minutes before measuring BP appears to provide a better representation of true BP. These 
findings have relevance to appropriate diagnosis of hypertension as well as the design of 
clinical trials in which brachial and central BP are measured. 
Office brachial BP changes over time. Numerous studies have reported a time-dependent 
decrease in seated brachial BP.
185, 186, 229, 237-240
 The exact mechanisms of this BP drop are yet 
to be elucidated, but may be explained by a gradual decrease in systemic vascular resistance 
caused by hemodynamic modifications to the seated position.
185
 Relaxation of the patient and 
sympathetic withdrawal over time may also be a potential cause of BP reduction.
185
  The 
magnitude of the brachial BP change over time has been consistently described in the 
literature. A large population study in 5999 participants reported a significant decrease 
(10.3 mmHg in men and 10.4 mmHg in women) in brachial systolic BP (but no change in 
diastolic BP) over 25 minutes of seated rest.
237
 This change resulted in a decrease in the 
prevalence of isolated systolic hypertension. Sala et al
185
 reported a similar decrease in 
systolic BP (10.7 ± 1.0 mmHg) and also a decrease in diastolic BP (3.4 ± 0.6 mmHg) in the 
period from two to 16 minutes of seated rest. These investigators also estimated that the bulk 
of the fall in systolic BP (75.3%) and diastolic BP (71.7%) occurred in the initial 10 minutes 
of seated rest. This finding has been repeated in a recent study by van der Wel et al.,
186
 who 
also showed that the plateau level of the systolic BP decline occurred after about 10 minutes 
of seated rest. Our findings are in agreement with these previous studies but have also 
focused on the potential clinical impact of the change in BP from five to 10 minutes of seated 
rest. Taken together, these studies suggest that five minutes is not a long enough period to 
wait before office BP measurements are acquired.  
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Clinical implications of BP changes over time. The change in brachial BP over time has 
potential clinical relevance as it may affect the evaluation and diagnosis of hypertension.  Our 
study showed that if only the BP after five minutes rest was considered, more participants 
would be classified as having uncontrolled BP compared with the BP at 10 minutes. Indeed, 
9.2% (n = 23) were reclassified from uncontrolled office BP to controlled office BP when the 
BP at 10 minutes was taken into account. In the clinical environment, this differential 
diagnosis could conceivably result in different (and possibly inappropriate) management of 
some individuals. A possible reason contributing to this change in classification could be 
related to a ‘white coat effect’20 given that this was 6% more likely if only the BP at five 
minutes was considered. Our finding on the reclassification regarding prevalence of masked 
hypertension is also of potential clinical relevance.
241
 An argument may be raised that it 
would be better to overestimate BP in these patients, as this may increase the chances for 
more appropriate diagnosis and treatment. Even though only a small number of participants 
were reclassified to having masked hypertension according to the 10 minute BP level (4 to 
8% depending on whether home or 24 hour ambulatory BP was used to determine out-of-
office BP), this finding provides additional support for routinely undertaking out-of-office BP 
to diagnose hypertension,
231
 which may be particularly relevant in patients with type 2 
diabetes.
22
  
Out-of-office BP recordings (home and daytime ambulatory BP) have been shown to be 
stronger predictors of CV risk than office brachial BP.
230, 231
 The lower prognostic value of 
office BP compared with out-of-office BP readings could potentially be attributed to 
inadequate time allowed before taking office BP recordings. Importantly, Myers et al
229
 have 
showed that office brachial BP, recorded by an automated device and averaged over 10 
minutes with the patient resting alone in a clinic room, was more similar with ambulatory 
daytime BP compared with standard five minutes BP measurements taken by either physician 
or technician.
229
 Although the 10 minutes automated office BP was more similar to 
ambulatory daytime BP, the automated BP was significantly lower even after correction for 
multiple comparisons.
229
 While the additional amount of time spent waiting may have 
contributed to the lower automated office BP readings at 10 minutes, the absence of the 
observer in itself may independently contribute to lower automated office BP readings. Our 
study is in agreement with the study of Myers et al,
229
 as we have also found that our 10 
minutes office BP was lower than daytime ambulatory BP. Although the difference between 
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these two BP measurements is greater in our study, this could be explained by different 
settings in which BP measurements were taken (patient’s physician referred ambulatory BP 
unit versus research setting) and different study population (hypertensive participants with 
nearly half untreated versus all treated hypertensive participants) and this may have 
contributed to our lower office BP values. Furthermore, we have also showed that brachial 
BP measured at 10 minutes (but not five minutes) were more similar to the average of seven-
day resting home BP readings than BP measurements taken during daytime ambulatory 
condition. Thus, waiting for extra time, taking more readings and bringing the office BP 
closer to out-of-office BP values may potentially improve the utility of office BP 
measurements.
229
  
Central BP indices have been shown to independently correlate with severe CV events and 
mortality.
12, 233
 While yet to be incorporated into general medicine, the consideration of 
central BP may improve identification and management of patients with hypertension or 
increased CV risk.
12, 38, 39, 242
 Indeed, two individuals with similar brachial systolic BP may 
have significantly different central systolic BP and, accordingly, may be classified into 
different risk groups related to BP.
39
 Furthermore, different BP-lowering drugs can 
differentially affect central BP compared with brachial BP and, looking to the future, this 
should be taken into account when assessing and deciding appropriate treatment options.
234, 
243, 244
 In our study, we have showed for the first time that central BP decreased over time, 
similarly to brachial BP. Our data indicates the potential for overestimating risk related to BP 
when based on five minutes central PP readings, since 6.4% less individuals would have been 
identified with high central PP on the basis of the 10 minute readings.
235
   
Limitations. Our study represents a cross-sectional analysis of data from patients with treated 
hypertension, and the findings may not be generalizable to other populations. Different 
oscillometric devices were used to measure office and home BP. Although both devices have 
been validated,
183, 190
 the use of separate machines might have affected study results. Central 
BP was measured by radial applanation tonometry using a generalized transfer function. 
Although this method has been validated and shown to be highly reproducible,
47, 48
 
calibration of the waveform using brachial BP may have resulted in error of central BP 
estimation.
245
 Furthermore, radial pressure waveforms were acquired only at one time point 
(after the BP measurements at five minutes) and the BP recorded at approximately 10 
minutes was used to recalibrate the radial pressure waveforms. Since another tonometry 
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reading was not acquired after 10 minutes, we may expect an under-estimation of the change 
in central BP from five to 10 minutes of seated rest, but this need to be tested in another 
study. In contrast to some previous studies,
246
 the home BP values in our study were lower 
than ambulatory BP measurements. This might be explained by the protocol used for home 
BP measurements, whereby the first BP reading was discarded from each duplicate reading. 
This is not entirely in keeping with European guidelines;
191
 however, the reason for this 
approach was based on the evidence that the first reading (morning and evening) has been 
shown to be persistently higher than any subsequent BP measurement, and the average of 
later measurements is a stronger correlate of ambulatory BP.
238
  
In conclusion, our study showed that both brachial and central BP decreased significantly 
when measured a few minutes after the recommended five minutes of seated rest in 
individuals treated for hypertension. This change in BP over time may have significant 
implications when assessing the BP-related risk and managing patients with hypertension. 
Given the increasing body of evidence indicating the superiority of out-of-office BP values in 
predicting CV risk and total mortality,
230, 231
 any advances that enable measurement of an 
office BP value that is closer to out-of-office BPs would be a valuable advancement in the 
clinical assessment of BP control. Although studies will be required to confirm, our finding 
that 10 minutes office BP was similar to seven-day home BP measurements may suggest that 
office BP measured after 10 minutes may provide better prognostic information about CV 
risk than the conventional five minutes wait period before measuring BP. In any case, this 
current study tends to support the work by Myers et al
229
 that multiple, automated office BP 
measurements with the patient sitting alone in a quiet examining room could be the most 
appropriate method to measure office BP. 
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Appendix 2 represents a separate study conducted in the same study population as in 
Chapter 6 to investigate a novel method for the normalisation of metabolomics data, which is 
a crucial step in metabolomics analysis. As this method proved useful, this normalisation 
method was used for metabolomics data normalisation in Chapter 6, with the details 
explained in this chapter. The primary analysis was conducted by Dr Karpievitch, but a 
significant input in regard to haemodynamic measures, study conception/design and data 
collection was provided by the author of this thesis.   
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A2.1 Abstract  
Background. Liquid chromatography mass spectrometry (LC-MS) has become one of the 
analytical platforms of choice for metabolomics studies. However, LC-MS metabolomics 
data can suffer from the effects of various systematic biases. These include batch effects, day-
to-day variations in instrument performance, signal intensity loss due to time-dependent 
effects of the LC column performance, accumulation of the contaminants in the MS ion 
source and MS sensitivity among others. We therefore propose the use of a singular value 
decomposition-based normalisation method (EigenMS) for metabolomics data.  
Methods. We analyzed a clinical human dataset where LC-MS serum metabolomics data and 
physiological measurements were collected from forty healthy subjects and forty with overt 
type 2 diabetes and applied EigenMS to detect and correct for any systematic bias. EigenMS 
works in several stages. First, it preserves the treatment group differences in the 
metabolomics data by estimating treatment effects with an ANOVA model (multiple fixed 
effects can be estimated and preserved). Singular value decomposition of the residuals matrix 
then determines the bias trends in the data. The number of bias trends is estimated via a 
permutation test and the effects of the bias trends are eliminated. 
 Results. EigenMS removed bias of unknown complexity from the LC-MS metabolomics 
data, allowing for increased sensitivity in differential analysis. Moreover, normalised samples 
better correlated with both other normalised samples and corresponding physiological data. 
Conclusion. We thus advocate the use of singular value decomposition-based normalisation 
for metabolomics data. 
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A2.2 Introduction 
Along with nuclear magnetic resonance, liquid chromatography coupled to mass 
spectrometry (LC-MS) has become one of the most common analytical platforms for 
studying cell, tissue or body fluid metabolomes.
247-253
 Advantages of the method include high 
sensitivity and the ability to discriminate thousands of features in a single experiment 
(particularly when using a high mass resolution instrument such as the ThermoFisher 
Orbitrap). Yet, as with any high-throughput technology, systematic biases are often observed 
in LC-MS metabolomics data.
254
 As the number of samples in the dataset increases so does 
the possibility of a time-dependent variation in the resulting metabolite data. Time-dependent 
trends in LC-MS metabolomics datasets typically result from analyte retention time drift due 
to changes in LC column performance or variations in signal intensity caused by fluctuations 
in MS sensitivity. While these issues can be addressed in part by careful experimental design 
and the use of quality control samples, there remains a need for robust post-acquisition data 
normalisation. Normalisation methods need to be flexible enough to capture biases of 
arbitrary complexity, while avoiding overfitting that would invalidate downstream statistical 
inference. Careful normalisation of metabolite peak intensities enables greater accuracy in 
quantitative comparisons between disease groups as well as better correlation of metabolite 
signals to any physiological or phenotypic data collected in tandem. We report here the 
application of a singular value decomposition-based method (SVD), called EigenMS, to 
remove systematic biases from metabolomics data in the presence of missing observations.
255
 
This normalisation method, previously shown to be effective in normalising LC-MS 
proteomics data,
255
 improved downstream differential analysis and increased correlation of 
the metabolite peak intensities with corresponding physiological measurements of what we 
call clinical biochemistry.  
A2.3 Methods 
To demonstrate the utility of our approach, we used a recently-acquired metabolomic dataset 
examining the serum of patients with type 2 diabetes (n = 40) and control subjects without 
diabetes (n = 39). Biological sample preparation and data acquisition followed the same 
protocol as reported in Nikolic et al.
10
 LC-MS data were acquired using an Orbitrap XL mass 
spectrometer (ThermoFisher Scientific) with XCalibur v2 software. Chromatographic 
separation was carried out using C18 reverse-phase HPLC. 
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We generated a pooled quality control (QC) sample in order to monitor LC and MS 
performance across sample runs by combining small aliquots (10 uL) of every sample in the 
study, as recommended by Sangster et al.
256
 This pooled QC sample was then used 
throughout the experiment as a process control as shown in.  Because all QC injections 
originated from the same mixture and thus should be chemically identical, QC samples allow 
one to detect variations in the observed intensities that may affect downstream statistical 
analyses.  
We monitored system performance using blocks of four experimental samples flanked by the 
QC samples between MS source and inlet cleaning. Thus our basic experimental running 
order included a cleanup of the ion spray cone and exterior surface of the ion transfer 
capillary with 50:50 methanol and water mixture between each block. At the end of each day 
of operation we used a more extensive cleaning protocol using 50:50 methanol and water to 
flush the sample transfer tube and atmospheric pressure ionization probe, according to the 
guidelines for daily operation of LTQ XL specified by the manufacturer. Mass spectral peak 
deconvolution and retention time correction were carried out in R using XCMS. The 
parameters for deconvolution were: method='centWave', ppm=3, peakwidth=5-30, 
snthresh=6, mzdiff=0.01; and for RT correction: method="obiwarp" and profStep=0.1, 
yielding ~7000 peaks.  
EigenMS uses a combination of ANOVA and singular value decomposition to capture and 
remove biases from LC-MS metabolomic peak intensity measurements while preserving the 
variation of interest. ANOVA is used first to capture and preserve the variation attributable to 
the treatment effect(s) under study. SVD is then applied to a matrix of residuals to find any 
systematic trends attributable to bias. The number of bias trends is determined by a 
permutation test and the effects of the bias trends are then removed from the data.  EigenMS 
is based on the surrogate variable analysis of Leek and Storey,
257
 with modifications 
including analysis of data with missing values that are typical in LC-MS experiments and an 
approach to prevent overfitting such that EigenMS could be integrated into any existing 
omics analysis pipeline. EigenMS is available as a stand-alone set of two functions 
implemented in R.  
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A2.4 Results and discussion 
A characteristic of biofluid metabolite analysis via LC-MS is progressive signal intensity loss 
due to the accumulation of contaminants within the MS ion source, sample transfer lines and 
the heated ion transfer capillary.
258
 We designed our experiment based on the guidelines 
outlined in Lai et al
258
 as well as based on in-house experimentation to establish the number 
of samples that could be run without large signal intensity loss on our instrumentation. We 
conditioned the LC column by running several QC samples as suggested by Want et al and 
others prior to running any experimental samples to avoid high signal variation during the 
first few runs.
254, 256
  
Within each block different treatment groups were matched and run order randomized.  
However, even using frequent cleaning, some signal loss was observed as is evident from the 
declining abundance profile within each day (Figure A2.1).  These data were acquired on the 
instrument operating in positive ion mode. We did not observe similar intensity loss 
throughout the data when the instrument was operating in the negative ion mode. However, 
we still observed variation that we could not easily explain. While careful experimental 
design (within-block treatment group matching) alleviated the influence of some of the biases 
and signal intensity loss that we and others have observed, we suggest that normalisation is 
needed to correct for any remaining intensity loss as well as any other known and unknown 
systematic biases. Further, if one wishes to identify relationships between LC-MS 
metabolomics data and other variables, normalisation becomes essential. 
Sample intensity loss makes comparisons between experimental groups more difficult, it also 
leads to an increased number of missing values in subsequent samples. Thus careful 
experimental design and sample run order randomization are required to minimize the 
introduction of systematic biases and any possible confounding of the results. Our experience 
leads us to strongly endorse others’ recommendation of QC samples to monitor the 
performance of an LC-MS instrument. 
We normalised the data with EigenMS. EigenMS identified 12 systematic bias trends and 
eliminated their effects from the data. Figure A2.2 shows boxplots of the intensities for the 
disease and control groups before (top panel) and after (bottom panel) normalisation for the 
same date as in Figure A2.1. Samples in Figure A2.2 are grouped by disease group (red vs. 
green) and within each group they appear in the run order on the instrument, such that the 
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first sample in red was run right next to the first sample in green and so on.  Even with 
regular cleaning of the inlet we encountered some signal loss as evident from the downward 
trend in the means (middle bars) of the boxplots.  Figure A2.2 bottom panel shows that 
normalisation successfully adjusted for the signal loss and any other systematic biases and 
placed the means of each sample almost on a straight line.  
 
Figure A2.1. Boxplots of sample intensities.  
Boxplots of sample intensities in run order on the instrument for positive ion mode. Each box 
represents a sample. Each of five days is presented in different color. 
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Figure A2.2 Boxplots of the raw and normalised intensities 
Boxplots of the intensities before (top panel) and after (bottom panel) normalisation. Each 
box represents a sample. Samples are grouped by disease group (red vs. green) and are in 
chronological run order on the instrument within each group.   
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Figure A2.3 shows SVD trends in raw (left 3 panels) and normalised (right 3 panels) diabetes 
data. Samples are ordered by group and appear in chronological run order within each group 
in the same way as Figure A2.2. Trends are ordered from top to bottom by the decreasing 
amount of variation explained by each trend. Due to the nature of SVD, each trend is 
orthogonal to every other. Notably, 20 percent of the variation in the raw data is attributable 
to the signal loss that appears as the top trend. Note that SVD trends can be rotated around 
the x-axis, thus the top trend in the raw data represents signal intensity loss. The top trend 
also shows a jump in each group which occurred between days 3 and 4 of the experiment. All 
the processing was done following the same protocol, but we still observed a variation due to 
the day effect where samples run on days 4 and 5 were affected differently than samples run 
on days 1-3. The rest of the trends in the raw data are not easily interpretable and are 
attributed to unknown systematic biases. Figure A2.3 (right panel) shows the normalised 
data. The top trend is representative of the differences between the disease and control 
groups. Only 3.7% of variation is attributable to the differences between the disease groups, 
but nonetheless this trend is a major trend in the normalised data as compared to the signal 
intensity loss trend in the raw data. Most importantly we were able to report 2578 
discriminatory metabolite peaks in the normalised (p < 0.05) data as compared to only 1840 
metabolite signals in the raw data (compared using an unpaired t-test; p < 0.05 with after 
Benjamini-Hochberg multiple testing adjustment).
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We saw an improvement in correlations of normalised metabolite intensities to the 
physiology variables we measured for each subject. We selected 1100 peaks that we found to 
be significantly different between two groups with p-value below 0.001 in normalised data. 
We correlated these 1100 peaks to clinical measurements we obtained for each subject, such 
as: blood glucose level, glycated haemoglobin (HbA1c), exercise central augmentation 
pressure normalised to heart rate of 75, and total cholesterol. The first four of these are 
usually elevated in diabetics while cholesterol is typically higher in controls. If EigenMS 
works well we expect to see increased correlation between normalised metabolites and 
physiological variables, providing an easy test of EigenMS’ performance. 
Figure A2.4 shows correlations of raw (x-axis) and normalised (y-axis) metabolite intensities 
to glucose (top left), HbA1c (top right), exercise central augmentation pressure (bottom left) 
and cholesterol (bottom right). The blue lines show correlations of zero. The red lines 
indicate no difference between correlations obtained from normalised and raw data. The 
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scatter plots show that we obtained higher correlations of normalised metabolite peak 
intensities to the variables measured in the laboratory. For glucose, for example, correlations 
for most of the positively correlated peaks increased as is evident from the dots falling above 
the diagonal line. For negatively correlated metabolites most of the correlations fall near the 
diagonal line still producing more scatter below the diagonal line indicating increased 
correlations. Similar patterns are observed for the rest of the physiological variables.  
 
Figure A2.3 SVD trends in raw and normalised data 
SVD trends in raw (left panel) and normalised (right panel) clinical study data.  Percentage at 
the top of each subplot shows the percent of the variation in the data explained by each trend.  
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Figure A2.4 Correlations to physiology data  
Correlations of raw (x-axis) and normalised (y-axis) metabolite intensities to physiology data. 
Blue lines represent correlation of zero. Red diagonal line shows the line on which all dots 
would fall if there was not difference between correlations of raw and normalised data. 
Observed counter-clockwise shift of points indicates better correlation with physiological 
data. 
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A2.5 Conclusions 
Normalisation is an important step in MS data analysis, but it is complicated by the high 
complexity of biases. EigenMS has been shown to remove biases of arbitrary complexity 
from proteomics data.
255
 Here we show that it works equally well for metabolomics data. By 
extension, we believe that the method should work equally well for any omics data where the 
variation of interest can be preserved via the fixed effects in an ANOVA model and the 
matrix of residuals analyzed for the presence of bias trends. The ability of EigenMS to 
capture complex biases and eliminate them preserves the validity of any downstream 
statistical analysis. The software is implemented in R and is freely available from the authors’ 
website and SourceForge.  
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Appendix 3 
 
Additional analysis for Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3 provides information and data analysis that was not included in the final 
published version of the study contained in Chapter 5. Data analysis involves the exploration 
of the effects of the aldosterone antagonist spironolactone on exercise blood pressure in 
people with a hypertensive response to exercise.   
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A3.1 Background 
The exact mechanisms of the effects of spironolactone on exercise blood pressure (BP) in 
people with a hypertensive response to exercise (HRE) are unclear, but there are two possible 
pathways: a) by a direct BP-dependent effect of spironolactone on exercise BP or b) by BP-
independent effects of spironolactone to reduce aortic stiffness (widely proposed contributor 
of an HRE),
58-60
 and consequently decrease the exercise BP. However, the underlying 
mechanisms are unknown, and this was the additional aim of the study presented in 
Chapter 5 of this thesis.   
A3.2 Methods 
Exercise BP. Brachial exercise BP was measured every 1-2 minutes during the treadmill 
exercise stress testing using electrocardiographic monitoring (CASE 14; GE Medical 
Systems). Maximal exercise BP was recorded at the moment of maximal exhaustion.  
A3.3 Results 
A3.3.1 Exercise BP variables 
There were no statistically significant differences in exercise BP variables between placebo 
and spironolactone groups at either baseline or after three months of treatment (Table A3.1). 
However, the group that received spironolactone had a significant reduction in exercise 
systolic BP compared to the group that receive placebo. 
Table A3.1 Blood pressure variables in placebo compared to spironolactone group at baseline 
and at follow-up (after three months of treatment) 
BP variable (mmHg) Placebo      
(n = 43) 
Spironolactone 
(n = 49) 
p value 
Baseline exercise systolic BP  216 ± 17 222 ± 17 0.113 
Baseline exercise diastolic BP 94 ± 12 93 ± 13 0.589 
Follow-up exercise diastolic BP   215 ± 17 216 ± 17 0.805 
Follow-up exercise diastolic BP 91 ± 13 91 ± 13 0.965 
Δ systolic BP -1 ± 11 -6 ± 11 0.029 
Δ diastolic BP -3 ± 8 -1 ± 12 0.522 
BP, blood pressure; Δ, change  
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A3.3.2 Univariable correlates of the reduction in exercise BP after three months of 
treatment 
Changes in exercise BP were correlated with the post-spironolactone signal intensity for each 
of the metabolomic features of interest. There were no significant correlations between the 
change in exercise systolic BP and any metabolic features, including canrenoate and 
canrenone (p > 0.05 for all). Also, there were no significant associations between the 
reduction in exercise systolic BP and the decrease in aortic stiffness after three months of 
treatment with spironolactone. However, the change in exercise systolic BP was significantly 
associated with the reduction in 24 hour systolic BP (Figure A3.1).  
 
Figure A3.1 Correlations with the change in exercise systolic BP; LEFT: the change in aortic 
stiffness; RIGHT: the change in 24 hour systolic BP, both after three months of 
spironolactone treatment (n = 49). 
A3.3.3 Multiple regression analysis 
A multiple regression model for predictors of the change in exercise systolic BP was 
constructed, with the age, sex, body mass index, the use of statins and angiotensin converting 
enzyme inhibitors, canrenoate and the change in 24 hour systolic BP entered as independent 
variables. There were no significant independent predictors of the change in exercise systolic 
BP (Adjusted R
2 
= 0.139, p = 0.093). 
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A3.4 Conclusion 
Three months of spironolactone treatment reduced the exercise systolic BP most likely due to 
a BP-dependent effect on the reduction in ambulatory 24 hour BP; however, this reduction in 
exercise systolic BP was not independent of other cardiovascular risk factors and the use of 
statins and angiotensin converting enzyme inhibitors. This may suggest that other metabolic 
mechanisms (involved with the statins or angiotensin converting enzyme inhibitors treatment) 
may be contributing to an HRE, and future studies should explore the metabolic effects of 
other medications on exercise BP in more details. Importantly, the reduction of exercise 
systolic BP was not associated with the decrease in aortic stiffness, giving support to aortic 
stiffness not being as relevant to exercise hypertension as is widely believed.  
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